Document:

EX-10.18

 Exhibit 10.18 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

RESEARCH COLLABORATION AND LICENSE AGREEMENT 

by and between 
 PFIZER INC.

 and 
 BIONTECH RNA
PHARMACEUTICALS GmbH 
 and 

BIONTECH AG 

July 20, 2018 
  

 TABLE OF CONTENTS 

 

									
	 1.
	  	 DEFINITIONS
	  	 	1	 
			
	 2.
	  	 LICENSE GRANTS, TECHNOLOGY TRANSFER, EXCLUSIVITY AND OTHER RIGHTS
	  	 	18	 
				
		  	2.1.	  	Exclusive License from BioNTech to Pfizer	  	 	18	 
				
		  	2.2.	  	Non-Exclusive License from BioNTech to Pfizer	  	 	18	 
				
		  	2.3.	  	Additional Licenses	  	 	19	 
				
		  	2.4.	  	Pfizer Sublicensees	  	 	19	 
				
		  	2.5.	  	Direct Licenses to Affiliates	  	 	20	 
				
		  	2.6.	  	Non-Exclusive License from Pfizer to BioNTech	  	 	20	 
				
		  	2.7.	  	Right of Reference	  	 	20	 
				
		  	2.8.	  	Current Licenses	  	 	20	 
				
		  	2.9.	  	Future BioNTech Third Party Agreements	  	 	22	 
				
		  	2.10.	  	No Implied Rights	  	 	22	 
				
		  	2.11.	  	Right of First Refusal	  	 	23	 
				
		  	2.12.	  	Right of First Negotiation	  	 	24	 
				
		  	2.13.	  	Access to Other BioNTech Technology	  	 	25	 
			
	 3.
	  	 PAYMENTS BY PFIZER TO BIONTECH
	  	 	26	 
				
		  	3.1.	  	Up-Front Payment	  	 	26	 
				
		  	3.2.	  	Equity Investment	  	 	26	 
				
		  	3.3.	  	Development Payments	  	 	26	 
				
		  	3.4.	  	Sales Milestone Payments	  	 	27	 
				
		  	3.5.	  	Royalty Payments	  	 	28	 
				
		  	3.6.	  	Reports and Payments	  	 	29	 
				
		  	3.7.	  	No Guarantee of Success	  	 	32	 
			
	 4.
	  	 RESEARCH PLAN
	  	 	33	 
				
		  	4.1.	  	Scope of Research and Research Plan	  	 	33	 
				
		  	4.2.	  	Allocation of Responsibilities	  	 	33	 
				
		  	4.3.	  	Research Governance	  	 	35	 
				
		  	4.4.	  	Research Term Extension	  	 	38	 
				
		  	4.5.	  	Research Plan Expenses	  	 	38	 

  
 i 

							
		  	4.6.	  	Materials and Permitted Activities	  	38
			
	5.	  	MANUFACTURING AND SUPPLY	  	39
				
		  	5.1.	  	Development of Manufacture Process	  	39
				
		  	5.2.	  	Manufacture of CTM for FIH Study	  	39
				
		  	5.3.	  	Supply of CTM to Pfizer	  	39
				
		  	5.4.	  	Technology Transfer of Manufacturing Process	  	39
				
		  	5.5.	  	Transfer Activities and Consulting Support	  	40
			
	6.	  	PRODUCT DEVELOPMENT AND COMMERCIALIZATION	  	40
				
		  	6.1.	  	General	  	40
				
		  	6.2.	  	Diligence	  	40
				
		  	6.3.	  	Regulatory Matters	  	42
				
		  	6.4.	  	Commercialization Activities	  	43
				
		  	6.5.	  	Manufacturing	  	43
				
		  	6.6.	  	Progress Reporting	  	43
				
		  	6.7.	  	Other Pfizer Programs	  	44
			
	7.	  	INTELLECTUAL PROPERTY	  	44
				
		  	7.1.	  	Patent Committee	  	44
				
		  	7.2.	  	Ownership of Intellectual Property	  	45
				
		  	7.3.	  	Patent Rights	  	45
				
		  	7.4.	  	Enforcement of Know-How	  	56
			
	8.	  	CONFIDENTIALITY	  	57
				
		  	8.1.	  	Confidentiality	  	57
				
		  	8.2.	  	Authorized Disclosure	  	58
				
		  	8.3.	  	SEC Filings and Other Disclosures	  	59
				
		  	8.4.	  	Residual Knowledge Exception	  	59
				
		  	8.5.	  	Public Announcements; Publications	  	59
				
		  	8.6.	  	Obligations in Connection with Change of Control	  	60
			
	9.	  	REPRESENTATIONS AND WARRANTIES	  	61
				
		  	9.1.	  	Mutual Representations and Warranties	  	61
				
		  	9.2.	  	Mutual Covenants	  	61
				
		  	9.3.	  	Representations and Warranties of BioNTech	  	61

  
 ii 

							
		  	9.4.	  	Accuracy of Representations and Warranties	  	65
				
		  	9.5.	  	BioNTech Covenants	  	65
				
		  	9.6.	  	Pfizer Covenants	  	68
				
		  	9.7.	  	Notifications	  	69
				
		  	9.8.	  	Representation by Legal Counsel	  	69
				
		  	9.9.	  	BioNTech’s knowledge	  	69
				
		  	9.10.	  	Disclaimer	  	69
			
	10.	  	GOVERNMENT APPROVALS; TERM AND TERMINATION	  	70
				
		  	10.1.	  	Antitrust Filing	  	70
				
		  	10.2.	  	Termination Upon Antitrust Filing Denial	  	70
				
		  	10.3.	  	Other Government Approvals	  	70
				
		  	10.4.	  	Term	  	70
				
		  	10.5.	  	Termination for Cause by BioNTech	  	70
				
		  	10.6.	  	Termination by Pfizer	  	71
				
		  	10.7.	  	Effects of Termination	  	71
				
		  	10.8.	  	Provision for Insolvency	  	74
				
		  	10.9.	  	Change of Control of BioNTech	  	75
				
		  	10.10.	  	Effects of Change of Control	  	76
				
		  	10.11.	  	Effect on Certain Agreement Provisions	  	76
			
	11.	  	LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE	  	76
				
		  	11.1.	  	No Consequential Damages	  	76
				
		  	11.2.	  	Indemnification by Pfizer	  	77
				
		  	11.3.	  	Indemnification by BioNTech	  	77
				
		  	11.4.	  	Procedure	  	77
				
		  	11.5.	  	Insurance	  	79
			
	12.	  	MISCELLANEOUS	  	79
				
		  	12.1.	  	BioNTech AG	  	79
				
		  	12.2.	  	Assignment	  	79
				
		  	12.3.	  	Further Actions	  	80
				
		  	12.4.	  	Force Majeure	  	80
				
		  	12.5.	  	Interpretation	  	80
				
		  	12.6.	  	Notices	  	80

  
 iii 

							
		  	12.7.	  	Amendment	  	81
				
		  	12.8.	  	Waiver	  	81
				
		  	12.9.	  	Severability	  	81
				
		  	12.10.	  	Descriptive Headings	  	82
				
		  	12.11.	  	Global Trade Control Laws	  	82
				
		  	12.12.	  	Dispute Resolution	  	82
				
		  	12.13.	  	Governing Law	  	83
				
		  	12.14.	  	Consent to Jurisdiction and Venue	  	83
				
		  	12.15.	  	Entire Agreement	  	83
				
		  	12.16.	  	Independent Contractors	  	83
				
		  	12.17.	  	Counterparts	  	83
				
		  	12.18.	  	No Third Party Rights or Obligations	  	84

  
 iv 

 EXHIBITS 
  

			
		
	Exhibit A	  	Research Plan
		
	Exhibit B	  	Pfizer’s Anti-Bribery and Anti-Corruption Practices
		
	Exhibit C	  	Pfizer’s Corporate Policy regarding Animal Care and Use
		
	Exhibit D	  	Manufacturing Technology Transfer Plan

 SCHEDULES 
  

			
	Schedule 1.16	 	Pfizer’s CAN Criteria in Effect as of the Effective Date
		
	Schedule 1.112	 	Specified Persons
		
	Schedule 3.5.1	 	Marginal Royalty Rate Calculation Example
		
	Schedule 4.2.2	 	Approved Subcontractors
		
	Schedule 5.3	 	Supply Agreement Terms
		
	Schedule 9.3	 	Disclosure Schedule
		
	Schedule 9.3.3	 	Candidates Existing as of the Execution Date
		
	Schedule 9.3.4	 	BioNTech Patent Rights Existing as of the Execution Date
		
	Schedule 9.3.12	 	Current Licenses
		
	Schedule 9.6.3	 	Certain Terms of Current Licenses
		
	Schedule 9.9	 	BioNTech’s Knowledge
		
	Schedule 10.7.1(a)	 	Effects of Reversion Rights in case of Termination for Cause by BioNTech or Termination for Convenience by Pfizer

  
 v 

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (the “Agreement”) is entered into as of July 20, 2018 (the
“Execution Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, New York, 10017 United States
(“Pfizer”) and BioNTech RNA Pharmaceuticals GmbH, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany
(“BioNTech RNA”) and BioNTech AG, a corporation organized and existing under the laws of Germany and having a place of business at An der Goldgrube 12, D-55131 Mainz, Germany
(“BioNTech AG”). BioNTech RNA and BioNTech AG are collectively referred to herein as “BioNTech”).Pfizer and BioNTech may each be referred to herein individually as a “Party” and collectively as the
“Parties.” 
 WHEREAS, BioNTech owns or otherwise Controls (as defined below) certain patents, patent applications,
technology, know-how, scientific and technical information and other proprietary rights and information relating to the identification, research and development of Candidates (as defined below); 

WHEREAS, Pfizer has extensive experience and expertise in the development and commercialization of pharmaceutical and biopharmaceutical
products; 
 WHEREAS, subject to the terms of this Agreement, BioNTech wishes to grant to Pfizer, and Pfizer wishes to receive from
BioNTech, an exclusive license in the Field (as defined below) in the Territory (as defined below) under BioNTech’s and its licensors’ patents, patent applications, technology, know-how, scientific
and technical information and other proprietary rights and information relating to Candidates and Products (as defined below) to use, research, develop, manufacture and commercialize Candidates and Products; and 

WHEREAS, Pfizer and BioNTech wish to engage in collaborative research pursuant to the Research Plan (as defined below) to identify and develop
Candidates for inclusion in Products for further development and commercialization by Pfizer. 
 NOW THEREFORE, in consideration of the
mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: 

 

	1.	 DEFINITIONS 

As used in this Agreement, the following terms will have the meanings set forth below: 

1.1. “Affiliate” means any entity directly or indirectly controlled by, controlling, or under common control with, a Person,
but only for so long as such control will continue. For purposes of this definition, “control” (including, with correlative meanings, “controlled by”, “controlling” and “under common control with”) means
(a) possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial
ownership of more than 50% of the voting securities or other ownership or general partnership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests of an entity;
provided, however, that where an entity owns a majority of the voting power necessary to elect a majority of the board of directors or other 

  
 1 

 
governing board of another entity, but is restricted from electing such majority by contract or otherwise, such entity will not be considered to be in control of such other entity until such time
as such restrictions are no longer in effect. Notwithstanding the foregoing, for the purposes of this Agreement, AT Impf GmbH, having its place of business at Rosenheimer Platz 6, 81669 Munich, Germany, and any entity that directly or indirectly,
through one or more intermediaries, controls, is controlled by, or is under common control with AT Impf GmbH (other than BioNTech AG or any entity that is directly or indirectly controlled by BioNTech AG) (collectively, the “Impf
Group”) shall not be considered Affiliates of BioNTech. 
 1.2. “Antigen” means a
non-human polypeptide that is capable of eliciting an immune response. 
 1.3. “Antitrust
Clearance Date” means the earliest date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act and any Foreign Antitrust Laws with respect to consummation of the transactions contemplated hereunder
have expired or have been terminated. 
 1.4. “Bankruptcy Code” means Section 101(35A) of Title 11 of the United
States Code, as amended, or such other legislation, Law or code with effect in another jurisdiction to which BioNTech or its Affiliates is subject having equivalent or reasonably similar purpose or provisions to the foregoing. 

1.5. “Binding Obligation” means, with respect to a Party (a) any oral or written agreement or arrangement that binds or
affects such Party’s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement, (b) the provisions of such Party’s charter, bylaws or other organizational documents or
(c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party’s operations or property are bound. 

1.6. “BioNTech Improvement” means any Research Program Technology, regardless of inventorship, that is a modification or
improvement made to the RNA Technology or RNA Process Technology and (a) would also be applicable to one or more candidates or products other than the Candidates or Products (b) is not predominantly directed to the Candidates, or Products
or the Pfizer Technology and (c) could have reasonable been developed without the aid, use or application of Pfizer Materials, Pfizer Improvements or Pfizer’s Confidential Information or any improvements or enhancements thereto. For
avoidance of doubt, BioNTech Improvements excludes RNA Improvements. 
 1.7. “BioNTech
Know-How” means any Know-How, other than any Research Program Know-How or Pfizer Technology that (a) is Controlled
by BioNTech or any of its Affiliates as of the Effective Date or that comes into the Control of BioNTech or any of its Affiliates during the Research Term (other than through the grant of a license by Pfizer) and (b) relates to (i) any
Replicons or Modified RNA; or (ii) the Development, Manufacture or Commercialization of any immunogenic composition comprising RNA in the Field, provided that BioNTech Know-How shall exclude any Know-How Controlled by BioNTech or any of its Affiliates that predominantly relates to Payloads (including, for example, cytokines or antibodies) other than Antigens. 

1.8. “BioNTech Materials” means any tangible materials (but not information about or contained in such materials) owned or
Controlled by BioNTech that relate to or embody the BioNTech Know-How or BioNTech Patent Rights. 

1.9. “BioNTech Patent Right” means any Patent Right (other than Research Program Patent Rights and Pfizer Patent Rights) in
any form and whether pending or issued that (a) is Controlled by BioNTech or any of 

  
 2 

 
its Affiliates as of the Effective Date or comes into the Control of BioNTech or any of its Affiliates during the Research Term (other than through the grant of a license by Pfizer) and
(b) claims any (i) Candidate, or Product (including the composition of matter thereof), (ii) method of making any Candidate or Product, (iii) methods of using any Candidate or Product or (iv) BioNTech Know-How, provided that BioNTech Patent Rights shall exclude any Patent Right Controlled by BioNTech or any of its Affiliates that predominantly relates to Payloads (including, for example, cytokines or antibodies)
other than Antigens. BioNTech Patent Rights include the existing Patent Rights listed in Schedule 9.3.4. 
 1.10. “BioNTech
Technology” means the BioNTech Patent Rights, BioNTech Materials and BioNTech Know-How. 

1.11. “BioNTech Third Party Agreement” means any agreement between BioNTech (or any of its Affiliates) and any Third Party
(such Third Party, a “Third Party Licensor”) that (a) relates to any of the BioNTech Technology or Research Program Technology (b) otherwise grants a license or otherwise transfers any right to practice under any Patent
Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement. For clarity, all Current Licenses shall be deemed BioNTech Third Party Agreements hereunder and
all Current Licensors shall be deemed Third Party Licensors hereunder. 
 1.12. “Biologics License Application” or
“BLA” means an application requesting permission from the FDA to introduce, or deliver for introduction, a biological product into interstate commerce, or any similar application or submission for marketing authorization of a
product filed with a Regulatory Authority to obtain Regulatory Approval for such product in a country or group of countries. 
 1.13.
“Biosimilar Notice” means a copy of any application submitted by a Third Party to the FDA under 42 U.S.C. § 262(k) of the Public Health Service Act (or, in the case of a country of the Territory outside the United States, any
similar law) for Regulatory Approval of a biopharmaceutical product, which application identifies a Product as the Reference Product with respect to such product, and other information that describes the process or processes used to manufacture the
biopharmaceutical product. 
 1.14. “Biosimilar Version” means, with respect to a Product that is being sold in a country
or regulatory jurisdiction in the Territory (the “Reference Product”), a biopharmaceutical product sold by a Third Party (other than a Third Party acting on behalf of or in concert with Pfizer or any Pfizer Affiliate or Sublicensee)
in such country or regulatory jurisdiction in the Territory that through reference to the Regulatory Approval of the Reference Product, is eligible for and has achieved Regulatory Approval in such country or regulatory jurisdiction pursuant to an
abbreviated follow-on biological approval pathway established by the Regulatory Authority in such country or regulatory jurisdiction pursuant to the applicable Law, or otherwise is approved for marketing and
sale in such country or regulatory jurisdiction by an abridged procedure in reliance, in whole or in part, on the prior Regulatory Approval of the Reference Product or on the safety and efficacy data generated for the prior Regulatory Approval (in
such country or regulatory jurisdiction) of the Reference Product, including any such biopharmaceutical product that (i) with respect to such biopharmaceutical product in the United States, has been approved as a biosimilar or interchangeable
product by the FDA pursuant to 42 U.S.C. § 262 of the Public Health Service Act, (ii) with respect to such biopharmaceutical product subject to the regulatory jurisdiction of the EMA, has been approved as a similar biological medicine
product by EMA as described in CHMP/437/04, issued 30 October 2005, as may be amended, or any subsequent or superseding law, statute or regulation or (iii) with respect to such biopharmaceutical product outside the United States and in a
country which is not subject to the regulatory jurisdiction of the EMA, has otherwise obtained Regulatory Approval from a Regulatory Authority pursuant to similar statutory or regulatory requirement as that described in the foregoing subsections
(i) and (ii) in such other country or regulatory jurisdiction in the Territory. 

  
 3 

 1.15. “Business Day” means a day other than a Saturday, Sunday or bank or
other public holiday in New York, New York, United States of America or Mainz, Germany. 
 1.16. “CAN Selection Criteria”
means the criteria used by Pfizer’s Vaccines Research and Development organization to determine whether to select a candidate as a CAN. Pfizer’s current CAN Selection Criteria is set forth in Schedule 1.16, which may be updated from
time-to-time by Pfizer during the term. 
 1.17.
“Candidate” means an immunogenic composition in the Field that comprises Modified RNA Technology or Replicon Technology that (a) arises from the Research Plan, (b) is Controlled by BioNTech and exists as of the Effective
Date or (c) is Exploited by Pfizer, its Affiliates or Sublicensees pursuant to the exercise or use of the rights licensed under Section 2.1 of this Agreement. Those Candidates Controlled by BioNTech and existing as of the Execution Date
are set forth on Schedule 9.3.3. 
 1.18. “Calendar Quarter” means the respective periods of three
consecutive calendar months ending on March 31, June 30, September 30 and December 31. 
 1.19. “Calendar
Year” means any twelve (12) month period beginning on January 1 and ending on the next subsequent December 31. 
 1.20.
“Change of Control” means, with respect to a Party (a) the acquisition of beneficial ownership, directly or indirectly, by any Person (other than such Party or an Affiliate of such Party, and other than by virtue of obtaining
irrevocable proxies) of securities or other voting interest of such Party representing of the combined voting power of such Party’s then outstanding securities or other voting interests, (b) any merger, reorganization, consolidation or
business combination involving such Party with a Third Party that results in the holders of beneficial ownership (other than by virtue of obtaining irrevocable proxies) of the voting securities or other voting interests of such Party (or, if
applicable, the ultimate parent of such Party) immediately prior to such merger, reorganization, consolidation or business combination ceasing to hold beneficial ownership of at least 50% of the combined voting power of the surviving entity
immediately after such merger, reorganization, consolidation or business combination, (c) any sale, lease, exchange, contribution or other transfer (in one transaction or a series of related transactions) of all or substantially all of the
assets of such Party to which this Agreement relates, other than a sale or disposition of such assets to an Affiliate of such Party or (d) the approval of any plan or proposal for the liquidation or dissolution of such Party (other than in
circumstances where such Party is deemed a Debtor pursuant to Section 10.8). 
 1.21. “Clinical Trial” means a human
clinical study conducted on sufficient numbers of human subjects that is designed to (a) establish that a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical
product for its intended use, and to define warnings, precautions and adverse reactions that may be associated with the pharmaceutical product in the dosage range to be prescribed or (c) support Regulatory Approval of such pharmaceutical
product or label expansion of such pharmaceutical product. Without limiting the foregoing, Clinical Trial includes any Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial conducted by or on behalf of one or both Parties in
connection with this Agreement. 

  
 4 

 1.22. “Clinical Trial Material” or “CTM” means a batch of
one or more Candidates or Products, as applicable, Manufactured to cGMP by or on behalf of either Party for Clinical Trials. 
 1.23.
“Combination Product” means a product comprising a Candidate or Product in combination with one or more other therapeutically active ingredients (which includes any prophylactic activity) that are
co-formulated as part of the same dosage form or packaged and administered to patient together. For the avoidance of doubt, adjuvants, including molecular adjuvants, are not considered therapeutically active
ingredients for the purposes of this definition regardless of whether or not such adjuvant is packaged together with a Candidate or Product but in a separate container. 

1.24. “Commercialize” or “Commercializing” means to (a) market, promote, distribute, offer for sale,
sell, have sold, import, have imported, export, have exported or otherwise commercialize a compound or product and (b) conduct discovery, pre-clinical, research or other Development activities with
respect to a compound or product after such compound or product has received Regulatory Approval. When used as a noun, “Commercialization” means any and all activities involved in Commercializing. 

1.25. “Commercially Reasonable Efforts” means, with respect to the efforts to be expended by a Party with respect to any
objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. With respect to any efforts relating to the Development, Regulatory Approval
or Commercialization of a Candidate or Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised Commercially Reasonable Efforts if such Party has exercised those efforts
normally used by such Party, in the relevant country, with respect to a compound or protein, product or product candidate, as applicable (a) of similar modality Controlled by such Party, (b) to which such Party has similar rights,
(c) which is of similar market potential in such country, and (d) which is at a similar stage in its development or product life cycle, as any Candidate or Product, in each case, taking into account all Relevant Factors in effect at the
time such efforts are to be expended. Further, to the extent that the performance of a Party’s obligations hereunder is adversely affected by the other Party’s failure to perform its obligations hereunder, the impact of such performance
failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations. 

1.26. “Compassionate Use Purposes” means, with respect to the Product, providing Product under compassionate use or expanded
access programs, or in jurisdictions or to vulnerable populations experiencing emergency pandemic, or crisis epidemic, flu conditions. 

1.27. “Competitive Product” means a pharmaceutical product [***] that has been or is being Exploited by a Third Party. For
avoidance of doubt, Competitive Product does not include Candidates or Products. 
 1.28. “Compliance” means the adherence
by the Parties in all material respects to all applicable Laws and Party Specific Regulations, in each case with respect to the activities to be conducted under this Agreement. 

1.29. “Confidential Information” means, with respect to each Party, all Know-How or
other information, including proprietary information and materials (whether or not patentable) regarding or embodying such Party’s or its Representatives’ technology, products, business information or objectives, that is communicated by or
on behalf of the Disclosing Party to the Receiving Party or its permitted recipients, on or after the Execution Date, but only to the extent that: (a) such Know-How or other

  
 5 

 
information in written form is marked in writing as “confidential” at the time of disclosure, (b) such Know-How or other information
disclosed orally or in non-tangible form is identified by the Disclosing Party as “confidential” at the time of disclosure or within 30 days thereafter, or (c) such Know-How or other information (regardless of the form of disclosure) is disclosed in circumstances of confidence or would be understood by the Parties, exercising reasonable business judgment, to be confidential.
Confidential Information does not include any Know-How or other information to the extent the Receiving Party can demonstrate by competent proof that such Know-How or
other information (a) was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by or on behalf of the Disclosing Party, (b) was generally available to
the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party, (c) became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than
through any act or omission of the Receiving Party in breach of its obligations under this Agreement, (d) was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the
Disclosing Party not to disclose such information to the Receiving Party or (e) was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information belonging to the Disclosing Party.
The terms and conditions of this Agreement will be considered Confidential Information of both Parties. Joint Know-How shall be deemed Confidential Information of either Party and either Party shall be deemed
the Receiving Party in respect of Joint Know-How. 
 1.30. “Control” or
“Controlled” means with respect to any Intellectual Property Right or material (including any Patent Right, Know-How or other data, information or material), the ability (whether by sole,
joint or other ownership interest, license or otherwise, other than pursuant to this Agreement) to, without violating the terms of any agreement with a Third Party, grant a license or sublicense or provide access or other right in as provided in
this Agreement, to or under such Intellectual Property Right or material. 
 1.31. “Copyright” means any copyright which
pertains to the promotional materials and literature utilized by Pfizer in connection with the Commercialization of Products in the Territory. 

1.32. “Core BioNTech Patent Rights” means those of the BioNTech Patent Rights (excluding any Patent Rights solely owned by a
Third Party and licensed hereunder pursuant to a Current Licence to the extent BioNTech has no enforcement rights in the Field in respect of the same) and Patent Rights Covering BioNTech Improvements that are material to and used by BioNTech, its
Affiliates or its or their licensees in connection with the Development or Commercialization of products outside the Field (excluding those Patent Rights and countries for which Pfizer is paying for maintenance or Prosecution Proceedings pursuant to
Section 7.3.1). Once any such product is Commercialized, a Patent Right shall be regarded as “material” for such product if the Manufacturing or sale of such product would, but for the ownership of or licence to the applicable Patent
Right, infringe such Patent Right. The Core BioNTech Patent Rights identified at the time of the Execution Date are designated as such in Schedule 9.3.4. 

1.33. “Core RNA Technology” means the mRNA technology platform [***]. 

1.34. “Cover” means, with respect to a given Candidate or Product and Patent Right, that a Valid Claim of such Patent Right
would, absent a license thereunder or ownership thereof, be infringed by the making, sale, offer for sale or importation of such Candidate or Product. 

  
 6 

 1.35. “Current Good Manufacturing Practices” or “cGMP”
means all applicable standards and applicable Laws relating to manufacturing practices for products (including ingredients, testing, storage, handling, intermediates) promulgated by the U.S. Food and Drug Administration and any other governmental
authority (including, European Union or member state level and Japan), including, but not limited to, standards in the form of applicable laws, guidelines, advisory opinions and compliance policy guides, and current interpretations of the applicable
authority or agency thereof (as applicable to pharmaceutical and biological products and ingredients), as the same may be updated, supplemented or amended from time to time, in each case of those jurisdictions in which the products are Manufactured.

 1.36. “Current Licenses” means any agreement (a) that BioNTech or its Affiliates has entered into or enters into
prior to the Effective Date with a Third Party and (b) pursuant to which BioNTech or its Affiliates are (i) granted rights to any BioNTech Technology as of the Effective Date or (ii) granted a license or otherwise transferred any
right to practice under any Patent Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement. BioNTech’s Current Licenses are disclosed on Schedule
9.3.12. 
 1.37. “Current Licensor” means any Third Party that is a party to a Current License. 

1.38. “Delivery Technology” means the BioNTech Know-How applicable to formulating
nucleic acids to enable the delivery of such nucleic acids to target cells in vivo. For clarity, Delivery Technology does not include Replicon Technology or Modified RNA Technology. 

1.39. “Develop” or “Developing” means to discover, research or otherwise develop or improve a process,
compound or product, including planning and conducting non-clinical and clinical research and development activities prior to Regulatory Approval. When used as a noun, “Development” means any and all
activities involved in Developing. 
 1.40. “Development Event” means each Development event listed in the table that
appears in Section 3.3. 
 1.41. “Effective Date” means the later of (a) the Execution Date, (b) if a
determination is made pursuant to Section 10.2 that a notification of this Agreement is not required to be made under the HSR Act or under any antitrust, competition or other similar laws, rules, regulations and judicial doctrines of
jurisdictions other than the United States (“Foreign Antitrust Laws”), the date of such determination, or (c) if notification of this Agreement is required to be made under the HSR Act or any Foreign Antitrust Laws, the
Antitrust Clearance Date. 
 1.42. “EMA” means the European Medicines Agency or any successor agency thereto. 

1.43. “Exploit” means to Develop, Manufacture, Commercialize, use or otherwise exploit. Cognates of the word
“Exploit” will have correlative meanings. 
 1.44. “FD&C Act” means the United States Federal Food, Drug, and
Cosmetic Act, as amended, and the rules and regulations promulgated thereunder. 
 1.45. “FDA” means the United States Food
and Drug Administration or any successor agency thereto. 

  
 7 

 1.46. “FIH Study” means one or more limited Phase I Clinical Trials
sponsored by BioNTech and conducted in Germany for the purpose of initial clinical translation and evaluation of one or more Candidates or Products selected by the JSC for such clinical evaluation, as further described in the Research Plan. 

1.47. “Field” means [***]. 

1.48. “First Commercial Sale” means, with respect to any Product and with respect to any country of the Territory, the first
sale of such Product by Pfizer or an Affiliate or Sublicensee of Pfizer to a Third Party in the Field in such country after such Product has been granted Regulatory Approval by the appropriate Regulatory Authority in such country. 

1.49. “GAAP” means United States generally accepted accounting principles, consistently applied. 

1.50. “GEIA” means the German Employee Invention Act. 

1.51. “GEIA Technology” means all BioNTech Technology and Research Program Technology invented by employees of BioNTech or
its Affiliates (solely or jointly with employees of Third Parties) under the jurisdiction of GEIA. 
 1.52. “Governmental
Authority” means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision. 

1.53. “Government Official”, to be broadly interpreted, means (a) any elected or appointed government official (e.g., a
member of a ministry of health), (b) any employee or person acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental function, (c) any political party, candidate for public office,
officer, employee, or person acting for or on behalf of a political party or candidate for public office, and (d) any employee or person acting for or on behalf of a public international organization (e.g., the United Nations). For clarity,
healthcare providers employed by government-owned hospitals will be considered Government Officials. 
 1.54. “HSR Act”
means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the rules and regulations promulgated thereunder. 
 1.55.
“HSR Filing” means filings by Pfizer and BioNTech with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice of a Notification and Report Form for Certain Mergers and
Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, together with all required documentary attachments thereto. 

1.56. “Human Material” means any biological samples of one or more Subjects collected, provided or utilized by BioNTech
during the Research Plan pursuant to this Agreement. 
 1.57. “ICF” means an informed consent form that was approved by a
qualified Institutional Review Board or Independent Ethics Committee (“IRB / IEC”) in accordance with all applicable Laws and recognized international standards for the protection of human research subjects. 

  
 8 

 1.58. “IND” means an Investigational New Drug Application submitted under
the FD&C Act, or an analogous application or submission with any analogous agency or Regulatory Authority outside of the United States for the purposes of obtaining permission to conduct Clinical Trials. 

1.59. “Intellectual Property Rights” means any and all (a) Patent Rights, (b) proprietary rights in Know-How, including trade secret rights, (c) proprietary rights associated with works of authorship and software, including copyrights, moral rights, and copyrightable works, and all applications,
registrations, and renewals relating thereto, and derivative works thereof, (d) other forms of proprietary or intellectual property rights however denominated throughout the world, other than trademarks, service marks, trade names, domain names
and other indicators of origin. 
 1.60. “Joint Steering Committee” or “JSC” means the steering committee
described in Section 4.3.2(a). 
 1.61. “Joint Know-How” means any Research
Program Know-How, whether or not patentable, made or created jointly by (a) BioNTech or any of its Representatives and (b) Pfizer or any of its Representatives. 

1.62. “Joint Patent Rights” means Research Program Patent Rights that claim or disclose any invention included in Joint Know-How. 
 1.63. “Joint Technology” means the Joint
Know-How and the Joint Patent Rights. 
 1.64.
“Know-How” means any proprietary invention, discovery, development, data, information, process, method, technique, technology, result, cell line, cell, antibody or other protein, compound,
probe, nucleic acid, (including RNAi) or other sequences or other know-how, whether or not patentable, and any physical embodiments of any of the foregoing or any information contained in any of the foregoing.

 1.65. “Law” means any law, statute, rule, regulation, order, judgment or ordinance of any Governmental Authority. 

1.66. “Major EU Market Country” means any of France, Germany, Italy, Spain or the United Kingdom. 

1.67. “Major Market Country” means the Major EU Market Countries, the United States and Japan. 

1.68. “Manufacture” or “Manufacturing” means to make, produce, manufacture, process, fill, finish, package,
label, perform quality assurance testing, release, ship or store, and for the purposes of further Manufacturing, distribute, import or export, a compound or product or any component thereof. When used as a noun, “Manufacture” or
“Manufacturing” means any and all activities involved in Manufacturing a compound or protein, device or product or any component thereof. 

1.69. “Modified RNA Product” means any Product comprising Modified RNA Technology. 

1.70. “Modified RNA” means an mRNA that has been modified by the incorporation of one or more modified nucleotides, excluding
the 5’ CAP. 

  
 9 

 1.71. “Modified RNA Technology” means the BioNTech Know-How applicable to Modified RNA. For clarity, Modified RNA Technology does not include Replicon Technology or Delivery Technology. 

1.72. “Net Sales” means with respect to a Product, gross receipts from sales by Pfizer and its Affiliates and Sublicensees of
such Product to Third Parties in the Territory, less in each case (a) bad debts and (b) sales returns and allowances actually paid, granted or accrued, including trade, quantity and cash discounts and any other adjustments, including those
granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargeback rebates, reimbursements or similar payments granted or given to wholesalers or other distributors, buying
groups, health care insurance carriers, chain pharmacies, mass merchandisers, staff model HMO’s, pharmacy benefit managers or other institutions, adjustments arising from consumer discount programs or other similar programs, customs or excise
duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes) or duties relating to sales, any payment in respect of sales to the United States government, any state government or any foreign government, or to any other
Governmental Authority, or with respect to any government-subsidized program or managed care organization, and freight and insurance (to the extent that Pfizer, its Affiliates or its Sublicensees bear the cost of freight and insurance for the
Product). 
 Net Sales will be determined from books and records maintained in accordance with GAAP, as consistently applied by Pfizer with respect to sales
of the Product. If, in respect of Product, Pfizer, its Affiliates or Sublicensees receive non-cash consideration or in the case of transactions not at arm’s length (except in each case where the case of
disposal of Product is in furtherance of Compassionate Use Purposes), Net Sales will be calculated based on the fair market value of such consideration or transaction, at the time of the transaction, assuming an arm’s length transaction made in
the ordinary course of business. 
 Net Sales for Products sold as part of a Combination Product in a country shall be calculated as follows: Net Sales will
be calculated by multiplying the Net Sales (as described above) of the Combination Product during the applicable royalty reporting period by the fraction A/(A+B), where A is the average sale price of the Product when sold separately in finished form
(or where such average sale price cannot be determined, the fair market value of such Product), and B is the average sale price of the other therapeutically active ingredient(s) included in the Combination Product when sold separately in finished
form (or where such average sale price cannot be determined, the fair market value of such other therapeutically active ingredient(s)), in each case in the applicable country of sale during the applicable royalty reporting period. To the extent Net
Sales are calculated on the basis of fair market values, the Parties shall seek to determine such fair market values by mutual agreement and, in the absence of such mutual agreement, the Parties shall engage an independent valuation firm (and
equally bear the costs of engaging such firm) to determine such fair market values. 
 1.73. “Party Specific Regulations”
means all non-monetary judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or
undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party’s activities contemplated by this Agreement. 

1.74. “Patent Rights” means any and all (a) issued patents, (b) pending patent applications, including all
provisional applications, non-provisional applications, substitutions, continuations, continuations-in-part, divisions and
renewals, applications sharing a priority claim and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by
existing or future 

  
 10 

 
extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor’s
certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing. 

1.75. “Payload” means a [***]. The term “Payload” excludes polypeptides that are used to enable expression of a
payload from the RNA, such as an RNA-dependent RNA polymerase. 
 1.76. “Person”
means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity
or organization, including a government or political subdivision or department or agency of a government. 
 1.77. “Pfizer Diligence
Obligations” means Pfizer’s Development and Regulatory Approval diligence obligations under Section 6.2.1 and Pfizer’s Commercialization diligence obligations under Section 6.2.2. 

1.78. “Pfizer Improvements” means any Research Program Technology, regardless of inventorship, that is a modification or
improvement to the Pfizer Technology and (a) would also be applicable to one or more candidates or products other than the Candidates or Products, (b) is not predominantly directed to the Candidates or Products or the RNA Technology or RNA
Process Technology and (c) could have reasonable been developed without the aid, use or application of BioNTech Materials, BioNTech Improvements or BioNTech’s Confidential Information or any improvements or enhancements thereto. 

1.79. “Pfizer Know-How” means any Know-How
that (a) is Controlled by Pfizer or any of its Affiliates on the Effective Date or that comes into the Control of Pfizer or any of its Affiliates during the Term (other than through the grant of a license by BioNTech), including Pfizer’s
rights in any Research Program Know-How, and (b) relates to one or more Candidates or Products or the Development, Manufacture or Commercialization of any of the foregoing. 

1.80. “Pfizer Patent Right” means any Patent Right that (a) is Controlled by Pfizer or any of its Affiliates on the
Effective Date or that comes into the Control of Pfizer or any of its Affiliates during the Term (other than through the grant of a license by BioNTech), including Pfizer’s rights in any Research Program Patent Rights, and (b) claims any
(i) Candidate or Product (including the composition of matter thereof), (ii) method of making any Candidate or Product, (iii) methods of using any Candidate or Product or (iv) Pfizer Know-How.

 1.81. “Pfizer Quarter” means each of the four (4) thirteen (13) week periods (a) with respect to the United
States, commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1 of any Pfizer Year. 

1.82. “Pfizer Technology” means the Pfizer Patent Rights, Pfizer Materials and Pfizer
Know-How. 
 1.83. “Pfizer Year” means the twelve month fiscal periods observed by
Pfizer (a) commencing on January 1 with respect to the United States and (b) commencing on December 1 with respect to any country in the Territory other than the United States. 

  
 11 

 1.84. “Phase I Clinical Trial” means a Clinical Trial that generally
provides for the first introduction into humans of a pharmaceutical product with the primary purpose of determining safety, metabolism and pharmacokinetic properties and clinical pharmacology of such product, in a manner that is generally consistent
with 21 CFR § 312.21(a), as amended (or its successor regulation), provided, however, a Phase I Clinical Trial does not include any study generally characterized by the FDA as an “exploratory IND study” in CDER’s Guidance for
Industry, Investigators, and Reviewers Exploratory IND Studies, January 2006, irrespective of whether or not such study is actually performed in the United States or under an IND. A so-called Phase I/II
Clinical Trial shall be deemed to be a Phase I Clinical Trial unless such trial, when completed, allows Pfizer to proceed directly to a Phase III Clinical Trial. 

1.85. “Phase II Clinical Trial” means a Clinical Trial, the principal purpose of which is to make a preliminary determination
as to whether a pharmaceutical product is safe for it intended use and to obtain sufficient information about such product’s efficacy, in a manner that is generally consistent with 21 CFR § 312.21(b), as amended (or its successor
regulation), to permit the design of further Clinical Trials. 
 1.86. “Phase III Clinical Trial” means a pivotal Clinical
Trial with a defined dose or a set of defined doses of a pharmaceutical product designed to ascertain efficacy and safety of such product, in a manner that is generally consistent with 21 CFR § 312.21(c), as amended (or its successor
regulation), for the purpose of enabling the preparation and submission of an NDA. 
 1.87. “Price Approval” means, in any
country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such
reimbursement authorization or pricing approval or determination (as the case may be). 
 1.88. “Product” means any
pharmaceutical product in a formulation suitable for administration to human subjects that incorporates (a) a Candidate selected by Pfizer for further Development in a Phase I Clinical Trial (other than the FIH Study) or Phase II Clinical
Trial, including by selection as CAN based on Pfizer’s CAN Selection Criteria, or (b) any derivative of such Candidate Developed by or on behalf of Pfizer or its Affiliates or Sublicensees in the Field comprising Modified RNA Technology or
Replicon Technology. 
 1.89. “Product Know-How” means (a) any Research
Program Know-How or (b) any BioNTech Know-How Controlled by BioNTech as of the Effective Date, in each case of (a) and (b) that is predominantly directed to
the composition of matter, treatment with, or the delivery of, Manufacture, form, formulation, or use of a Candidate or Product in the Field. For avoidance of doubt, Product Know-How shall exclude Know-How Controlled by BioNTech as of the Effective Date that is predominantly directed to the use or application of Modified RNA Technology or Replicon Technology that are generally applicable to products in the
field of infectious disease or oncology. 
 1.90. “Product Patent Rights” means any Patent Right that claims any invention
included in Product Know-How. 
 1.91. “Product Technology” means all Product Know-How and Product Patent Rights. 
 1.92. “Public Health Service Act” or “PHS
Act” means the United States Public Health Service Act (42 U.S.C. 201 et seq), as amended from time to time (including any rules and regulations promulgated thereunder) or any subsequent or superseding law, statute or regulation 

  
 12 

 1.93. “RNA Improvement” means any Intellectual Property Right arising after
the expiration of the Research Term and [***] solely or jointly made by Pfizer’s Representatives, and solely to the extent such Intellectual Property Right is an improvement or modification made to the Replicon Technology, Modified RNA
Technology, Delivery Technology or RNA Process Technology and provided that such Replicon Technology, Modified RNA Technology, Delivery Technology or RNA Process Technology used (a) had been disclosed to Pfizer or Pfizer’s Representatives
by BioNTech prior to the time of improvement or modification and (b) was BioNTech’s Confidential Information at the time of such disclosure. 

1.94. “RNA Process Technology” means the BioNTech Know-How used to Manufacture
Candidates or Products. 
 1.95. “RNA Technology” means Replicon Technology, Modified RNA Technology and Delivery
Technology that is, in each case, used by BioNTech in the Research Program 
 1.96. “Regulatory Approval” means all
technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of NDAs, supplements and amendments, pre- and post-approvals and labeling approvals) of any
Regulatory Authority, necessary or useful for the use, Development, Manufacture, and Commercialization of a pharmaceutical or biopharmaceutical product in a regulatory jurisdiction, including commercially reasonable Price Approvals and commercially
reasonable Third Party reimbursement approvals. 
 1.97. “Regulatory Authority” means, with respect to a country in the
Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or
other Governmental Authority involved in the granting of a Regulatory Approval or, to the extent required in such country, Price Approval, for pharmaceutical products in such country. 

1.98. “Relevant Factors” means all relevant factors that may affect the Development, Regulatory Approval or Commercialization
of a Candidate or Product, including (as applicable): [***]. 
 1.99. “Replicon” means an RNA molecule(s) that comprises a
gene encoding a polymerase that can, when the RNA molecule(s) is introduced into a cell, replicate the same or a different RNA molecule(s), that also comprises a gene encoding at least one Antigen and does not comprise the full set of genes required
to make an infectious virus and is capable, when introduced into a cell, of expressing detectable levels of the encoded Antigen. 
 1.100.
“Replicon Product” means any Product comprising Replicon Technology. 
 1.101. “Replicon Technology” means
the BioNTech Know-How applicable to Replicons. For clarity, Replicon Technology does not include Modified RNA Technology or Delivery Technology. 

1.102. “Representatives” means (a) with respect to Pfizer, Pfizer, its Affiliates, its Sublicensees and each of their
respective officers, directors, employees, consultants, contractors and agents and (b) with respect to BioNTech, BioNTech, its Affiliates and each of their respective officers, directors, employees, consultants, contractors and agents. 

1.103. “Research Plan” means the research plan attached hereto as Exhibit A, as it may be amended from time to time
pursuant to Section 4.1. 

  
 13 

 1.104. “Research Program” means the program of collaboration between the
Parties to Develop and Manufacture Candidates and Products in the Field including the activities described in the Research Plan. 
 1.105.
“Research Program Know-How” means any and all Know-How, Candidates and Products, whether or not patentable, made or created solely by or on behalf of
either Party or its Representatives in the conduct of activities under the Research Plan or made jointly by or on behalf of (i) BioNTech or its Representatives and (ii) Pfizer or its Representatives in the conduct of activities under the
Research Plan. 
 1.106. “Research Program Patent Rights” means any and all Patent Rights claiming or disclosing any
invention included in Research Program Know-How. 
 1.107. “Research Program
Technology” means the Research Program Patent Rights and Research Program Know-How. 

1.108. “Research Term” means the period of time beginning on the Effective Date and expiring on the date that is the third
anniversary thereof or such later date as may be established pursuant to Section 4.4, unless earlier terminated pursuant to the terms of this Agreement. 

1.109. “Residual Knowledge” means knowledge, techniques, experience and Know-How that
(a) are, or are based on, any Confidential Information of the Disclosing Party and (b) are retained in the unaided memory of any authorized Representative of the Receiving Party after having access to such Confidential Information. An
individual’s memory will be considered to be unaided if the individual has not intentionally memorized the Confidential Information for the purpose of retaining and subsequently using or disclosing it. 

1.110. “Reversion Technology” means, as of the effective date of termination of this Agreement and with respect to a
Continuation Product, (a) Pfizer’s rights in any Research Program Know-How and (b) any Pfizer Patent Right if and solely to the extent such Pfizer Patent Right claims any Research Program Know-How described in clause (a) above, in each case of clause (a) and (b) to the extent necessary or useful to Develop, Commercialize or Manufacture such Continuation Product. 

1.111. “Royalty Term” means (a) for all Modified RNA Products, on a country-by-country basis, the period of time from the First Commercial Sale of the first Modified RNA Product in such country in the Field until the later of (i) the period during which the manufacture,
sale, offer for sale or importation of such first Modified RNA Product in such country would infringe, but for the license granted herein, a Valid Claim Covering such first Modified RNA Product in such country, (ii) the tenth (10th) anniversary of the date of the First Commercial Sale of such first Modified RNA Product in such country in the Field, or (iii) lapse of regulatory data exclusivity for such first Modified RNA
Product in such country (or region to which the country is a member state); and (b) for all Replicon Products, on a country-by-country basis, the period of time
from the First Commercial Sale of the first Replicon Product in such country in the Field until the later of (i) the period during which the manufacture, sale, offer for sale or importation of such first Replicon Product in such country would
infringe, but for the license granted herein, a Valid Claim Covering such first Replicon Product in such country, (ii) the tenth (10th) anniversary of the date of the First Commercial Sale of
such first Replicon Product in such country in the Field, or (iii) lapse of regulatory data exclusivity for such first Replicon Product in such country (or region to which the country is a member state). If a Product comprises both Modified RNA
Technology and Replicon Technology (“Combined Product”), where it is the first Product to achieve a First Commercial Sale in any country in the Territory, it shall be 

  
 14 

 
classified by Pfizer as either a Modified RNA Product or a Replicon Product (but not both) for the purposes of this definition in such country until such time as a different Product that
comprises either Modified RNA Technology or Replicon Technology (but not both) achieves a First Commercial Sale in such country, whereupon the second Product shall be classified under this definition as either a Modified RNA Product or Replicon
Product according to the technology it comprises and the Combined Product shall thereafter be deemed to fall within the other definition. If a Combined Product is the second Product to achieve a First Commercial Sale in a country in the Territory,
it will be deemed to fall within the definition of Modified RNA Product if the first Product was a Replicon Product and vice versa. For the avoidance of doubt, per country there will be no more than two (2) different Royalty Terms for all
Products in such country. 
 1.112. “Specified Persons” means the list of companies set forth in Schedule 1.112,
their subsidiaries and any of their successors and assigns in respect of their vaccines business. 
 1.113. “Subject” means
the individual donor of the Human Material or of the original tissues from which the Human Material was derived. 
 1.114.
“Sublicensee” means any Person to whom Pfizer grants or has granted, directly or indirectly, a sublicense of rights licensed by BioNTech to Pfizer under this Agreement. 

1.115. “Territory” means worldwide. 

1.116. “Third Party” means any Person other than Pfizer, BioNTech or their respective Affiliates. 

1.117. “Trademark” means any trademark, trade name, service mark, service name, brand, domain name, trade dress, logo, slogan
or other indicia of origin or ownership, including the goodwill and activities associated with each of the foregoing. 
 1.118. “UPC
Agreement” means the treaty Agreement on the Unified Patent Court signed 19 February 2013, as may be amended or superseded from time. 

1.119. “Valid Claim” means, with respect to a particular country, (a) a claim of an issued and unexpired Patent Right
included within the BioNTech Patent Rights, or Research Program Patent Rights claiming the Product or the Manufacture or use thereof that (i) has not been held permanently revoked, unenforceable or invalid by a decision of a court or other
governmental authority of competent jurisdiction, which decision is unappealed or unappealable within the time allowed for appeal, and (ii) has not been cancelled, withdrawn, abandoned, disclaimed or admitted to be invalid or unenforceable
through reissue, disclaimer or otherwise; or (b) a bona fide claim of a pending patent application included within the BioNTech Patent Rights or Research Program Patent Rights claiming the Product or the Manufacture or use thereof that has not
been (i) cancelled, withdrawn or abandoned without being refiled in another application in the applicable jurisdiction or (ii) finally rejected by an administrative agency action from which no appeal can be taken or that has not been
appealed within the time allowed for appeal, provided that any claim in any patent application pending for more than seven (7) years from the earliest date on which such patent application claims priority shall not be considered a Valid Claim
for purposes of the Agreement from and after such seven (7) year date; provided, further, that in no event will any claim of Patent Right that would otherwise be expired except for a Patent Term Extension with respect to a product that is not a
Product or Candidate be considered a Valid Claim. 

  
 15 

 1.120. The following terms are defined in the section of this Agreement listed opposite each
term: 
  

			
	Defined Term	  	 Section in

Agreement

	Acquirer	  	10.10.2
	Acquisition Program	  	2.10.3
	Additional Patent Jurisdictions	  	7.3.1(a)
	Additional Third Party License	  	3.5.3(a)
	Agreement	  	Preamble
	Antitrust Filings	  	10.1
	Approved Subcontractors	  	4.2.2
	BioNTech	  	Preamble
	BioNTech AG	  	Preamble
	BioNTech Indemnified Party	  	11.2
	BioNTech JSC Members	  	4.3.2(a)
	BioNTech Owned Research Program Patent Rights	  	7.3.1(b)
	BioNTech Prosecution Patent Rights	  	7.3.1(a)
	BioNTech Review Period	  	8.5.3
	BioNTech RNA	  	Preamble
	BioNTech ROFN Notice	  	2.12.1
	BioNTech ROFR Notice	  	2.11.1
	Change of Control Party	  	8.6
	Change of Control Term	  	10.9
	CMO	  	5.4
	Combined Product	  	1.111
	Competitive Product Infringement	  	7.3.2(b)
	Continuation Product	  	10.7.1(a)(ii)(A)
	Continuation Product Net Sales	  	Schedule 10.7.1(a)
	Continuation Product Royalty Term	  	Schedule 10.7.1(a)
	Continuing Party	  	7.3.1(c)
	Cure Plan	  	2.8.3
	Debtor	  	10.8.1
	Declining Party	  	7.3.1(c)
	Development Payment	  	3.3
	Diligence Issue	  	6.2.5
	Disputed Matter	  	4.3.2(e)
	Disclosing Party	  	8.1
	Enforcement Action	  	7.3.2(a)
	Execution Date	  	Preamble
	Foreign Antitrust Laws	  	1.41
	Future BioNTech Third Party Agreement	  	2.9
	Global Trade Control Laws	  	12.11
	hCMV	  	2.11
	HCPs	  	9.3.23
	Impf Group	  	1.1
	Incremental Withholding Tax	  	3.6.4(a)
	Indemnified Party	  	11.4.1
	Indemnifying Party	  	11.4.1
	Infringement Claim	  	7.3.6

  
 16 

			
	Defined Term	  	 Section in

Agreement

	IRB / IEC	  	1.57
	JSC Chair	  	4.3.2(b)
	Key Patent Jurisdictions	  	7.3.1(a)
	Liabilities	  	11.2
	Licensed Activities	  	7.3.5(a)
	Litigation Conditions	  	11.4.2
	Marginal Royalty Rate	  	3.5.1
	Manufacturing Technology Transfer Plan	  	5.4
	Necessary	  	3.5.3(a)
	Notice of Dispute	  	12.12.1
	Other BioNTech Technology	  	2.13
	Partnered Field and Partnered Fields	  	2.11
	Party or Parties	  	Preamble
	Patent Committee	  	7.1
	Patent Term Extension	  	7.3.1(e)
	Pfizer	  	Preamble
	Pfizer Indemnified Party	  	11.3
	Pfizer JSC Members	  	4.3.2(a)
	Pfizer Materials	  	4.6.1
	Pfizer Review Period	  	8.5.2
	Product Technology Transfer Plan	  	4.3.2(d)(x)
	Prosecution Proceedings	  	7.3.1(f)
	Policies	  	9.3.24
	Program Director and Program Directors	  	4.3.1(a)
	Receiving Party	  	8.1
	Reference Product	  	1.14
	Regulatory Materials	  	Schedule 10.7.1(a)
	Restricted Market	  	12.11.1
	Restricted Parties	  	12.11.2
	Right of First Negotiation	  	2.12
	Right of First Refusal	  	2.11
	RNA	  	1.33
	ROFN Negotiation Period	  	2.12.2
	ROFN Partnering Terms	  	2.12.2
	ROFN Term	  	2.12
	ROFR Negotiation Period	  	2.11.3
	ROFR Partnering Terms	  	2.11.3
	ROFR Term	  	2.11
	RSV	  	2.11
	Sales Milestone Payment	  	3.4
	Term	  	10.4
	Third Party Claim	  	11.4.1
	Third Party IP Rights	  	7.3.5(b)
	Third Party Licensor	  	1.11
	Total Annual Net Sales	  	3.4
	Transition Plan	  	Schedule 10.7.1(a)

  
 17 

			
	Defined Term	  	 Section in

Agreement

	Useful	  	3.5.3(a)
	VAT	  	3.6.4(b)
	Withholding Tax	  	3.6.4(a)

  

	2.	 LICENSE GRANTS, TECHNOLOGY TRANSFER, EXCLUSIVITY AND OTHER RIGHTS 

2.1. Exclusive License from BioNTech to Pfizer. Subject to the terms and conditions of this Agreement, effective as of the
Effective Date, BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to Pfizer an exclusive (exclusive even as to BioNTech and its Affiliates except to the extent necessary (a) to perform
BioNTech’s activities under the Research Plan during the Research Term and (b) to Manufacture Clinical Trial Material as provided in this Agreement or the Supply Agreement) sublicensable (through multiple tiers) license and, to the extent
any BioNTech Technology is Controlled by BioNTech or its Affiliates pursuant to a BioNTech Third Party Agreement existing as of the Effective Date and, subject to Section 2.9, Future BioNTech Third Party Agreements, a sublicense, as applicable,
under the BioNTech Technology and BioNTech’s and its Affiliates’ interest in the Research Program Technology (including any BioNTech Improvements), to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize,
have Commercialized and otherwise Exploit Candidates, Products and [***] in the Territory. Without prejudice to Section 2.10.2, the foregoing license shall not prevent BioNTech and its Affiliates from conducting internal research directed
outside the Field where flu antigens or BioNTech Technology are used solely as comparators in such research. For avoidance of doubt, [***]: (i) which is not a Candidate or Product, (ii) which is Exploited by Pfizer under the foregoing license,
and (iii) the Exploitation of which would, absent such foregoing license, infringe a valid claim under the BioNTech Patent Rights or BioNTech’s rights in the Research Program Patent Rights (with “valid claim” being construed by
applying Section 1.119 mutatis mutandis) shall be considered a Candidate or Product for the purposes of this Agreement. 
 2.2.
Non-Exclusive License from BioNTech to Pfizer. Without limiting any other license or sublicense granted under this Agreement and subject to the terms and conditions of this Agreement, BioNTech on
behalf of itself and its Affiliates, effective as of the Effective Date, hereby grants (and will procure that its Affiliates grant) to Pfizer a non-exclusive, royalty-free, fully
paid-up, sublicensable license and, to the extent any BioNTech Technology is Controlled by BioNTech or its Affiliates pursuant to a BioNTech Third Party Agreement existing as of the Effective Date and, subject
to Section 2.9, Future BioNTech Third Party Agreements, a sublicense, as applicable, under all Patent Rights, Know-How and other Intellectual Property Rights Controlled by BioNTech or its Affiliates and
existing as of or after the Effective Date (to the extent such Patent Rights, Know-How and other Intellectual Property Rights are not exclusively licensed or sublicensed to Pfizer pursuant to
Section 2.1), to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit Candidates and Products in the Field in the Territory during the Term. 

  
 18 

 2.3. Additional Licenses. 

2.3.1. To Pfizer. 

Without limiting any other license or sublicense granted under this Agreement and subject to the terms and conditions of this Agreement,
BioNTech on behalf of itself and its Affiliates, effective as of the Effective Date, hereby grants (and will procure that its Affiliates grant) to Pfizer a non-exclusive, royalty-free, fully paid-up, sublicensable license under all BioNTech Improvements that were solely or jointly invented by Pfizer Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured,
Commercialize, have Commercialized and otherwise Exploit any products or processes in any field. In addition to the obligations set forth in Section 2.10 for the avoidance of doubt, the license granted in this Section 2.3.1 shall not
include or imply a right of Pfizer to use any BioNTech’s Confidential Information (that is not a BioNTech Improvement) outside the Field. 

2.3.2. To BioNTech. 

(a) Without limiting any other license or sublicense granted under this Agreement and subject to the terms and conditions of
this Agreement, Pfizer, effective as of the Effective Date, hereby grants to BioNTech a non-exclusive, royalty-free, fully paid-up, sublicensable license under all
Pfizer Improvements that were solely or jointly invented by BioNTech Representatives to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise Exploit any products or processes
outside the Field. 
 (b) Without limiting any other license or sublicense granted under this Agreement and subject to the
terms and conditions of this Agreement, Pfizer, effective as of the Effective Date, hereby grants to BioNTech a non-exclusive, royalty-free, fully paid-up, sublicensable
license under (i) all RNA Improvements and (ii) Pfizer’s interest in the Research Program Technology, in each case of (i) and (ii) to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have
Commercialized and otherwise Exploit any products or processes outside the Field. 
 (c) For the avoidance of doubt, the
licenses granted in this Section 2.3.2 shall not include or imply a right of BioNTech to use any Pfizer Confidential Information (that is not a Pfizer Improvement, RNA Improvements or Research Program Technology). 

2.4. Pfizer Sublicensees. Pfizer will have the right through multiple tiers to grant sublicenses and, as applicable, sub-sublicenses to its Affiliates and Third Parties of any and all rights granted to Pfizer under this Agreement by BioNTech, including any and all rights licensed to Pfizer pursuant to Section 2.1 or
Section 2.2. In respect of such sublicenses (or sub-sublicenses): 
 (a) Pfizer
will remain responsible for the payment to BioNTech of all Sales Milestone Payments and royalties payable under this Agreement with respect to Net Sales of Products made by such Pfizer Affiliates or Sublicensees; 

(b) Pfizer shall be responsible for failure by its Sublicensees to comply with the terms and conditions of this Agreement; 

(c) Pfizer shall notify BioNTech in writing of any sublicenses granted to Third Parties and, upon BioNTech’s written
request, provide BioNTech with a written summary of key terms of the respective sublicense agreement (excluding any terms reasonably deemed commercially sensitive or confidential by Pfizer); and 

  
 19 

 (d) Unless otherwise agreed between the Parties on a case-by-case basis (e.g. with a view of converting certain sublicenses into direct licenses with BioNTech), all sublicenses shall automatically terminate (and Pfizer shall
ensure that all sublicenses automatically terminate) upon termination (for whatever reason) of a license granted hereunder, but only to the extent necessary to terminate the sublicense in so far as it corresponds to any terminated licenses granted
in this Agreement. 
 2.5. Direct Licenses to Affiliates. Pfizer may, from time to time, request that BioNTech grants on
behalf of itself and its Affiliates (and will procure that its Affiliates grant) licenses or sublicenses directly to Affiliates of Pfizer by giving written notice, upon receipt of which BioNTech and its Affiliates will enter into and sign a separate
direct license or sublicense agreement with such designated Affiliate of Pfizer. All such direct license or sublicense agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by
applicable Laws in the country in which the direct license or sublicense will be exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct licenses or sublicenses
and this Agreement to the terms of this Agreement as set forth on the Execution Date. All reasonable costs of making such direct license or sublicense agreement(s), including BioNTech’s reasonable attorneys’ fees, under this
Section 2.5 will be borne by Pfizer. 
 2.6. Non-Exclusive License from Pfizer to
BioNTech. Subject to the terms and conditions of this Agreement, Pfizer hereby grants to BioNTech a non-exclusive, royalty-free, fully paid-up license in the
Territory in the Field, with no right to grant sublicenses other than to its Affiliates, and to permitted subcontractors under Section 4.2.2, under the Pfizer Technology solely: (i) during the Research Term to the extent necessary to
perform BioNTech’s activities under the Research Plan; and (ii) to the extent necessary to Manufacture Clinical Trial Material as provided in this Agreement or the Supply Agreement. 

2.7. Right of Reference. BioNTech on behalf of itself and its Affiliates hereby grants (and will procure that its Affiliates grant) to
Pfizer, its Affiliates and its Sublicensees a “Right of Reference,” as that term is defined in 21 C.F.R. § 314.3(b) (or any analogous Law recognized outside of the United States), to all data (including any regulatory filings or
Regulatory Approvals) Controlled by BioNTech or its Affiliates that relates to any Candidate or Product, and BioNTech will provide a signed statement to this effect, if requested by Pfizer, in accordance with 21 C.F.R. § 314.50(g)(3) (or any
analogous Law outside of the United States). 
 2.8. Current Licenses. 

2.8.1. Maintenance of Current Licenses. BioNTech will maintain in full effect and will perform all of its obligations in
a timely manner under each of the Current Licenses. Absent Pfizer’s prior written consent (which may be provided, conditioned or withheld in Pfizer’s sole discretion), BioNTech will not terminate, modify or amend any Current License in any
manner that would adversely affect any of the rights granted or that may be granted to Pfizer under this Agreement or that would impose any obligations upon Pfizer hereunder that are in addition to those obligations that would exist under this
Agreement based on the Current Licenses as they exist on the Effective Date or adversely affect BioNTech’s ability to perform its obligations under this Agreement. Further, BioNTech will not take any action or omit to take any action that would
cause it to be in breach of any Current License or that would give rise to a right of any Current Licensor to terminate the applicable Current License. 

  
 20 

 2.8.2. Communications and Performance. Notwithstanding anything to
the contrary in this Agreement, BioNTech will use Commercially Reasonable Efforts to facilitate any communications between Pfizer and any Current Licensor required for Pfizer to exercise the rights granted to it pursuant to Section 2 and will use
Commercially Reasonable Efforts to cause each applicable Current Licensor to perform all of its obligations under the applicable Current License. 

2.8.3. Breach of Current License by BioNTech. If BioNTech receives notification of any actual or potential breach or
otherwise becomes aware of its breach of any Current License (and if uncured, such breach could give rise to the termination of the applicable Current License), then BioNTech will immediately notify Pfizer of such breach. To the extent that any act
or omission on the part of Pfizer is the cause of such breach of a Current License, Pfizer will take all actions and provide BioNTech with all cooperation necessary to cure such breach, in each case as reasonably requested by BioNTech and at
Pfizer’s sole cost and expense. To the extent that Pfizer is not the cause of such breach of a Current License, BioNTech will have the first opportunity to cure such breach in accordance with a plan to be mutually agreed upon by the Parties in
writing, acting reasonably (each, a “Cure Plan”). If (a) BioNTech, at any time, is not using diligent efforts to cure such breach pursuant to the applicable Cure Plan or (b) BioNTech is unable to cure such breach in
accordance with the applicable Cure Plan or it becomes reasonably apparent that BioNTech will not be able to cure such breach pursuant to the applicable Cure Plan, then Pfizer may, at its election and in its sole discretion and without prejudice to
its other remedies against BioNTech, act reasonably to cure such breach and BioNTech will take all actions and provide Pfizer with all cooperation to cure such breach, in each case as directed by Pfizer. Further, if Pfizer is not the cause of such
breach of a Current License, then BioNTech will, at Pfizer’s sole election, (i) reimburse Pfizer for all out-of-pocket costs and expenses incurred by or on
behalf of Pfizer or any of its Representatives in connection with curing such breach; or (ii) permit Pfizer to offset any such costs and expenses incurred by or on behalf of Pfizer or any of Pfizer’s Representatives in connection with
curing such breach against Pfizer’s future payment obligations to BioNTech (or any of its successor or assigns) under this Agreement. 

2.8.4. Termination of any Current License. In the event that any Current License is terminated by the applicable Current
Licensor and this Agreement, as of the effective date of such termination, has not otherwise been terminated, Pfizer, to the extent permitted by such Current License (or if not permitted or addressed in such Current License, to the extent permitted
by the applicable Current Licensor), will have the right without prejudice to its other remedies against BioNTech, at Pfizer’s election, to convert the sublicenses granted under this Agreement by BioNTech to Pfizer under such Current License to
a direct license from the applicable Current Licensor to Pfizer on the terms and conditions contained in such Current License (with Pfizer assuming the applicable obligations of BioNTech thereunder) or such other terms and conditions as may be
negotiated by Pfizer and the applicable Current Licensor. In the event Pfizer enters into any such direct license with a Current Licensor, BioNTech will, at Pfizer’s sole election and without prejudice to its other remedies hereunder: 

  
 21 

 (a) in respect of royalties payable by Pfizer under such direct license to
the Current Licensor, to the extent such royalties are due in connection with the sale of Candidates or Products hereunder, reimburse to Pfizer the difference between (i) the amount that would have been payable by BioNTech to the Current
Licensor under the Current License if the Current License had not been terminated and (ii) the account that would have to be reimbursed by Pfizer to BioNTech in accordance with Section 3.5.3(b) in relation to the Current License if the Current
License had not been terminated; or 
 (b) permit Pfizer to offset any such reimbursement amounts (to the extent not
reimbursed pursuant to clause (a) above), against Pfizer’s future payment obligations to BioNTech (or any of its successor or assigns) under this Agreement. 

2.8.5. Consents and Waivers. BioNTech represents, warrants and covenants to Pfizer that, to the extent any terms and
conditions of this Agreement do not (or will not at any time during the Term) conform to any requirements relating to the grant of sublicenses under any Current License, it has obtained the irrevocable consent (or, if applicable, the waiver of any
resultant conflict) from the applicable Current Licensor that is necessary to permit the activities contemplated under this Agreement, including, such that BioNTech may grant the applicable sublicenses granted or to be granted hereunder and perform
all of its obligations hereunder and Pfizer may exercise all of its rights and perform all of its obligations hereunder, in each case, without breaching the applicable Current License. In the event that any provision in any Current License which
conflicts with this Agreement or adversely impacts the activities contemplated under this Agreement comes to the attention of either BioNTech or Pfizer or which otherwise, at any time during the Term, would cause the representation, warranty and
covenant set forth in the preceding sentence to be untrue, BioNTech, in consultation with Pfizer, will obtain any and all additional required consents or waivers from the applicable Current Licensor(s) which may be necessary to align the conflicting
provision(s) of the applicable Current License with this Agreement and to permit the activities contemplated by this Agreement. 
 2.9.
Future BioNTech Third Party Agreements. If BioNTech enters into bona fide discussions with a Third Party after the Effective Date which would, if an agreement is finally executed with such Third Party, give BioNTech rights to any Intellectual
Property Rights that could reasonably be applicable to the Candidates or Products in the Field, then BioNTech shall notify the JSC for discussion pursuant to Section 4.3.2(d)(vii). Any Intellectual Property Rights Controlled by BioNTech
pursuant to a BioNTech Third Party Agreement executed between BioNTech and such Third Party (each, a “Future BioNTech Third Party Agreement”) shall only be included in the licenses granted to Pfizer under this Agreement if and when
Pfizer: (a) notifies BioNTech in writing that such Intellectual Property Rights be included in the licenses granted to Pfizer under this Agreement; (b) agrees to reimburse BioNTech [***] of the royalties payable by BioNTech to the Third Party
Licensor under such Future BioNTech Third Party Agreements (i) solely to the extent such royalties are due in connection with the sale of Candidates or Products hereunder and (ii) provided that the [***] cap on royalties payable by Pfizer
to BioNTech set forth in Section 3.5.3(b)(y) shall not apply in respect of such reimbursement; and (c) agrees to comply with the terms of such Future BioNTech Third Party Agreement applicable to Pfizer as a sublicensee. BioNTech shall not
in any circumstance conclude any agreement with a Third Party so as to prevent Pfizer gaining access to such Third Party’s Intellectual Property Rights within the Field for any Candidate or Product. 

2.10. No Implied Rights. Except as expressly provided in this Agreement, neither Party will be deemed to have granted the other
Party (by implication, estoppel or otherwise) any right, title, license or other interest in or with respect to any Patent Rights, Know-How or other Intellectual Property Rights or information Controlled by
such Party. 

  
 22 

 2.10.1. Exclusivity. 

2.10.2. Except for the Research Program, during the Term, BioNTech shall not, and shall procure that its Affiliates shall not
Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized or otherwise Exploit or have Exploited any [***] itself or with or on behalf of a Third Party in the Field, except that BioNTech may continue any BioNTech
Third Party Agreement for non-clinical research in the Field with academic institutions and consortia. As of the Effective Date, BioNTech shall not (and shall procure that its Affiliates shall not) enter into
any new agreements with any Third Party in the Field without a discussion at and pre-approval by the JSC pursuant to Section 4.3. 

2.10.3. During the Research Term, Pfizer and its existing Affiliates shall not enter into any research collaboration or other
license agreement with [***] unless and until the JSC mutually agrees pursuant to Section 4.3. For avoidance of doubt, the foregoing exclusivity obligation shall not apply to any agreement with a Third Party possessing supplementary technology
to RNA that may enhance the efficiency of a Candidate or Product in the Field, including bioinformatics, automation, DNA synthesis, formulations, selection of epitopes, syringe or other delivery device companies, or the like. 

Notwithstanding the foregoing, if a Change of Control occurs with respect to Pfizer and a Third Party during the Research Term, or if Pfizer or
any of its existing Affiliates acquires or merges with a Third Party during the Research Term, and such Third Party is, at the time of such Change of Control or acquisition or merger, conducting activities that would cause Pfizer or one of its
Affiliates to violate this Section 2.10.3 (such activities, a “Acquisition Program”), then Pfizer or such Third Party shall be permitted to continue such Acquisition Program and such continuation will not constitute a violation of
this Section 2.10.3; provided that (a) no Confidential Information of BioNTech or its Affiliates is used in such Acquisition Program and (b) Pfizer shall implement and maintain, in accordance with Pfizer’s internal commercially
reasonable practices, an information barrier between the working teams involved in the day to day conduct of Pfizer’s internal program of Development and Manufacture of Candidates and Products under this Agreement and the equivalent teams under
such Acquisition Program. 
 2.11. Right of First Refusal. Commencing on the Effective Date and expiring on the [***] anniversary
thereof (“ROFR Term”), BioNTech on behalf of itself and its Affiliates hereby grants (and procures the grant to) Pfizer the exclusive right of first refusal (“Right of First Refusal”) to acquire a worldwide,
exclusive license, with the right to sublicense (through multiple tiers), under Intellectual Property Rights Controlled by BioNTech and its Affiliates to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have
Commercialized and otherwise Exploit immunogenic compositions comprising RNA that encodes at least one Antigen for prophylaxis against respiratory syncytial virus (“RSV”) or human cytomegalovirus (“hCMV”) in the
Territory (each a “Partnered Field” and collectively, the “Partnered Fields”) as follows: 

2.11.1. During the ROFR Term,BioNTech shall notify Pfizer in writing before it or any Affiliate enters into an agreement with a
Third Party in the Territory in one or both of the Partnered Fields. BioNTech’s writing shall identify the Partnered Field(s) and provide reasonable details of the terms of the proposed agreement with the Third Party, including the financial
terms, and a written report in reasonable detail of any of BioNTech’s and its Affiliates’ existing data that may be relevant to candidates/products in the Partnered Field( s) that Pfizer is otherwise unaware of

  
 23 

 
(“BioNTech ROFR Notice”), and, if Pfizer so requests, BioNTech shall provide access to the same set of data and information that such Third Party has had access via a data room
or other means. For avoidance of doubt, if BioNTech’s written notice applies to only one Partnering Field, then Pfizer’s Right of First Refusal for the other Partnering Field shall not be affected and continue to apply. 

2.11.2. Within [***] days after receiving a BioNTech ROFR Notice, Pfizer shall respond in writing as to whether Pfizer has a
good faith desire to obtain such rights on the same terms as set out in the BioNTech ROFR Notice. If Pfizer responds in the negative, or fails to respond within the [***] days, then Pfizer shall have no further rights under this Section 2.11 as
to the applicable Partnering Field(s), provided however, that under no circumstances may BioNTech nor its Affiliate during the ROFR Term enter into an agreement with a Third Party with respect to such Partnering Field(s) containing terms, taken as a
whole, that are more favorable to such Third Party than the terms and conditions set forth in the BioNTech ROFR Notice. 

2.11.3. If Pfizer responds in the affirmative within the [***] days, then this shall commence a [***] day period (“ROFR
Negotiation Period”) of good faith exclusive negotiations between the Parties acting reasonably as to the terms upon which BioNTech would partner with or license to Pfizer in the applicable Partnering Field(s) (“ROFR Partnering
Terms”). During the ROFR Negotiation Period, BioNTech shall not and shall procure its Affiliates shall not negotiate with any Third Party the terms upon which BioNTech or its Affiliates would partner with or license to such Third Party in
the Partnering Field(s). If the Parties are unable to agree on the ROFR Partnering Terms and conclude a respective definitive written agreement during the ROFR Negotiation Period, then Pfizer shall have no further rights under this Section 2.11
as to the Partnering Field(s), provided, however, that under no circumstances may BioNTech nor its Affiliates during the ROFR Term enter into an agreement with a Third Party with respect to such Partnering Field(s) containing terms, taken as a
whole, that are more favorable to such Third Party than the terms and conditions set forth in the BioNTech ROFR Notice. 

2.11.4. The ROFR excludes agreements for research in the Field with academic institutions and consortia, which are subject to
JSC approval under Section 4.3.2(d). 
 2.12. Right of First Negotiation. Effective as of the expiration of the ROFR Term and
terminating as of the expiration of the Research Term (“ROFN Term”), if BioNTech or its Affiliate elects to license or otherwise grant rights to a Third Party under Intellectual Property Rights Controlled by BioNTech or its
Affiliates in Partnering Field(s), then Pfizer shall have a right of first negotiation with respect to the first license or other partnership agreement for each of the Partnering Field(s) (“Right of First Negotiation”) as follows:

 2.12.1. During the ROFN Term, upon the request of the JSC, such request not to be made more than twice per Calendar Year,
BioNTech shall provide the JSC with an oral summary regarding any Development activities it may have conducted or is planning to conduct in respect of the Partnering Fields. During the ROFN Term, (a) if Pfizer provides BioNTech with a written notice
electing the Right of First Negotiation with respect to one or both Partnering Fields or (b) prior to BioNTech entering into bona fide negotiations with a Third Party with respect to the negotiation of a definitive legal agreement for a grant
of rights to Intellectual Property Rights Controlled by BioNTech and its Affiliates for the Partnering Field(s), BioNTech shall first notify Pfizer in writing. BioNTech’s written notice shall identify the Partnered Field(s) and provide a

  
 24 

 
written report in reasonable detail of any of BioNTech’s and its Affiliates’ existing data that may be relevant to candidates/products in the Partnered Field(s) that Pfizer is otherwise
unaware of (“BioNTech ROFN Notice”), and, if Pfizer so requests, provide access to any relevant data and information via a data room or by other mutually agreed upon means. For avoidance of doubt, if BioNTech’s written notice
applies to only one Partnering Field, then Pfizer’s Right of First Negotiation for the other Partnering Field shall not be affected and shall continue. 

2.12.2. Within [***] days after receiving a BioNTech ROFN Notice, Pfizer shall respond in writing as to whether Pfizer elects
to negotiate terms with BioNTech. If Pfizer responds in the negative, or fails to respond within the [***] days, then Pfizer shall have no further rights under this Section 2.13, as to the applicable Partnering Field(s). If Pfizer elects to
commence a ROFN or responds to a ROFN Notice in the affirmative within the [***] days, then this shall commence an exclusive [***] day negotiation period (“ROFN Negotiation Period”) during which the Parties shall negotiate, in good
faith and acting reasonably, a definitive written agreement between the Parties as to the terms upon which BioNTech and its Affiliates would partner with or license to Pfizer Intellectual Property Rights Controlled by BioNTech and its Affiliates for
the Partnering Field(s) (“ROFN Partnering Terms”). During the ROFN Negotiation Period, BioNTech shall not and shall procure its Affiliates shall not negotiate with any Third Party the terms upon which BioNTech or its Affiliates
would partner with or license to such Third Party Intellectual Property Rights Controlled by BioNTech and its Affiliates for the Partnering Field(s).If the Parties are unable to agree on the ROFN Partnering Terms and do not conclude a respective
definitive written agreement during the ROFN Negotiation Period, then the ROFN Negotiation Period shall expire and BioNTech shall be free to continue discussions with Pfizer or institute discussions on the same opportunity for the applicable
Partnering Field(s) with Third Parties. For clarity, the Right of First Negotiation set forth in this Section 2.12 shall apply a maximum of [***] times only; once for each of the RSV and hCMV fields. 

2.13. Access to Other BioNTech Technology. From time to time, Pfizer may, in addition to the licences granted hereunder, request a
license from BioNTech to Other BioNTech Technology for use in a Candidate or Product in the Field as Pfizer may identify, such license to be of comparable scope and comparable terms to the licenses granted under Sections 2.1 in respect of Candidates
and Products in the Field.For the purposes of this Agreement, “Other BioNTech Technology” means those Intellectual Property Rights Controlled by BioNTech or its Affiliates from time to time that do not constitute BioNTech Know-how or BioNTech Patent Rights.Upon Pfizer’s election for such as license, the Parties shall negotiate such license terms in good faith and acting reasonably (which shall be based on the terms of this
Agreement) for a period of not more than [***] days and BioNTech shall neither seek nor require any royalty rate or other financial provisions greater than (i) the mean royalty rate due to BioNTech by other licensees of the same Other BioNTech
Technology (reasonably adjusted in so far as it is licensed with other Intellectual Property Rights) in existence as of the date of any notice electing for such a licence pursuant to this Section or (ii) if no such other licenses are in
existence as of the date of such notice, the average royalty rate applied in comparable license agreements for similar technologies in the market.Any such license fees agreed pursuant to this Section shall be deemed license payments due under
Additional Third Party Licenses for the purposes of Section 3.5.3(a) and accordingly Pfizer shall be entitled to deduct [***] of such license fees. If, however, the Parties cannot reach an agreement within such [***] day period, then the terms
of such license for such Other BioNTech Technology shall be determined, taking into account all then-relevant factors including the provisions of this Section 2.13, by an independent Third Party expert knowledgeable in pharma licensing to be
agreed between the Parties (and if the Parties cannot agree on such Third Party expert within [***]days of the expiration of the above negotiation period, the Third Party expert shall be 

  
 25 

 
independently appointed upon either Party`s request by the International Chamber of Commerce). Each Party shall be obliged to submit its final proposal for the terms of such transition of or
license to the Other BioNTech Technology to the Third Party expert, and such proposal shall remain confidential and shall not be disclosed to the other Party. The decision of the Third Party expert shall be final and binding on both Parties. The
costs of the Third Party Expert shall be borne by both Parties at equal shares. 
  

	3.	 PAYMENTS BY PFIZER TO BIONTECH 

3.1. Up-Front Payment. Pfizer will make a one-time
payment of Fifty Million Dollars ($50,000,000) to BioNTech RNA within 30 days of receipt of BioNTech RNA’s invoice (such invoice to be delivered on or following the Effective Date of this Agreement). 

3.2. Equity Investment. Pfizer and BioNTech AG shall enter into an “Investment Agreement” contemporaneously with this Agreement
pursuant to which Pfizer shall agree to subscribe for shares in BioNTech AG subject to achievement of certain conditions as prescribed in such Investment Agreement. 

3.3. Development Payments. Pfizer will pay BioNTech RNA the one-off amounts set forth
below within 60 days following the first occurrence of each event described below for the first Candidate or Product (as applicable) Covered by a Valid Claim in the applicable country of Development or Commercialization in the Territory to achieve
such event (each, a “Development Payment”). 
  

					
	 	  	 Development Event
	  	 Development Payment

	(i)	  	Initiation of Manufacture of the CTM for such Candidate for the FIH Study (whereas “Initiation of Manufacture” shall mean the start of the Manufacturing of the first batch of CTM by BioNTech that is suitable for use in the
FIH Study)	  	[***]
			
	(ii)	  	Dosing of the first subject in the first FIH Study of such Candidate	  	[***]
			
	(iii)	  	Pfizer’s selection of such Candidate for further Development in a Phase I Clinical Trial (other than the FIH Study) or Phase II Clinical Trial including by selection as CAN based on Pfizer’s CAN Selection Criteria	  	[***]
			
	(iv)	  	Dosing of the first subject in the first Phase I or Phase I/II Clinical Trial (neither being the FIH Study) of a Product	  	[***]
			
	(v)	  	Initiation of Manufacture of the CTM that is suitable for a Product for a Phase III Clinical Trial by or on behalf of Pfizer following technology transfer (whereas “Initiation of Manufacture” shall mean the first
successful completion of the Manufacturing of an engineering run by or on behalf of Pfizer	  	[***]
			
	(vi)	  	Dosing of the first subject in the first Phase III Clinical Trial of such Product in a Major Market Country	  	[***]

  
 26 

					
	 	  	 Development Event
	  	 Development Payment

	(vii)	  	First Commercial Sale of such Product by Pfizer, its Affiliates or Sublicensees in the United States	  	[***]
			
	(viii)	  	First Commercial Sale of such Product by Pfizer, its Affiliates or Sublicensees in at least three of the Major EU Market Countries	  	[***]
			
	(ix)	  	First Commercial Sale of such Product by Pfizer, its Affiliates or Sublicensees in Japan	  	[***]

 Each of the Development Payments set forth above will be payable one time only (regardless of the number of Candidates or
Products with respect to which, or the number of times with respect to any Candidate or Product, the specified Development Event occurs). No Development Payments will be payable by Pfizer for any subsequent Candidate or Product regardless of the
number of Candidates or Products Developed. For clarification, if one Candidate or Product replaces another Candidate or Product in Development, then such replacement Candidate or Product will only be subject to Development Payments that have not
previously been triggered by one or more prior Candidates or Products. The maximum amount payable by Pfizer under this Agreement with respect to all Development Payments if all Development Events occur will be [***]. 

If Pfizer achieves one of the Development Events set forth in rows (iii), (iv) or (vi) of the table set forth in Section 3.3, but had not achieved
the preceding Development Event set forth (as applicable) in rows (iii) or (iv) of the table set forth in Section 3.3, then those preceding Development Event(s) set forth (as applicable) in rows (iii) or (iv) of the table set forth in
Section 3.3 shall be deemed to have occurred and all Development Payments for such preceding Development Event(s) shall become payable. If Pfizer achieves one of the Development Events set forth in rows (vii), (viii) or (ix) of the table
set forth in Section 3.3, but had not achieved any of Development Events set forth in rows (iii), (iv) or (vi) of the table set forth in Section 3.3, then those Development Event(s) set forth (as applicable) in rows (iii), (iv) or
(vi) of the table set forth in Section 3.3 shall be deemed to have occurred and all Development Payments for such Development Event(s) shall become payable. Notwithstanding the foregoing, Pfizer’s achievement of one of the Development
Events set forth in rows (iii), (iv), ( vi), (vii), (viii) or (ix) of the table set forth in Section 3.3 in response to a request by a Governmental Authority or Regulatory Authority to perform such Development Event due to pandemic flu
emergency conditions shall not trigger the payment of any preceding Development Event. 
 3.4. Sales Milestone Payments. Pfizer will
pay BioNTech RNA the following one-time payments (each, a “Sales Milestone Payment”) when aggregate Net Sales of all Products on which royalties have been paid to BioNTech under
Section 3.5.1 in a Pfizer Year in the Territory (the “Total Annual Net Sales”) first reach the respective thresholds indicated below: 

[***] 

  
 27 

 Pfizer will make any Sales Milestone Payment payable with respect to a Pfizer Year within [***] days after
the end of the applicable Pfizer Year, and such payment will be accompanied by a report identifying the Products, Net Sales of each Product (including breakdown of gross receipts and permitted deductions), and the amount payable to BioNTech under
this Section 3. 4. For the avoidance of doubt: (a) each of the Sales Milestone Payments set forth above will be payable one time only, regardless of the number of times the corresponding Total Annual Net Sales levels are achieved in any number
of Pfizer Years; and (b) if Total Annual Net Sales first reach multiple thresholds indicated above in the same Pfizer Year, all respective Sales Milestone Payments shall be payable with respect to that Pfizer Year and shall not be payable
again. 
 3.5. Royalty Payments. 

3.5.1. Royalties. Subject to the provisions of Section 3.5.3, Pfizer will pay BioNTech RNA royalties on a tiered
marginal royalty rate basis during the course of a Pfizer Year as set forth below (the “Marginal Royalty Rates”) based on the applicable royalty percentage calculated against the applicable proportion of the annual aggregate
Territory-wide Net Sales resulting from the sale of all Products in all countries in the Territory for which the applicable Royalty Term is in effect, during each Pfizer Year: 

[***] 
 Each Marginal Royalty Rate set forth in the table above
will apply only to that portion of the Net Sales of the Products in all countries in the Territory for which the applicable Royalty Term is in effect during a given Pfizer Year and that falls within the indicated range. An example calculation of
royalties under this Section 3.5.1 is set forth in Schedule 3.5.1. 
 3.5.2. Fully Paid-Up, Royalty Free License. Following expiration of the Royalty Term for any Product in a given country, no further royalties will be payable in respect of sales of such Product in such country and,
thereafter the licenses granted to Pfizer under Sections 2.1, 2.2, 2.3.1 and 2.7 with respect to such Product in such country will automatically become exclusive, fully paid-up, perpetual, irrevocable and
royalty-free. 
 3.5.3. Royalty Adjustments. The following adjustments will be made, on a Product-by-Product and country-by-country basis, to the royalties payable pursuant to
Section 3.5.1: 
 (a) Third Party Patents. If it is Necessary or Useful for Pfizer to license one or more Patent
Rights from one or more Third Parties in respect of the Development, Manufacture, Commercialization, Exploitation or use of any Product in any country, whether directly or through any Pfizer Affiliate or Sublicensee, then Pfizer may, in its
reasonable discretion, negotiate and obtain a license under such Patent Right(s) (each such Third Party license referred to herein as an “Additional Third Party License”). Any royalty otherwise payable to BioNTech under this
Agreement with respect to Net Sales of such Product in such country by Pfizer, its Affiliates or Sublicensees will be [***] For the avoidance of doubt, this Section 3.5.3(a) shall not apply to any direct licenses entered into

  
 28 

 
by Pfizer with a Current Licensor in accordance with Section 2. 8. 4. For the purposes of this Section 3.5.3(a): ( i) “Necessary” means that, without a license to use
the Patent Right in question, the Development, Manufacture, Commercialization or use of any Candidate or Product, in Pfizer’s opinion, infringes such Patent Right and (ii) “Useful” means that Pfizer has determined that such
Third Party’s Patent Right would reasonably enhance the potential, including by reducing cost or complexity of Manufacture, of such Licensed Product.

(b) No Adjustment for BioNTech Third Party Agreements. Subject to Section 2.9, BioNTech will be solely responsible for
(i) all obligations (including any royalty or other obligations that relate to the BioNTech Technology or BioNTech’s interest in the Research Program Technology) under its agreements with Third Parties that are in effect as of the
Effective Date or that BioNTech enters into during the Term and (ii) all payments to inventors (other than inventors that are Representatives of Pfizer) of BioNTech Technology or Research Program Technology, including payments under
inventorship compensation Laws, except that Pfizer will [***] (x) solely to the extent such royalties are due in connection with the sale of Candidates or Products hereunder and (y) provided that, notwithstanding anything in the Agreement to
the contrary, [***]. 
 (c) Expiry of Valid Claim Coverage. In the event that, with respect to any particular Product
in any particular country in the Territory, the Royalty Term for such Product in such country extends beyond the date on which such Product is not Covered by any Valid Claim in such country, Net Sales in any such country shall be reduced by [***]
for the remainder of the applicable Royalty Term, provided, however, that if this Section 3.5.3(c) applies to a Product, Pfizer may not also apply Section 3.5.3(e). 

(d) Existing Pfizer Third Party Agreements. Pfizer will be solely responsible for all obligations (including royalty
obligations) that relate to Products under its agreements with Third Parties that are in effect on or prior to the Effective Date. 

(e) Biosimilar Entry. Notwithstanding the foregoing, for any royalty otherwise payable to BioNTech under this Agreement
with respect to Net Sales based on sales of a Product in a given country in the Territory, any payments owed with respect to such Product in such country pursuant to this Section 3.5 [***]. 

(f) Royalty Floor. Notwithstanding the provisions of this Section 3.5.3, the maximum reduction of royalties [***].

 3.6. Reports and Payments. 

3.6.1. Cumulative Royalties. The obligation to pay royalties under this Agreement will be imposed only once with respect
to any sale of any Product. 
 3.6.2. Single Payee. All payments due and payable by Pfizer or its Affiliates or
sublicenses under this Section 3 shall be solely made to BioNTech RNA in full satisfaction of all consideration due hereunder in exchange for the rights granted by BioNTech. 

  
 29 

 3.6.3. Royalty Statements and Payments. Within [***] days of the end
of each Calendar Quarter, Pfizer will deliver to BioNTech a report setting forth, for the most recent Pfizer Quarter ending during such Calendar Quarter, the following information, on a
country-by-country and Territory-wide basis: [***]. No such reports will be due for any such Product (i) before the First Commercial Sale of such Product or
(ii) after the Royalty Term for such Product has expired in all countries in the Territory. The total royalty due for the sale of all such Products during such Pfizer Quarter will be remitted at the time such report is made; provided
that to the extent any royalties are payable by Pfizer hereunder on Net Sales of a Product in a country solely due to a Valid Claim Covering such Product in such country that is subject to a revocation, invalidity or unenforceability ruling that
is appealable or being appealed, during the time of such appeal or appealability, such royalties payable by Pfizer shall be placed into an escrow account and either (x) returned to Pfizer upon a final, unappealable determination that such
revocation, invalidity or unenforceability ruling is upheld or (y) released to BioNTech in the event such revocation, invalidity or unenforceability ruling is not upheld in a final, unappealable determination. In the event that BioNTech
disagrees with the basis of Pfizer’s calculations of royalties due because BioNTech believes that a Valid Claim Covering a Product was incorrectly omitted from Pfizer’s royalty calculations, BioNTech shall notify Pfizer within [***] days
of receipt of the relevant royalty statement. 
 3.6.4. Taxes and Withholding. 

(a) Withholding Taxes. The Parties agree to use commercially reasonable efforts to cooperate with one another and use
commercially reasonable efforts to avoid or reduce, to the extent permitted by applicable Law, tax withholding or similar obligations in respect of royalties, milestone payments, and other payments made by the paying Party to the receiving Party
under this Agreement (“Withholding Taxes”). If Withholding Taxes are imposed on any payment under this Agreement, the liability for such Withholding Taxes shall be the sole responsibility of the receiving Party, and the paying Party
shall (i) deduct or withhold such Withholding Taxes from the payment made to the receiving Party, (ii) timely pay such Withholding Taxes to the proper taxing authority, and (iii) send proof of payment to the receiving Party within
[***] days following such payment. Each Party shall comply with (or provide the other Party with) any certification, identification or other reporting requirements that may be reasonably necessary in order for the paying Party to not withhold
Withholding Taxes or to withhold Withholding Taxes at a reduced rate under an applicable bilateral income tax treaty. Each Party shall provide the other with commercially reasonable assistance to enable the recovery, as permitted by applicable Law,
of Withholding Taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing the cost of such Withholding Taxes under this Section 3.6.4 (Taxes and Withholding).
Notwithstanding the foregoing, if as a result of any assignment or sublicense by the paying Party, any change in the paying Party’s tax residency, any change in the entity that originates the payment, or any failure on the part of the paying
Party to comply with applicable Law with respect to Withholding Taxes (including filing or record retention requirements), Withholding Taxes are imposed that would not otherwise have been imposed (“Incremental Withholding Taxes”),
then the paying Party shall be solely responsible for the amount of such Incremental Withholding Taxes and shall increase the amounts payable to the receiving Party so that the receiving Party receives a sum equal to the sum which it would have
received had there been no such imposition of Incremental Withholding Taxes. 

  
 30 

 (b) Value Added Tax. All payments between the Parties under this
Agreement are exclusive of applicable statutory value added tax or similar taxes (“VAT”), if any, which shall be listed separately on each invoice. If and to the extent any VAT will become payable due to any supplies or services
rendered under this Agreement and if and to the extent such VAT is to be paid by the Party providing the supply or service to the competent tax authorities, the receiving Party shall pay an amount equal to such VAT to the providing Party upon
receipt of a valid invoice allowing for the recovery of such VAT. 
 3.6.5. Currency, Source of Payments. All amounts
payable and calculations under this Agreement will be in United States dollars, and Pfizer agrees to make all payments from a source in the United States of America. As applicable, Net Sales and any royalty deductions will be translated into United
States dollars at the exchange rate used by Pfizer for public financial accounting purposes. If, due to restrictions or prohibitions imposed by national or international authority, a given payment cannot be made as provided in this
Section 3.6.5, the Parties will consult with a view to finding a prompt and acceptable solution. If the Parties are unable to identify a mutually acceptable solution regarding such payment, then Pfizer may elect, in its sole discretion, to
deliver such payment in the relevant jurisdiction and in the local currency of the relevant jurisdiction. 
 3.6.6. Method
of Payment. Except as permitted pursuant to Section 3.6.5, each payment hereunder will be made by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other
means of electronic funds transfer, at Pfizer’s election, to such bank account set forth below or as BioNTech RNA will designate in writing to Pfizer at least [***] days before the payment is due. All invoice or billing related questions should
be referred to Pfizer’s Accounting Department at 800.601.1357 or go to the Accounts Payable Invoice Portal at ap.pfizer.com. 

[***] 

3.6.7. Record Keeping. Pfizer will keep and will cause its Affiliates and use Commercially Reasonable Efforts to cause
its Sublicensees to keep books and accounts of record in connection with the sale of Products in sufficient detail to permit accurate determination of all figures necessary for verification of royalties and Sales Milestone Payments to be paid
hereunder. Pfizer and its Affiliates will maintain, and Pfizer shall use Commercially Reasonable Efforts to cause its Sublicensees to maintain, such records for a period of at least [***] years, or such longer period of time required under a Current
License, insofar as applicable to the rights sub-licensed pursuant to such Current License and used by Pfizer, its Affiliates and Sublicensees, after the end of the Pfizer Quarter in which they were generated.

 3.6.8. Audits. Upon [***] days prior notice from BioNTech, Pfizer will permit (and shall use Commercially
Reasonable Efforts to cause its Sublicensees to permit) an independent certified public accounting firm of nationally recognized standing selected by BioNTech and reasonably acceptable to Pfizer, to examine, at BioNTech’s sole expense, the
relevant books and records of Pfizer and its Affiliates (and where possible, its Sublicensees) as may be reasonably necessary to verify the amounts reported by Pfizer in accordance with Section 3.6.3 and the payment of royalties and Sales
Milestone Payments hereunder. An examination by BioNTech under this Section 3.6.8 will occur not more than once in any Calendar Year and will be limited to the pertinent books and records for any Calendar Year ending not more than [***] years
before the date of the request. The 

  
 31 

 
accounting firm will be provided access to such books and records at Pfizer’s or its Affiliates’ (or where possible its Sublicensees’) facility(ies) where such books and records
are normally kept and such examination will be conducted during Pfizer’s or its Affiliates’ (or, where possible, its Sublicencees’) normal business hours. Pfizer may require the accounting firm to sign a reasonably acceptable non-disclosure agreement before providing the accounting firm with access to Pfizer’s or its Affiliates’ (or where possible its Sublicensees’) facilities or records. Upon completion of the audit, the
accounting firm will provide both Pfizer and BioNTech the same written report disclosing any discrepancies in the reports submitted by Pfizer or the royalties or Sales Milestone Payments paid by Pfizer, and, in each case, the specific details
concerning any discrepancies. No other information will be provided to BioNTech. Where Pfizer is not able to cause its Sublicensees to permit an audit according to this Section 3.6.8 (despite using Commercially Reasonable Efforts), Pfizer shall on
BioNTech’s request exercise its own audit rights under the relevant sublicense agreement; provided, however, that (a) BioNTech shall not request such audit exercise more than once in a Calendar Year, (b) the audit shall be limited
to the pertinent books and records for any Calendar Year ending not more than [***] years before the date of the request and (c) if the amount of any underpayment of royalties by any such Sublicensee is less than [***] of the royalties properly
payable to BioNTech, then BioNTech shall reimburse Pfizer for Pfizer’s out-of-pocket costs in connection with the audit. 

3.6.9. Underpayments/Overpayments. If such accounting firm concludes that additional royalties or Sales Milestone
Payments were due to BioNTech, then Pfizer will pay to BioNTech the additional royalties or Sales Milestone Payments within [***] days of the date Pfizer receives such accountant’s written report. Further, if the amount of such underpayments
exceeds more than [***] of the amount that was properly payable to BioNTech, then Pfizer will reimburse BioNTech for BioNTech’s out-of-pocket costs in connection
with the audit. If such accounting firm concludes that Pfizer overpaid royalties or Sales Milestone Payments to BioNTech, then BioNTech will refund such overpayments to Pfizer, within [***] days of the date BioNTech receives such accountant’s
report. 
 3.6.10. Confidentiality. Notwithstanding any provision of this Agreement to the contrary, all reports and
financial information of Pfizer, its Affiliates or its Sublicensees which are provided to or subject to review by BioNTech will be deemed to be Pfizer’s Confidential Information and subject to the provisions of Section 8. 

3.7. No Guarantee of Success. 

3.7.1. Pfizer and BioNTech acknowledge and agree that payments to BioNTech pursuant to Section 3.3, Section 3.4 and
Section 3.5: (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if a certain Product is successfully Developed or Commercialized in such country, as applicable; (b) are solely intended to
allocate amounts that may be achieved upon successful Development or Commercialization of such Product as applicable, between Pfizer (who will receive all Product sales revenues) and BioNTech; (c) are not intended to be used as a measure of
damages if this Agreement is terminated for any reason, including pursuant to Pfizer’s right to terminate for convenience, before any such success is achieved and such amounts become due; and (d) will only be triggered, and will only be
relevant as provided, in accordance with the terms and conditions of such provisions. 

  
 32 

 3.7.2. Pfizer and BioNTech further acknowledge and agree that nothing in
this Agreement, or in any document or presentation provided by Pfizer to BioNTech prior to the Effective Date will be construed as representing any estimate or projection of (i) the successful Development or Commercialization of any Product
under this Agreement, (ii) the number of Products that will or may be successfully Developed or Commercialized under this Agreement, (iii) anticipated sales or the actual value of any Products that may be successfully Developed or
Commercialized under this Agreement or (iv) the damages, if any, that may be payable if this Agreement is terminated for any reason. 

3.7.3. Pfizer makes no representation, warranty or covenant, either express or implied, that (A) it will successfully
Develop, Manufacture, Commercialize or continue to Develop, Manufacture or Commercialize any Product in any country, (B) if Commercialized, that any Product will achieve any particular sales level, whether in any individual country or
cumulatively throughout the Territory or (C) Pfizer will devote, or cause to be devoted, any level of diligence or resources to Developing or Commercializing any Product in any country, or in the Territory in general, other than is expressly
required under Section 6.2. 
  

	4.	 RESEARCH PLAN 

4.1. Scope of Research and Research Plan. Pfizer and BioNTech will collaborate during the Research Term to conduct research to identify,
Develop and evaluate Candidates and Products in accordance with the Research Plan and the terms and conditions set forth in this Section 4. Pfizer reserves the right to modify the Research Plan, in its sole discretion, at any time during the
Research Term; provided that any such changes shall be approved by JSC pursuant to Section 4.3. 
 4.2. Allocation of
Responsibilities. 
 4.2.1. General. Each Party will use Commercially Reasonable Efforts to perform its
obligations and activities identified under the Research Plan in a professional manner in accordance with target dates set forth in Research Plan. Further, each Party will perform its obligations under the Research Plan in compliance with all Laws
applicable to its activities under the Research Plan. 
 4.2.2. Subcontractors. BioNTech will not subcontract any of
its responsibilities under the Research Plan or otherwise under this Agreement without Pfizer’s prior written consent; provided that (a) any Affiliates of BioNTech, (b) any subcontractors expressly identified in the Research
Plan to conduct specific activities thereunder and (c) those subcontractors set forth on Schedule 4.2.2 (“Approved Subcontractors”) shall be deemed to have received such consent from Pfizer. BioNTech shall be responsible
for the management of all permitted subcontractors (which will include any BioNTech Affiliate). The engagement by BioNTech or its Affiliate of any subcontractor in compliance with this Section 4.2.2, including the Approved Subcontractors, shall
be in writing and shall not relieve BioNTech of its obligations under this Agreement or the Research Plan. Any agreement between BioNTech or its Affiliate and a permitted subcontractor or Approved Subcontractor pertaining to the Research Plan
activities shall be consistent with the provisions of this Agreement including (i) an obligation to assign all Intellectual Property rights generated during its performance of such Research Plan to BioNTech free of any encumbrance such that
BioNTech may fulfil its licensing and assignment obligations hereunder and (ii) terms and conditions under which such Third Party is obligated to preserve the confidentiality of the Research Program, Research Program Technology and any
Confidential Information of Pfizer received by such Third Party from the BioNTech that are at least as restrictive as those described in Section 8.2.1. 

  
 33 

 4.2.3. Personnel Matters. Each Party acknowledges and agrees that it
is solely responsible for the compensation of its personnel assigned to the Research Plan, and shall be responsible for withholding all national, state, local or other applicable taxes and similar items for such personnel. Each Party also shall be
responsible for all other of its employer related obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each of its employees. BioNTech
personnel assigned to the Research Plan activities are not nor shall they be deemed to be employees of Pfizer, and Pfizer personnel assigned to the Research Plan activities are not nor shall they be deemed to be employees of BioNTech. 

4.2.4. BioNTech Disclosure and Knowledge Transfer Obligations. Without limiting BioNTech’s obligations pursuant to
Section 4.2.1, during the Research Term, BioNTech will: 
 (a) disclose to Pfizer all newly developed RNA Technology and
RNA Process Technology and all other newly generated data developed in connection with the Research Plan, in each case in such format as Pfizer may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by Pfizer); 
 (b) upon Pfizer’s request, disclose
and provide to Pfizer research grade samples of each Candidate identified by BioNTech as a potential development candidate within a commercially reasonable period not to exceed [***] days; 

(c) provide to Pfizer a written summary of all activities, discoveries, developments and results attained by BioNTech under the
Research Plan in the regular course of research and no less frequently than every [***] days; 
 (d) promptly notify Pfizer
of any suspected or actual research misconduct, issues pertaining to data integrity or any other information that could reasonably signify or result in a lack of confidence in the accuracy or collection methods of data, each as such may relate to
the activities being conducted under the Research Plan; 
 (e) in accordance with the Product Technology Transfer Plan agreed
upon by the JSC pursuant to Section 4.3.2(d)(x), or earlier upon request by Pfizer in the event that BioNTech commits a material breach of any of its obligations under this Agreement and such material breach remains uncured for [***] Business
Days, measured from the date written notice of such material breach is given to BioNTech, transfer the Candidates or Products requested by Pfizer and all BioNTech Know-How relating to such Candidates or
Products 

  
 34 

 4.3. Research Governance. 

4.3.1. Collaboration Management. 

(a) Program Directors. Each Party will appoint a program director to oversee all activities conducted under the Research
Plan (each, a “Program Director” and together the “Program Directors”). Each Party may change its designated Program Director at any time upon written notice to the other Party. The Program Directors will coordinate
the efforts of their respective Party in conducting activities under the Research Plan. The Program Directors for Pfizer and BioNTech are Philip Dormitzer and Birgit Pless, respectively. 

4.3.2. Joint Steering Committee. 

(a) Composition. As of the Effective Date, the Parties will establish a Joint Steering Committee, comprised of at least
two (2) representatives of BioNTech (including the Program Director for BioNTech) and at least two (2) representatives of Pfizer (including the Program Director for Pfizer). The JSC representatives for each of Pfizer and BioNTech will be
referred to herein as the “Pfizer JSC Members” and the “BioNTech JSC Members,” respectively. As of the Effective Date, the Pfizer JSC Members shall be (1) [***] and (2) [***] and the BioNTech JSC Members shall be
(1) [***] and (2) [***]. 
 Each Party may replace its representatives to the JSC at any time upon notice to the other Party, provided
that at all times an equal number of representatives from each Party are appointed to the JSC and each Party shall be responsible for ensuring any replaced representative is fully briefed and apprised of the Research Project. Each Party shall
procure that its JSC representatives shall make themselves available to attend JSC meetings upon reasonable notice and in accordance with this Agreement. Each Party may invite non-voting employees and
consultants to attend meetings of the JSC. All members of the JSC and any invitees of either Party described above will agree in writing to be bound to obligations of confidentiality and assignment of Intellectual Property Rights no less restrictive
than those that bind the Parties under this Agreement. 
 (b) Committee Chair. The JSC will be chaired by a Pfizer JSC
Member (the “JSC Chair”). Pfizer may replace the JSC Chair at any time upon notice to BioNTech. The responsibilities of the JSC Chair will be: 

(i) to notify each Party at least 30 days in advance of each JSC meeting; 

(ii) to collect and organize agenda items for each JSC meeting; and 

(iii) to prepare the written minutes of each JSC meeting and circulate such minutes for review and approval by the Parties,
and identify action items to be carried out by the Parties. 
 (c) Meetings. During the Research Term, the JSC will
meet on a Calendar Quarter basis (or less or more frequently as the JSC so determines), either in-person or by audio or video teleconference. Meetings of the JSC will occur at such times and places as mutually
agreed by the Parties; provided, however, that no more than two (2) in-person meetings will be required in any Calendar Year. Any sub-committees or working groups
established in accordance with Section 4.3.2(d) may meet via audio or video teleconference on a regular basis and in-person at such times and places as the Parties may agree. Meetings of the JSC will only
occur if at least one representative of each Party is present at the 

  
 35 

 
meeting or participating by teleconference or videoconference. Each Party will be responsible for, and will not be entitled to any reimbursement from the other Party with respect to, any and all
personnel costs or expenses (including travel expenses) which are incurred by or on behalf of its personnel in connection with participation in any JSC meetings or sub-committee or working group meetings, or
any other travel required to be undertaken by either Party’s personnel in connection with the performance of the Agreement. The Parties will endeavor to schedule meetings of the JSC at least [***] months in advance. The JSC Chair will use good
faith efforts to (i) prepare and circulate to BioNTech each JSC meeting agenda no later than five Business Days prior to the scheduled date for each JSC meeting and (ii) circulate for review and approval by BioNTech written minutes of each
JSC meeting within [***] days after such meeting. The Parties will agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JSC. 

(d) Responsibilities. The JSC will coordinate and provide operational and strategic oversight of the activities to be
performed under the Research Plan by each Party and, within such scope will: 
 (i) monitor and assess the progress of
activities under the Research Plan; 
 (ii) determine whether to initiate GLP toxicology studies for any Candidate prior to
the FIH Study; 
 (iii) select the Candidates or Products that will be studied in the FIH Study on a schedule that takes
into account BioNTech’s manufacturing schedule capacity; 
 (iv) determine the design of the FIH Study, including the
protocol governing the FIH Study; 
 (v) revise and approve any revisions of the Research Plan, except that (i) any
modification to the Research Plan that would result in an increase in more than [***] by BioNTech ([***]) (ii) any decision who will bear the costs which exceed [***] and (iii) subject to Section 2.13, any revision to the Research Plan
that would require BioNTech to use, disclose or license any Other BioNTech Technology, would require the JSC’s unanimous vote, provided that if BioNTech’s Representatives withhold their consent, the fact that BioNTech has refused
(in whole or part) to participate in additional or revised Development or Manufacturing activities, or to share in the respective costs, or to use, disclose or license such Other BioNTech Technology, as applicable, shall be a factor considered in
determining whether Pfizer has exercised its Commercially Reasonable Efforts under this Agreement; 
 (vi) assess and
discuss any future agreement between BioNTech and a Third Party involving the use or application of the RNA Technology in the Field or any future agreement between Pfizer and a Third Party for the research or development of Core RNA Technology in
the Field during the Research Term, in each case which would require a unanimous vote of the JSC; 

  
 36 

 (vii) discuss any Intellectual Property Rights of a Third Party which may
be relevant to Candidates and Products that are brought to the JSC pursuant to Section 2.9; 
 (viii) oversee the
Development of Manufacturing processes relating to the Candidates or Products; any decisions relating to such Development shall require a unanimous vote; 

(ix) form such other committees and sub-committees as the JSC may deem appropriate,
provided that such committees and sub-committees may make recommendations to the JSC but may not be delegated JSC decision-making authority; 

(x) develop a plan, upon Pfizer’s written request and not later than [***] days prior to completion of the FIH Study to
transfer and oversee the transfer of BioNTech Know-How to Pfizer to enable the rights licensed to Pfizer in Sections 2.1 and 2.3.1 which shall set out at minimum the responsibilities of each Party in
connection with the transfer, deliverables and estimated timelines and budgets (“Product Technology Transfer Plan”); 

(xi) address such other matters relating to the activities of the Parties under the Research Plan as either Party may bring
before the JSC, including any matters that are expressly for the JSC to decide as provided in this Agreement; and 
 (xii)
attempt to resolve any disputes between the Parties with respect to (i) the performance of activities under the Research Plan on an informal basis or (ii) matters before the Patent Committee, in each case subject to Section 4.3.2(e).

 (e) Decision-making. Notwithstanding the number of Pfizer JSC Members or BioNTech JSC Members, each Party will have
one (1) vote, and the JSC will make decisions on a unanimous basis. The JSC will use good faith efforts to reach agreement on any and all matters properly brought before it. If, despite such good faith efforts, the JSC is unable to reach
unanimous agreement on a particular matter, within [***] days after the JSC first meets to consider such matter, or such later date as may be mutually acceptable to the Parties (each such matter, a “Disputed Matter”), then either
Party may refer that Disputed Matter for resolution by the appropriate senior officer of each Party, and such senior officers will promptly initiate discussions in good faith to resolve such Disputed Matter. If the senior officers of each Party are
unable to resolve the Disputed Matter within [***] days of it being referred to them, then Pfizer will have final decision-making authority with respect to all Disputed Matters, subject only to specific issues identified in this Agreement as
expressly requiring mutual consent or unanimous vote of the Parties. 
 (f) Limits on JSC Authority. Notwithstanding
any provision of this Section 4.3 to the contrary, (i) each Party will retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in the JSC unless
such delegation or vesting of rights is expressly provided for in 

  
 37 

 
this Agreement or the Parties expressly so agree in writing, (ii) the JSC will not have the power to amend this Agreement or otherwise modify or waive compliance with this Agreement in any
manner and (iii) neither Party will require the other Party to (A) breach any obligation or agreement that such other Party may have with or to a Third Party to the extent such obligation or agreement existed prior to the Execution Date or
(B) perform any activities that are materially different or greater in scope or more costly than those provided for in the Research Plan then in effect. 

(g) JSC Term. The JSC will be dissolved immediately upon the later of the expiration of the Research Term or the
completion of the Manufacturing technology transfer described in Section 5.4. 
 4.4. Research Term Extension. During the
Research Term, to the extent the completion of the activities or deliverables set forth in the Research Plan in accordance with the specifications set forth for such activities or deliverables in the Research Plan is delayed as a consequence of
BioNTech’s material breach of its obligations under the Research Plan notified by Pfizer to BioNTech in writing, then the Research Term shall be automatically extended by a reasonable amount of time corresponding to the amount of time between
the time predicted for completion of such activity in the Research Plan and actual time the activity is completed. In addition, Pfizer may in its sole discretion extend the Research Term at its option by (a) up to [***] days or (b) until the
[***] of the initial Research Term. The extension option pursuant to (a) above must be exercised by providing notice to BioNTech no later than on the last JSC meeting before the end of the initial Research term. The extension option pursuant
(b) above must be exercised by providing notice to BioNTech no later than on the last JSC meeting before the end of the initial Research term or, if the option according to (a) has already been exercised, no later than [***] days after the
end of the initial Research Term. [***] 
 4.5. Research Plan Expenses. Except as expressly set forth otherwise in this
Agreement (including in Section 4.3.2(d)(v), each Party will bear all costs and expenses it incurs in connection with its activities under the Research Plan. 

4.6. Materials and Permitted Activities. 

4.6.1. Transfer. From time to time during the Research Term, Pfizer shall provide BioNTech with tangible chemical or
biological materials (the “Pfizer Materials”) as set forth in the Research Plan or as otherwise mutually agreed between the Parties (if any). Pfizer represents and warrants to BioNTech as of the date of delivery of the Pfizer
Material (i) to Pfizer’s knowledge, Pfizer has the right to provide the Pfizer Materials to BioNTech for the uses in accordance with the Research Plan, (ii) the Pfizer Materials comply with any requirements set forth in the Research Plan
or otherwise mutually agreed between the Parties (if any) in writing and (iii) to Pfizer’s knowledge, the use of the Pfizer Materials authorized herein does not infringe any Third Party rights. Except as expressly set forth in the preceding
sentence, the Pfizer Materials are provided by Pfizer on an “as-is” basis without any representation or warranty of any type, express or implied, including any representation or warranty of
merchantability or fitness for a particular purpose, each of which is hereby expressly disclaimed by Pfizer. 
 4.6.2.
Title to Pfizer Materials and BioNTech Materials. All right, title and interest in and to the Pfizer Materials (including any modifications or progeny thereof) will remain the sole and exclusive property of Pfizer notwithstanding the transfer
to and use by BioNTech of the same. All right, title and interest in and to the BioNTech Materials will remain the sole and exclusive property of BioNTech notwithstanding the transfer to and use by Pfizer of the same. 

  
 38 

 4.6.3. Permitted Activities. Notwithstanding anything to the contrary
in this Agreement save for BioNTech’s exclusivity obligations and restrictions (including those at Section 2.1 and 2.10.2) and Pfizer’s exclusivity obligations and restrictions (including those at Section 2.10.3, nothing in this
Agreement shall be deemed to prevent or restrict in any way the ability of either Party or its Affiliates to conduct any activities in the Territory, which activities would be allowed under any safe harbor, research exemption, government or
executive declaration of urgent public health need, or similar right available in law or equity if conducted by a Third Party. 

4.6.4. Return of Proprietary Materials. Upon termination or expiration of the Research Term, BioNTech shall, at
Pfizer’s option, either destroy or return to Pfizer all unused Pfizer Materials. 
  

	5.	 MANUFACTURING AND SUPPLY 

5.1. Development of Manufacture Process. Beginning on the Effective Date of the Agreement and throughout the Research Term (including
any extension pursuant to Section 4.4), BioNTech and Pfizer shall jointly Develop a scalable process for Manufacture of Candidates and Products in the Field. Should Pfizer request any assistance from BioNTech to Develop (or continue to Develop)
a scalable process for Manufacture of the Candidates and Products in the Field after the Research Term (including any extension pursuant to Section 4.4), BioNTech shall provide such assistance after such Research Term at an hourly rate of [***]
for its support and efforts in connection with such Development. Such payments shall be governed by the terms of Section 3.6 and BioNTech shall be required to keep, and provide to Pfizer, detailed reports and timesheets for those personnel
involved. 
 5.2. Manufacture of CTM for FIH Study. BioNTech shall Manufacture, at its cost, all CTM for the Candidates or Products
that are the subject of the FIH Study described in the Research Plan. 
 5.3. Supply of CTM to Pfizer. BioNTech shall supply Pfizer
with CTM for the Products it studies in any Phase I Clinical Trial and Phase II Clinical Trial. Without prejudice to that obligation, the Parties shall negotiate in good faith and acting reasonably a mutually agreed upon Quality Agreement and Supply
Agreement which shall be executed on or before [***]; such Supply Agreement shall be consistent with the heads of terms set forth in Schedule 5.3. Pfizer’s schedule for Clinical Trials would take into account the Manufacturing capacity
available at BioNTech and the Parties would agree on a [***] month Manufacturing capacity plan for Clinical Trial batches no later than [***] months in advance of any delivery date for such batch. If Pfizer so requests during the term of such Supply
Agreement, Pfizer and BioNTech shall discuss an extension of such Supply Agreement at an appropriate time and negotiate in good faith if Pfizer requires a bridge to Pfizer for CTM for Pfizer’s Phase III Clinical Trials or for Pfizer’s
commercial supply. 
 5.4. Technology Transfer of Manufacturing Process. BioNTech will provide Pfizer with all reasonable assistance
necessary or useful to effect the timely and orderly transfer of the process for Manufacturing Products in the Field to enable Pfizer or Pfizer’s named contract manufacturing organization (“CMO”) to successfully Manufacture
such Products on Pfizer’s behalf. Without limiting BioNTech’s obligations set forth elsewhere under this Agreement, the Parties will use their Commercially Reasonable Efforts to perform all technology transfer activities as set forth under
the initial Manufacturing technology 

  
 39 

 
transfer plan set forth in Exhibit D (the “Manufacturing Technology Transfer Plan”). BioNTech will cause all technology transfer activities to be performed under the
Manufacturing Technology Transfer Plan to be carried out by the specific individuals identified to perform such activities in the Manufacturing Technology Transfer Plan (if any) and otherwise by appropriately skilled and experienced individuals
familiar with the Manufacture of such Products. Such Manufacturing Technology Transfer Plan will be updated by the JSC no later than [***] months after the Effective Date. In case of a technology transfer to a CMO, technology transfer shall only be
initiated if and when: (a) such CMO has entered into confidentiality undertakings in respect of BioNTech Technology, Research Program Technology and Confidential Information of BioNTech or its Representatives on customary terms comparable to
and no less restrictive than those that bind the Parties under this Agreement either (i) directly with BioNTech or (ii) with Pfizer but including BioNTech as third party beneficiary, and (b) BioNTech has been provided with a copy of
such confidentiality undertakings. For clarity, such CMO would not have the right to use any BioNTech Technology, Research Program Technology or Confidential Information of BioNTech or its Representatives licensed to and transferred to Pfizer or the
CMO for any purpose other than the Manufacture of Products in the Field on Pfizer’s behalf. 
 5.5. Transfer Activities and
Consulting Support. In addition to the support provided under the Manufacturing Technology Transfer Plan and the Product Technology Transfer Plan,BioNTech will provide Pfizer with up to [***] hours of FTE support reasonably requested by Pfizer
and associated with Pfizer’s Development, Manufacture or Commercialization of the Candidates and Products. Pfizer will pay BioNTech [***] for each FTE. Such payments shall be governed by the terms of Section 3.6 and BioNTech shall be
required to keep, and provide to Pfizer, detailed reports and timesheets for those personnel involved. Any Intellectual Property Rights generated pursuant to services under this Section shall be deemed work product from a work for hire arrangement
and shall be owned by Pfizer. 
  

	6.	 PRODUCT DEVELOPMENT AND COMMERCIALIZATION 

6.1. General. Subject to the provisions of Sections 4.2, 4.3, 5.2, 5.3 and 6.2, Pfizer will have sole authority over and control of the
Development, Manufacture, Regulatory Approval and Commercialization of Candidates and Products and will retain final decision-making authority with respect thereto. 

6.2. Diligence. 

6.2.1. Development Diligence. Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory
Approval for one Product in the Field in [***]. Pfizer will have no other diligence obligations with respect to the Development or Regulatory Approval of Products under this Agreement. 

6.2.2. Commercial Diligence. Pfizer will use its Commercially Reasonable Efforts to Commercialize a given Product in the
Field in each Major Market Country in the Territory where Pfizer or its designated Affiliates or Sublicensees has received Regulatory Approval for such Product. Pfizer will have no other diligence obligations with respect to the Commercialization of
Products under this Agreement. 

  
 40 

 6.2.3. Exceptions to Diligence Obligations. Notwithstanding any
provision of this Agreement to the contrary, Pfizer will be relieved from and will have no obligation to undertake any efforts with respect to any diligence obligation under Section 6.2.1 or Section 6.2.2 with respect to a given Candidate
or Product in the event that: 
 (a) Pfizer or BioNTech receives or generates any safety, tolerability or other data
reasonably indicating or signaling, as measured by Pfizer’s safety and efficacy evaluation criteria and methodology, that such Candidate or Product has or would have an unacceptable risk-benefit profile or is otherwise not reasonably suitable
for initiation or continuation of Clinical Trials; 
 (b) Pfizer or BioNTech receive any notice, information or
correspondence from any applicable Regulatory Authority, or any applicable Regulatory Authority takes any action, that reasonably indicates that such Candidate or Product is unlikely to receive Regulatory Approval; or 

(c) that BioNTech fails to fulfill its Development or other obligations under the Research Plan or this Agreement and such
failure prevents Pfizer from fulfilling the Pfizer Diligence Obligations. 
 For the avoidance of doubt, the Pfizer Diligence Obligations in
respect of Candidates and Products not affected by the circumstances described in this Section 6.2.3 shall continue to apply. 

6.2.4. Deemed Satisfaction of Pfizer Diligence Obligations. Without in any way expanding Pfizer’s obligations under
this Agreement: 
 (a) Pfizer’s achievement of any Development Event entitling BioNTech to receive a specific
Development Payment described in Section 3.3 will be conclusive evidence that Pfizer has satisfied all Pfizer Diligence Obligations under this Agreement up to the date that such Development Event is achieved; 

(b) on a Major Market Country-by-Major Market
Country basis, Pfizer’s payment, and BioNTech’s acceptance, of any royalties to BioNTech pursuant to Section 3.5 with respect to Net Sales in such Major Market Country will be conclusive evidence that Pfizer has satisfied all Pfizer
Diligence Obligations under this Agreement in respect of such Major Market Country to the date of such payment; provided that if BioNTech does not return in full a payment of royalties by Pfizer with a written rejection of such payment within
ten days of receipt, BioNTech shall be deemed to have accepted such royalty payment; and 
 (c) Pfizer’s payment of any
Sales Milestone Payment as set forth in Section 3.4 will be conclusive evidence that Pfizer has satisfied all Pfizer Diligence Obligations under this Agreement to the date of such payment. 

For the avoidance of doubt, the provisions of Sections 6.2.4(a) through 6.2.4(c) are intended only as examples of diligence constituting
satisfaction of the Pfizer Diligence Obligations.Pfizer may fully satisfy the Pfizer Diligence Obligations without achieving any of the specific diligence examples set forth in Sections 6.2.4(a) through 6.2.4(c) above, provided that Pfizer
otherwise complies with the provisions of Section 6.2.1 or Section 6.2.2, as applicable. 

  
 41 

 6.2.5. Assertion of Pfizer Diligence Obligation Claims. If BioNTech
is or becomes aware of facts that might form a reasonable basis to allege that Pfizer has failed to meet any Pfizer Diligence Obligation, then BioNTech will promptly notify Pfizer in writing of such potential alleged performance failure (each such
potential alleged performance failure, a “Diligence Issue”). Promptly upon Pfizer’s receipt of any notice of a Diligence Issue pursuant to this Section 6.2.5, the Pfizer Program Director will contact the BioNTech Program
Director to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than [***] days after Pfizer’s receipt of such a notice, (a) the Parties have not reached
consensus regarding whether Pfizer has failed to satisfy its obligations pursuant to Section 6.2.1 or Section 6.2.2 and (b) the Parties’ respective Program Directors have not agreed upon an appropriate corrective course of action
for such Diligence Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 12.12. If BioNTech fails to notify Pfizer of a Diligence Issue pursuant to this Section 6.2.5
within [***] days after the date on which BioNTech first discovers such Diligence Issue, then Pfizer will be deemed to have satisfied its Diligence Obligations with respect to such Diligence Issue. 

6.2.6. Remedies for Breach of Pfizer Diligence Obligations. If Pfizer materially breaches any Pfizer Diligence
Obligation and fails to remedy such breach within [***] days of Pfizer’s receipt of notice of such breach from BioNTech, then BioNTech may, in its sole discretion, elect to either: (a) terminate this Agreement pursuant to the provisions of
Section 10.5, but only to the extent that a Product in a given Major Market Country in the Territory is directly and adversely impacted by such uncured material breach (and for the avoidance of doubt, the [***] day period set forth in this
Section 6.2.6, shall be deemed the same [***] day cure period set out pursuant to Section 10.5); or (b) convert any exclusive license or sublicense granted to Pfizer under this Agreement with respect to a Product in a given Major Market
Country in the Territory where such breach occurred and remains unremedied into a non-exclusive license or sublicense, as applicable, but only to the extent that such Product in such Major Market Country is
directly and adversely impacted by such uncured material breach. BioNTech acknowledges and agrees that the elections set forth in this Section 6.2.6: (i) have been negotiated by the Parties to fully address any harm that BioNTech may incur as a
result of Pfizer’s material breach of the Pfizer Diligence Obligations and (ii) constitute BioNTech’s sole and exclusive remedies with respect to any breach by Pfizer of any Pfizer Diligence Obligation. 

6.2.7. Performance by Pfizer’s Affiliates or Sublicensees. For avoidance of doubt, any actions taken by
Pfizer’s Affiliates or Sublicensees (or their respective subcontractors) under this Agreement shall be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 6.2. 

6.3. Regulatory Matters. 

6.3.1. Regulatory Reporting. Pfizer or its designated Affiliate(s) will have the sole authority to make or file all
filings, reports and communications with all Regulatory Authorities with respect to any Candidate or Product in the Field in the Territory, including all reports required to be filed in order to obtain or maintain any Regulatory Approvals granted
for Products in the Field in the Territory and adverse drug experience reports with the exception of the FIH Study, which will be managed and sponsored by BioNTech. Upon Pfizer’s request, BioNTech will provide to Pfizer the data arising from
the FIH Study, as well as any data or other information in BioNTech’s possession or Control reasonably necessary or useful to support its filings, reports or communications with Regulatory Authorities and otherwise provide reasonable assistance
to Pfizer in connection with any such filings, reports and communications with Regulatory Authorities. 

  
 42 

 6.3.2. Regulatory Approvals. Pfizer or its designated Affiliate(s)
will have the sole authority to prepare and file applications, in its own name, for Regulatory Approval for Candidates or Products in the Field in the Territory, including communicating with any Regulatory Authority both prior to and following
Regulatory Approval. BioNTech hereby assigns any and all INDs, Regulatory Approvals or any other rights or permissions granted by any Regulatory Authority to Pfizer, together with all other regulatory filings and development data, to the extent such
assignment is permissible under applicable Law and requested by Pfizer. Further, BioNTech will take all actions and provide all assistance reasonably requested by Pfizer to effect the assignments in this Section 6.3.2. 

6.3.3. Cooperation. If reasonably requested by Pfizer, BioNTech shall assist and cooperate with Pfizer in connection
with the preparation of filings, reports and communications to Regulatory Authorities with respect to any Candidate or Product in the Field in the Territory, at Pfizer’s sole expense. BioNTech will and will cause its Affiliates to cooperate
with Pfizer and all Pfizer Representatives in the event of any inspection by a Regulatory Authority related to any Candidate or Product or any activities to be performed under this Agreement. 

6.4. Commercialization Activities. 

6.4.1. General. Subject to Section 6.2, Pfizer will have sole and exclusive control over all matters relating to the
Commercialization of Products in the Field in the Territory, including sole and exclusive control over (a) pricing of Products and (b) the negotiation of Product pricing with Regulatory Authorities and other Third Parties, in each case in
the Field in the Territory. 
 6.4.2. Branding and Product Packaging. Pfizer or its designated Affiliates or
Sublicensees will select and own all Trademarks and Copyrights used in connection with the Commercialization of any and all Products in the Field in the Territory. Neither BioNTech nor its Affiliates will use or seek to register, anywhere in the
world, any Trademark which is confusingly similar to any Trademark used by or on behalf of Pfizer, its Affiliates or Sublicensees in connection with any Product. [***]. 

6.5. Manufacturing. With respect to Candidates or Products to be Commercialized in the Field in the Territory and except to the extent
BioNTech has Manufacturing obligations under the Research Plan or as described in Section 5, Pfizer will have the exclusive right to Manufacture such Candidates or Products itself or through one or more Affiliates or Third Parties selected by
Pfizer in its sole discretion. For clarity, Pfizer will have no diligence obligations with respect to the Manufacture of Products except to the extent necessary to fulfill its obligations under Section 6.2.1 or Section 6.2.2. 

6.6. Progress Reporting. After the first to occur of expiration of the Research Term or dissolution of the JSC and expiring on the
First Commercial Sale of a Product, Pfizer will provide BioNTech with annual written reports summarizing Pfizer’s activities to Develop and Commercialize Products in the preceding year. Any information or written report provided by Pfizer to
BioNTech pursuant to this Section 6.6 will be deemed to be Pfizer’s Confidential Information and subject to the provisions of Section 7.1. 

  
 43 

 6.7. Other Pfizer Programs. Subject to Pfizer’s exclusivity obligations
set forth in Section 2.10.3, BioNTech understands and acknowledges that Pfizer may have present or future initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving products, programs,
technologies or processes that are similar to, and in some instances may compete with, a Candidate or Product, program, technology or process covered by this Agreement. BioNTech acknowledges and agrees that nothing in this Agreement will be
construed as a representation, warranty, covenant or inference that Pfizer will not itself Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or
Commercialize products, programs, technologies or processes that are similar to or that may compete with any Candidate or Product, program, technology or process covered by this Agreement, provided that, for clarity, Pfizer will not use
BioNTech’s Confidential Information in breach of this Agreement. 
  

	7.	 INTELLECTUAL PROPERTY 

7.1. Patent Committee. Within the first [***] months following the Effective Date, the Parties will establish a patent committee (the
“Patent Committee”), comprised of at least one (1) representative of BioNTech and at least one (1) representative of Pfizer (which representative may be replaced by either Party at any time through written notice to the
other Party). The Patent Committee shall coordinate all activities in relation to Patent Rights applicable to the terms of this Agreement. In particular, the Patent Committee shall: 

7.1.1. coordinate all activities in relation to the filing and prosecution of Patent Rights relating to this Agreement pursuant
to Sections 7.2.1 and 7.3.1 of this Agreement, 
 7.1.2. discuss any actual, potential or suspected infringement of such
Patent Rights pursuant to Section 7.3.2(a), 
 7.1.3. regularly review which BioNTech Patent Rights may be relevant to
Candidates and Products, and 
 7.1.4. regularly review and update the Core BioNTech Patent Rights listed in Schedule
9.3.4 on the basis of the then-existing Development or Commercialization activities and programs of BioNTech, its Affiliates and licensees outside the Field, and acting in good faith to add and remove BioNTech Patent Rights from time to time,
provided that no Core BioNTech Patent Rights shall be removed from the list in Schedule 9.3.4 which BioNTech continues to regard in good faith as material for Development or Commercialization activities and programs of BioNTech, its
Affiliates and licensees outside the Field. 
 The Patent Committee shall meet (either in-person or
by audio or video conference) as often as determined by the Patent Committee as well as upon the reasonable request of either Party. It is acknowledged that particularly in the case of any Enforcement Action the Patent Committee may need to meet at
very short notice and be required to expedite and make decisions very quickly and the Parties shall procure that the Patent Committee shall meet urgently as quickly as reasonably required in connection with any Enforcement Action. The Patent
Committee will be chaired by a Pfizer Patent Committee member. The Patent Committee shall operate in good faith and acting reasonably. Sections 4.3.2(b) and 4.3.2(c), unless otherwise mutually agreed between the Parties, shall apply mutatis
mutandis. The Patent Committee will use good faith efforts to reach agreement on all matters properly brought before it. If, despite such good faith efforts, the Patent Committee is unable to reach unanimous agreement on a particular matter,
such matter shall be escalated in accordance with Section 4.3.2(e), and following the JSC’s dissolution, such Section being interpreted omitting the reference to the JSC in such provision. 

  
 44 

 7.2. Ownership of Intellectual Property. 

7.2.1. Ownership of Research Program Technology. Except for BioNTech Improvements and Pfizer Improvements, the ownership
of Research Program Technology will be allocated based on inventorship as defined under the Laws of the United States. Notwithstanding the foregoing: 

(a) During the Term, and without prejudice to Section 7.3 the Parties (through the Patent Committee) shall cooperate and
discuss in good faith with respect to the timing, scope and filing of any Patent Rights claiming or disclosing any Research Program Technology; and 

(b) Except as otherwise agreed in writing by the Parties, neither Party shall file any patent applications under the Product
Patent Rights without Pfizer’s prior consent. 
 7.2.2. Ownership of Joint Technology. Subject to
Section 7.2.1 (and excluding Pfizer Improvements and BioNTech Improvements), the Parties will jointly own any Joint Technology. Subject to (a) the grant of licenses or sublicenses to Pfizer under Section 2.1, (b) BioNTech’s
representations, warranties and covenants under Section 9 and (c) the Parties’ other rights and obligations under this Agreement (including Section 2.10.1), each Party will be free to exploit, either itself or through the grant of
licenses to Third Parties (which Third Party licenses may be further sublicensed), Joint Technology throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty
to account or otherwise make any payment of any compensation to the other Party. 
 7.2.3. Ownership of BioNTech
Improvements and Pfizer Improvements. As between the Parties, BioNTech will own all BioNTech Improvements and Pfizer will own all Pfizer Improvements and RNA Improvements. 

7.2.4. Ownership of Other Intellectual Property. Except as set forth in Sections 7.2.1, 7.2.2 and 7.2.3, each Party will
own all right, title and interest in and to any and all Know-How, Patent Rights or other Intellectual Property Rights that such Party owns as of the Effective Date or otherwise acquires during the Term. For
the purposes of determining ownership under this Agreement, as applicable, inventorship will be determined in accordance with United States patent laws. 

7.3. Patent Rights. 

7.3.1. Filing, Prosecution and Maintenance of Patent Rights. 

(a) Prosecution by BioNTech. BioNTech will have the first right, and a Commercially Reasonable Efforts obligation,
to file, prosecute and maintain the BioNTech Patent Rights owned by BioNTech or its Affiliates and Patent Rights claiming BioNTech Improvements (together the “BioNTech Prosecution Patent Rights”) at BioNTech’s sole

  
 45 

 
expense using counsel of its own choice reasonably acceptable to Pfizer in Australia, Canada, the member states of the European Patent Convention, Japan, the United States, Brazil, Russia, India,
China, Mexico and South Korea (“Key Patent Jurisdictions”). Upon request of Pfizer, BioNTech shall file one or more BioNTech Prosecution Patent Rights in one or more jurisdictions other than the Key Patent Jurisdictions
(“Additional Patent Jurisdictions”), and BioNTech will have the first right, and a Commercially Reasonable Efforts obligation, to file, prosecute and maintain such BioNTech Prosecution Patent Rights in such Additional Patent
Jurisdictions at Pfizer’s sole expense (until such time as Pfizer elects not to maintain such Patent Rights in such Additional Patent Jurisdictions whereupon BioNTech can elect to abandon or surrender the same or to continue the prosecution and
maintenance of such Patent Rights at its own expense) using counsel of its own choice reasonably acceptable to Pfizer. BioNTech will keep Pfizer advised on the status of the preparation, filing, prosecution, and maintenance of the Patent Rights
included within BioNTech Prosecution Patent Rights in all the jurisdictions where filed. Further, in respect of any jurisdiction, BioNTech will (i) allow Pfizer a reasonable opportunity and reasonable time to review and provide comments to
BioNTech’s patent counsel regarding relevant substantive communications to BioNTech and drafts of any responses or other proposed substantive filings by BioNTech before any applicable filings are submitted to any relevant patent office (or
Governmental Authority) with respect to any BioNTech Prosecution Patent Rights and (ii) reflect any reasonable and timely comments offered by Pfizer in any final filings submitted by BioNTech to any relevant patent office (or Governmental
Authority) with respect to any BioNTech Prosecution Patent Rights. If BioNTech elects not to file a Patent Right included in the BioNTech Prosecution Patent Rights in any Key Patent Jurisdiction or Additional Patent Jurisdiction or elects to cease
the prosecution or maintenance of one or more Patent Rights included in the BioNTech Prosecution Patent Rights in any Key Patent Jurisdiction or Additional Patent Jurisdiction and no Third Party has agreed to continue the prosecution or maintenance
of such Patent Rights under agreements concluded before the Effective Date, BioNTech will provide Pfizer with written notice of its decision not to file, prosecute or maintain not less than 60 days before any action is required to avoid abandonment
or lapse. In the event of any such notice, if Pfizer elects to file or continue such prosecution or maintenance in the name of BioNTech at Pfizer’s sole expense, (x) Pfizer shall be entitled to do so and take all steps in such prosecution
and maintenance at its sole discretion; (y) BioNTech will reasonably cooperate to promptly transfer the necessary files and execute the necessary forms regarding such transfer and (z) Pfizer will keep BioNTech advised on the status of such
filing, prosecution and maintenance and will reasonably consider any comments made by BioNTech in connection therewith. If Pfizer elects not to file or continue such prosecution or maintenance, then BioNTech may immediately abandon, allow to lapse,
or omit to prosecute such Patent Right, as the case may be. BioNTech will promptly, and no later than 60 days after written request by Pfizer, by written notice to Pfizer update Schedule 9.3.4 to identify all BioNTech Patent Rights to be
added thereto. 
 (b) Prosecution by Pfizer. 

(i) BioNTech Owned Research Program Patent Rights. Pfizer will have the first right, but not the obligation, to file,
prosecute and maintain any Research Program Patent Rights (excluding Patent Rights claiming BioNTech Improvements) that are solely owned by BioNTech or its Affiliates (the 

  
 46 

 
“BioNTech Owned Research Program Patent Rights”) at Pfizer’s sole expense using counsel of its own choice reasonably acceptable to BioNTech in the Key Patent Jurisdictions.
Upon request of BioNTech, Pfizer shall file one or more BioNTech Owned Research Patent Rights in Additional Patent Jurisdictions, and Pfizer will have the first right, but not the obligation, to file, prosecute and maintain such BioNTech Owned
Research Program Patent Rights in such Additional Patent Jurisdictions at BioNTech’s sole expense (until such time as BioNTech elects not to maintain such Patent Rights in such Additional Patent Jurisdictions whereupon Pfizer can elect to
abandon or surrender the same or to continue the prosecution and maintenance of such Patent Rights at its own expense) using counsel of its own choice reasonably acceptable to BioNTech. Pfizer will keep BioNTech advised on the status of the
preparation, filing, prosecution, and maintenance of the Patent Rights included within BioNTech Owned Research Program Patent Rights in all the jurisdictions where filed. Further, in respect of any jurisdiction, Pfizer will (i) allow BioNTech a
reasonable opportunity and reasonable time to review and provide comments to Pfizer’s patent counsel regarding relevant substantive communications to Pfizer and drafts of any responses or other proposed substantive filings by Pfizer before any
applicable filings are submitted to any relevant patent office (or Governmental Authority) with respect to any BioNTech Owned Research Program Patent Rights and (ii) reflect any reasonable and timely comments offered by BioNTech in any final
filings submitted by Pfizer to any relevant patent office (or Governmental Authority) with respect to any BioNTech Owned Research Program Patent Rights. If Pfizer elects not to file a Patent Right included in the BioNTech Owned Research Program
Patent Rights in any Key Patent Jurisdiction or Additional Patent Jurisdiction or elects to cease the prosecution or maintenance of one or more Patent Rights included in the BioNTech Owned Research Program Patent Rights in any Key Patent
Jurisdiction or Additional Patent Jurisdiction, Pfizer will provide BioNTech with written notice of its decision not to file, prosecute or maintain not less than 60 days before any action is required to avoid abandonment or lapse. In the event of
any such notice, if BioNTech elects to file or continue such prosecution or maintenance at BioNTech’s sole expense, (x) BioNTech shall be entitled to do so and take all steps in such prosecution and maintenance at its sole discretion;
(y) Pfizer will reasonably cooperate to promptly transfer the necessary files and execute the necessary forms regarding such transfer and (z) BioNTech will keep Pfizer advised on the status of such filing, prosecution and maintenance and
will reasonably consider any comments made by Pfizer in connection therewith. If BioNTech elects not to file or continue such prosecution or maintenance, then Pfizer may immediately abandon, allow to lapse, or omit to prosecute such Patent Right, as
the case may be. 
 (ii) Other Patent Rights. Except as provided in Sections 7.3.1(a), 7.3.1(b)(i) and 7.3.1(c),
Pfizer will have the sole right, but not the obligation, to file, prosecute and maintain the Product Patent Rights, the Research Program Patent Rights, the Pfizer Patent Rights (including RNA Improvements) and Patent Rights that it owns or to which
it otherwise has control of prosecution rights in its sole discretion. At BioNTech’s reasonable request, Pfizer will provide to BioNTech status information for any Research Program Patent Right in any Key Patent Jurisdiction and will consider
in good faith any recommendations made by BioNTech in regard to the filing, prosecution or maintenance of any such Patent Right. 

  
 47 

 (iii) Reference of Research Program
Know-how. If Pfizer chooses to file, and thereafter prosecute and maintain, Patent Rights after the expiration of the Research Term, including any extension to the Research Term under Section 4.4,
Pfizer may use or incorporate Research Program Know-How in the filing or prosecution of such Patent Rights filed after the Research Term, if Pfizer determines in its sole discretion that it is necessary or
useful to use or incorporate such Research Program Know-How. 
 (c) Joint Patent
Rights. In the event the Parties make any Joint Know-How, the Parties will promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will
file any Joint Patent Right without mutual consent. Unless otherwise agreed between the Parties, if the Parties decide to seek patent protection for any Joint Know-How: (i) BioNTech will have the first
right, but not the obligation, to prepare, file, prosecute and maintain any Joint Patent Right predominantly relating to the RNA Technology or RNA Process Technology throughout the world, and (ii)Pfizer will have the first right, but not the
obligation, to prepare, file, prosecute and maintain any other Joint Patent Right throughout the world, in each case of (i) and (ii) with the respective provisions of Section 7.3.1(a) or 7.3.1(b)(i) to apply mutatis mutandis except
as provided in this Section 7.3.1(c). The non-filing Party will reimburse the filing Party for 50% of the costs reasonably incurred by the filing Party in preparing, filing, prosecuting and maintaining
such Joint Patent Rights, which reimbursement will be made pursuant to, and within 75 days of, invoices (including supporting documentation) submitted by the filing Party to the non-filing Party no more often
than once per Calendar Quarter. The non-prosecuting Party will cooperate with the prosecuting Party in taking reasonable measures to control costs and non-prosecuting
Party shall be responsible for 100% of (x) any fees or costs related to any correspondence of outside counsel with or instructions to outside counsel by such Party (or any of such Party’s Representatives) which is independent of joint
prosecution efforts, or (y) any patent office fees, and associated counsel/agent fees and costs, for extensions which are not incurred at the request of, and not due to the actions of, the prosecuting Party. If, once the Parties have agreed to
prepare and file an application of Joint Patent Rights, either Party (the “Declining Party”) at any time thereafter declines to participate in the preparation, filing, prosecution or maintenance of any Joint Patent Right or share in
the costs of filing, prosecuting and maintaining any Joint Patent Right, on a country-by-country basis, the Declining Party will provide the other Party (the
“Continuing Party”) with 30 days prior written notice to such effect, in which event, the Declining Party will (A) have no responsibility with respect to the filing, prosecution or maintenance of the applicable Joint Patent
Right after the end of such 30 day period, (B) have no responsibility for any expenses incurred in connection with such Joint Patent Right after the end of such 30 day period and (C) if the Continuing Party elects to continue filing,
prosecution or maintenance, the Declining Party, upon the Continuing Party’s request, will execute such documents and perform such acts, at the Continuing Party’s expense, as may be reasonably necessary (1) to assign to the Continuing
Party all of the Declining Party’s right, title and interest in and to such Joint Patent Right and (2) to permit the Continuing Party to file, prosecute and maintain such Joint Patent Right at its

  
 48 

 
sole expense. Where such Joint Patent Right is assigned to Pfizer as the Continuing Party, BioNTech will retain a non-exclusive, sublicensable, perpetual,
irrevocable, royalty-free, fully paid-up worldwide right and license to practice and exploit such Patent Right for any and all purposes excluding, during the Term, in the Field in the Territory; and where such
Joint Patent Right is assigned to BioNTech as the Continuing Party, it will be excluded from the definition of BioNTech Patent Rights, and Pfizer will retain a non-exclusive, sublicensable, perpetual,
irrevocable, royalty-free, fully paid-up worldwide right and license to practice and exploit such Joint Patent Right for any and all purposes. 

(d) Prosecution by Third Party Licensors. Except in the ordinary course of filing continuation applications, BioNTech
shall not decline to pay for or participate in the filing, prosecution or maintenance of any Patent Right under any BioNTech Third Party Agreement in any Key Patent Jurisdiction (or other country to the extent doing so may result in BioNTech’s
loss of license to such Patent Right in such country), to the extent BioNTech is obligated to pay for, or has the right to participate in, such filing, prosecution or maintenance, that is included in the BioNTech Patent Rights and that, in
Pfizer’s reasonable opinion, covers any Candidate, Product [***] in the Field, and the loss of which would result in loss of right to or would materially diminish the overall protection of such Candidate or Product, without Pfizer’s prior
written consent, not to be unreasonably withheld or delayed. 
 (e) Patent Term Restoration and Extension. Upon
the request of either Party, the Parties will (through the Patent Committee) reasonably discuss patent term extension and supplemental protection certificate strategies in relation to Patent Rights Covering Candidates or Products at any time.
Notwithstanding the above, within the time period specified by applicable Law upon receiving Regulatory Approval for a Product in any country in the Territory, Pfizer will have the right, but not the obligation, exercisable through written notice to
BioNTech, to seek, in BioNTech’s name, if so required, patent term extensions, and supplemental protection certificates and the like available under Law, including 35 U.S.C. § 156 and applicable foreign counterparts (the “Patent
Term Extension”), in such country in the Territory in relation to (i) any Research Program Patent Right other than Patent Rights claiming BioNTech Improvements and (ii) any BioNTech Prosecution Patent Right which is still eligible
for Patent Term Extension at that time under the applicable Law in such country, in each case of (i) and (ii) that Cover such Product. If Pfizer exercises such right, BioNTech and Pfizer will cooperate in connection with all such activities at
Pfizer’s expense. Pfizer, its agents and attorneys will give due consideration to all suggestions and comments of BioNTech regarding any such activities, but, in the event of a disagreement between the Parties in relation to a Patent Term
Extension for a BioNTech Prosecution Patent Right or Research Program Patent Right, Pfizer will have the final decision-making authority. For the avoidance of doubt, nothing in this Section 7.3.1(e) shall prevent BioNTech from seeking, or
allowing any other collaboration partner of BioNTech to seek, any Patent Term Extension in relation to any BioNTech Prosecution Patent Right prior to Pfizer exercising its rights under this Section 7.3.1(e). Notwithstanding the foregoing,
BioNTech shall not seek any Patent Term Extension in relation to any Patent Right with respect to any Product or Candidate without Pfizer’s prior written consent. 

  
 49 

 (f) Clarifications. For clarity, prosecution under this
Section 7.3.1 includes opposition, revocation and post-grant review proceedings before the granting patent office or other patent office proceedings (“Prosecution Proceeding”). If such Prosecution Proceedings are concurrent
with Third Party litigation under Section 7.3.2 and are applicable to or part of a coordinated enforcement of such rights, the prosecuting Party and the enforcing Party shall work together and closely align their prosecution and enforcement
strategy in accordance with Section 7.3.3 (including the right for one Party to have final control as stipulated in Section 7.3.3). 

(g) Liability. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right or otherwise
exercising its rights under this Section 7.3.1, such Party, and its Affiliates, employees, agents or representatives, will not be liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or
its Affiliates, employees, agents or representatives, in connection with such activities undertaken in good faith. 
 (h)
Recording. If either Party deems it necessary or useful to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority(ies) in one or more jurisdictions in the Territory,
the other Party will reasonably cooperate to execute and deliver to such Party any documents accurately reflecting or evidencing this Agreement that are necessary or useful, in such Party’s reasonable judgment, to complete such registration or
recordation. 
 (i) Joint Research Agreement. This Agreement shall be understood to be a joint research agreement
under 35 U.S.C. § 103(c)(3) for pre-AIA Patent Rights and 35 U.S.C. § 100(h) for post-AIA Patent Rights entered into for the purpose of researching,
identifying and Developing Candidates and Products. 
 7.3.2. Enforcement of Patent Rights. 

(a) Notification of Infringement and Decision about Enforcement Actions. Each Party will promptly notify the other
(through the Patent Committee) in the event of any actual, potential or suspected infringement of a patent under the BioNTech Patent Rights or Research Program Patent Rights by any Third Party. In the event of any such notification, the Parties will
(through the Patent Committee) discuss in good faith the relevant actual, potential and suspected infringement and the risks and chances of success as well as chances of settlement connected with the institution of any litigation or other step to
remedy infringement (any such steps, or threat of or assertion or enforcement of a Patent Right being an “Enforcement Action”) taking into account the possible uses of the relevant Patent Rights by each Party, its respective
Affiliates or its or their licensees and the revenues relating to or impacted by such Patent Rights, with the goal to agree on whether or not any Enforcement Action should be taken and, if yes, to closely coordinate so far as reasonably possible
their respective efforts and strategies. The Parties acknowledge that time shall be of the essence in connection with any Enforcement Action and each shall move urgently and expeditiously to discuss and seek agreement on any actual or proposed
Enforcement Action. 

  
 50 

 (b) Enforcement of Core BioNTech Patent Rights. Subject to
Section 7.3.2(a), and unless otherwise agreed between the Parties on a case-by-case basis, as between Pfizer and BioNTech, BioNTech shall have the first right, but
not the obligation, to institute any Enforcement Action in connection with the Core BioNTech Patent Rights in the Field, and any such Enforcement Action will be at BioNTech’s expense including BioNTech indemnifying and holding harmless Pfizer
and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates join any such Enforcement Action upon BioNTech’s request or where required by Law. BioNTech will not, without the prior written consent of Pfizer, enter
into any compromise or settlement relating to such litigation that (i) admits the invalidity or unenforceability of any Core BioNTech Patent Right or (ii) requires BioNTech to abandon any Core BioNTech Patent Right. Pfizer, upon request of
BioNTech, agrees to timely commence or to join in any such Enforcement Action, at BioNTech’s expense, and in any event to cooperate with BioNTech in such Enforcement Action at BioNTech’s expense. Pfizer will have the right to consult with,
and provide comments to, BioNTech about such Enforcement Action and to participate in and be represented by independent counsel in such Enforcement Action at Pfizer’s own expense, and BioNTech shall take into account any reasonable comments
provided by Pfizer in such Enforcement Action. Neither Party will incur any liability to the other Party (other than that related to a Party’s indemnification obligation pursuant to Section 11) as a consequence of any Enforcement Action
initiated or pursued pursuant to this Section 7.3.2(b)or any unfavorable decision resulting therefrom, including any decision holding any Core BioNTech Patent Right invalid or unenforceable. Any infringement recoveries resulting from such
litigation or steps relating to a claim of Third Party infringement, after deducting BioNTech’s out of pocket expenses (including counsel fees and expenses including any adverse cost award) in pursuing such claim, will be for Pfizer’s sole
account and be deemed Net Sales on which Pfizer will pay royalties. 
 In respect of an infringement of a BioNTech Core Patent Right in the
Field in connection with a Competitive Product in a Major Market Country (“Competitive Product Infringement”), if, following (i) discussion of any potential Enforcement Action pursuant to Section 7.3.2(a) and (ii) a
subsequent written request by Pfizer to initiate any Enforcement Action in connection with such Competitive Product Infringement, BioNTech does not initiate any Enforcement Action in connection with such Competitive Product Infringement within
thirty (30) days following receipt of such notices, or as soon as possible and in any event no later than ten (10) Business Days if preliminary injunction proceedings are a potential or likely recourse to remedy the infringement), or ten
(10) days before the time limit, if any, set forth in the applicable Laws for the filing of such actions, Pfizer shall have the right, but not the obligation, in place of BioNTech to institute any Enforcement Action in connection with such
Competitive Product Infringement (including Enforcement Actions in countries in which the Manufacturing of the Competitive Product (or part thereof) reasonably believed to be designated for Major Market Countries takes place as well as Enforcement
Actions in Belgium, Ireland or the Netherlands that are in parallel with Enforcement Actions in any of the Major EU Market Countries), and any such Enforcement Action will be at Pfizer’s expense and the provisions set forth in the first
paragraph of this Section 7.3.2(b) shall apply mutatis mutandis, provided that any infringement recoveries resulting from such litigation or steps relating to a claim of Third Party infringement, after deducting Pfizer’s out
of pocket expenses (including counsel fees and expenses including any adverse cost award) in pursuing such claim, shall be for Pfizer’s sole account and be deemed Net Sales on which Pfizer will pay royalties. 

  
 51 

 (c) Pfizer Enforcement in the Field. Subject to Section 7.3.2(
a) and unless otherwise agreed between the Parties on a case-by-case basis, as between Pfizer and BioNTech, Pfizer shall have the sole right, but not the obligation, to
institute any Enforcement Action in the Territory in connection with any BioNTech Patent Right (other than Core BioNTech Patent Rights or those solely owned by Third Parties and licensed pursuant to a Current Licence to the extent BioNTech has no
enforcement rights in the Field in respect of the same) or Research Program Patent Rights in the Field, and any such Enforcement Action will be at Pfizer’s expense including Pfizer indemnifying and holding harmless BioNTech and its Affiliates
from and against any adverse cost award, where BioNTech or its Affiliates join any such Enforcement Action upon Pfizer’s request or where required by Law, subject to BioNTech’s obligation to indemnify Pfizer for such expenses pursuant to
Section 11; provided that any infringement recoveries resulting from such litigation or steps relating to a claim of Third Party infringement, after deducting Pfizer’s out of pocket expenses (including counsel fees and expenses
including any adverse cost award) in pursuing such claim, will be deemed Net Sales. Pfizer will not, without the prior written consent of BioNTech, enter into any compromise or settlement relating to such Enforcement Action that (i) admits the
invalidity or unenforceability of any BioNTech Patent Right or Research Program Patent Right or (ii) requires Pfizer or BioNTech to abandon any BioNTech Patent Right or Research Program Patent Right. BioNTech, upon request of Pfizer, agrees to
timely commence or to join in any such Enforcement Action, at Pfizer’s expense, and in any event to cooperate with Pfizer in such Enforcement Action at Pfizer’s expense. BioNTech will have the right to consult with, and provide comments
to, Pfizer about such Enforcement Action and to participate in and be represented by independent counsel in such Enforcement Action at BioNTech’s own expense, and Pfizer shall take into account any reasonable comments provided by BioNTech in
such Enforcement Action. Neither Party will incur any liability to the other Party (other than that related to a Party’s indemnification obligation pursuant to Section 11 or otherwise in this
sub-section) as a consequence of any Enforcement Action initiated or pursued pursuant to this Section 7.3.2(c) or any unfavorable decision resulting therefrom, including any decision holding any Patent
Right invalid or unenforceable. 
 (d) BioNTech Enforcement outside the Field. Subject to Section 7.3.2(b) and
7.3.2(c)and unless otherwise agreed between the Parties on a case-by-case basis, as between Pfizer and BioNTech, BioNTech shall have the sole right, but not the
obligation, to institute any Enforcement Action in the Territory in connection with any BioNTech Patent Right or Research Program Patent Right (excluding the Product Patent Rights) solely or jointly owned by BioNTech outside the Field, and any such
Enforcement Action will be at BioNTech’s expense including BioNTech indemnifying and holding harmless Pfizer and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates join any such Enforcement Action upon
BioNTech’s request or where required by Law. BioNTech will not, without the prior written consent of Pfizer, enter into any compromise or settlement relating to such Enforcement Action that (i) admits the invalidity or unenforceability of
any BioNTech Patent Right or Research Program Patent Right solely or jointly owned by BioNTech or (ii) requires BioNTech to abandon any BioNTech Patent Right or Research Program Patent Right solely or jointly owned by BioNTech. Pfizer, upon

  
 52 

 
request of BioNTech, agrees to timely commence or to join in any such Enforcement Action, at BioNTech’s expense, and in any event to cooperate with BioNTech in such Enforcement Action at
BioNTech’s expense. Pfizer will have the right to consult with, and provide comments to, BioNTech about such Enforcement Action and to participate in and be represented by independent counsel in such Enforcement Action at Pfizer’s own
expense, and BioNTech shall take into account any reasonable comments provided by Pfizer in such Enforcement Action. Neither Party will incur any liability to the other Party (other than that related to a Party’s indemnification obligation
pursuant to Section 11 or otherwise in this sub-section) as a consequence of any Enforcement Action initiated or pursued pursuant to this Section 7.3.2(d) or any unfavorable decision resulting
therefrom, including any decision holding any BioNTech Patent Right or Research Program Patent Right invalid or unenforceable. 

(e) Pfizer Patent Rights. Subject to Sections 7.3.2(b) and 7.3.2(c), Pfizer shall have the sole right, but no
obligation, to institute litigation or take other steps to remedy infringement in connection with in any field in respect of any Patent Rights that it solely owns including any Pfizer Patent Right. In the event that any such Patent Rights are based
on inventions made or created solely or jointly by BioNTech, its Affiliates or its Representatives acting on BioNTech’s behalf, BioNTech shall provide reasonable assistance to Pfizer at Pfizer’s expense in connection with such litigation.

 (f) Biosimilar Notices. 

(i) BioNTech Cooperation. Upon Pfizer’s request, BioNTech will use Commercially Reasonable Efforts to assist and
cooperate with Pfizer in (A) establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and (B) preparing submissions responsive to any Biosimilar Notices received by Pfizer;
provided that Pfizer will make the final decisions with respect to such strategy and any such responses. 
 (ii)
Compliance with Biosimilar Notices. Pfizer will have the sole right in its discretion to comply with the applicable provisions of 42 U.S.C. § 262(l) (or any amendment or successor statute thereto), any similar statutory or regulatory
requirement enacted in the future regarding biologic products in the United States, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction, in each case,
with respect to any Biosimilar Notice received by Pfizer from any Third Party regarding any Product that is being Commercialized in the Field in the applicable jurisdiction, and the exchange of information between any Third Party and Pfizer pursuant
to such requirements; provided that, prior to any submission of information by Pfizer to a Third Party, BioNTech will have the right to review the patent information included in such proposed submission, solely with respect to BioNTech Patent
Rights, and to make suggestions as to any changes to such patent information that BioNTech reasonably believes to be necessary; provided further that Pfizer will determine the final content of any such submission. In the case of a Product
approved in the United States under the PHS Act (or, in the case of a country in the Territory other than the United States, any similar Law), to the extent permitted by applicable Law, Pfizer, as the sponsor of the application for the Product, will
be the “reference 

  
 53 

 
product sponsor” under the PHS Act. Pfizer will give written notice to BioNTech of receipt of a Biosimilar Notice received by Pfizer with respect to a Product, and Pfizer will consult with
BioNTech with respect to the selection of any BioNTech Patent Rights to be submitted pursuant to 42 U.S.C. § 262(l) (or any similar law in any country of the Territory outside the United States); provided that Pfizer will have final say
on such selection of BioNTech Patent Rights. BioNTech agrees to be bound and will cause its Affiliates and use Commercially Reasonable Efforts to cause all Third Party Licensors to be bound by the confidentiality provisions of 42 U.S.C. §
262(l)(1)(B)(iii). In connection with any action brought by Pfizer under this Section 7.3.2(f), BioNTech, upon Pfizer’s request, will reasonably cooperate and will cause its Affiliates and use Commercially Reasonable Efforts to cause all
Third Party Licensors to reasonably cooperate with Pfizer in any such action, including timely commencing or joining in any action brought by Pfizer under this Section 7.3.2(f). Solely to the extent any BioNTech Patent Rights are involved in
any such action, the Parties’ rights and responsibilities regarding any action will be determined in accordance with this Section 7.3.2(f). 

(g) Unified Patent Court. In respect of BioNTech Patent Rights, Research Program Patent Rights, Product Patent Rights
and Pfizer Patent Rights, for each and every such Patent Right having effect anywhere within any member state that was or is, from time to time, a signatory to the UPC Agreement, the Party in control of the filing, prosecution and maintenance of
such Patent Right (as determined in accordance with Section 7.3.1) shall have the sole discretion to decide whether to (i) opt in or opt out (and to opt in again), pursuant to Article 83 of the UPC Agreement, of the Unified Patent Court
system; and (ii) elect if such Patent Rights should, during their prosecution, be designated as a Unitary Patent or a European Patent. The other Party shall promptly do all things necessary and execute all documents and make all necessary
elections required to give effect to such decision(s) or election(s). 
 (h) Settlement Cross-Licensing. If pursuant to a
bona fide settlement of any Enforcement Action or Infringement Claim controlled by Pfizer, Pfizer grants to a Third Party (that was a party to the Enforcement Action or Infringement Claim) any sublicense to any of the Patent Rights licensed to
Pfizer under this Agreement in respect of that Third Party’s Competitive Product, then Pfizer shall pay to BioNTech (i) at a minimum, if such sublicense includes any of the rights granted to Pfizer under a Current License or Future
BioNTech Third Party Agreement (subject to Sections 2.1, 2.2, 2. 9), all royalties due by BioNTech to the relevant Third Party for such sublicense under any Current License and Future BioNTech Third Party Agreement in respect of licensed sales of
such Competitive Product and (ii) all other royalties received by Pfizer shall be deemed Net Sales pursuant to Section 7.3.2(c) provided that in no event shall such payment obligations exceed the maximum royalty that would be due had such
Third Party become a Sublicensee. For the avoidance of doubt, should the Third Party as part of the same agreement grant any cross-license to Pfizer for any Candidates or Products, such cross-license shall not be deemed “non-cash” consideration for the purpose of the Net Sales definition. 

  
 54 

 7.3.3. Other Actions by Third Parties. Separate from Prosecution
Proceedings, each Party will promptly notify the other Party in the event of any legal action by any Third Party involving any BioNTech Patent Right or Research Program Patent Right of which it becomes aware, including any nullity, revocation,
declaratory judgment, interference, inter partes reexamination, reexamination or compulsory license proceeding. The right to defend against any such action shall be with the Party controlling the filing, prosecution and maintenance of the
affected Patent Right (as determined in accordance with Section 7.3.1), and the provisions of Section 7.3.1 shall apply mutatis mutandis in respect of such defense. If any such action has been instituted by any Third Party in
response to, or in connection with, any Enforcement Action pursuant to Section 7.3.2, or any Enforcement Action is to be pursued as a consequence of such action being instituted by any Third Party, the Party controlling the Enforcement Action
and the Party controlling the defense shall work together and closely align their enforcement and defense strategy, which may include the (joint) appointment of the same patent counsel for all concurrent Third Party litigation and patent office
proceedings taking into account the impact on enforcement and potential for revenues relating to such Patent Rights, and in the absence of agreement, the enforcing Party shall have the final say over the Prosecution Proceedings in so far as the
Prosecution Proceeding will adversely impact the ongoing enforcement of such right, subject to having given good faith consideration to the comments and suggestions of the prosecuting Party. Further details of such joint proceeding may be agreed
between the Parties from time to time. 
 7.3.4. Purple Book Listings. To the extent of any BioNTech Patent Rights
Covering a Product, the Parties shall cooperate with each other to enable Pfizer to make filings with Regulatory Authorities, as required or allowed in connection with (i) in the United States, the FDA’s Purple Book and the Biologics Price
Competition and Innovation Act and (ii) outside the United States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents thereof. Pfizer shall consider BioNTech’s reasonable
requests in connection therewith, including meeting any submission deadlines, in each case, to the extent required or permitted by applicable Law. 

7.3.5. Allegations of Infringement and Right to Seek Third Party Licenses. 

(a) Notice. If either Party becomes aware that the Development, Manufacture, Commercialization or use of any Candidate
or Product, the practice of any BioNTech Technology or Research Program Technology in the Field, or the exercise of any other right granted by BioNTech to Pfizer or any of its Affiliates or Sublicensees hereunder (collectively, the “Licensed
Activities”) is alleged by a Third Party to infringe, misappropriate or otherwise violate such Third Party’s Patent Rights or other Intellectual Property Rights or either Party otherwise identifies any Third Party Patent Rights or
other Intellectual Property Rights that may be relevant to such Licensed Activities, such Party will, as soon as reasonably practicable, notify the other Party in writing. 

(b) Pfizer Option to Negotiate. If Pfizer determines, in its sole discretion, that, in order for Pfizer, its Affiliates
or Sublicensees to engage in the Licensed Activities, it is necessary or useful to obtain a license under one or more Patent Rights or other Intellectual Property Rights Controlled by a Third Party (collectively, “Third Party IP
Rights”), then Pfizer will have the sole right, but not the obligation, to negotiate and enter into a license or other agreement with such Third Party. The amounts payable under any such license or agreement with a Third Party will reduce
Pfizer’s royalty obligations under this Agreement as and to the extent provided in Section 3.5.3(a) or as otherwise agreed between the Parties. 

  
 55 

 7.3.6. Third Party Infringement Suits. Each of the Parties will
promptly notify the other in the event that any Third Party files any suit or brings any other action alleging patent infringement by Pfizer or BioNTech or any of their respective Affiliates or Sublicensees with respect to the Development,
Manufacture, Commercialization or use of any Candidate or Product or the practice of any BioNTech Technology or Research Program Technology (any such suit or other action referred to herein as an “Infringement Claim”). In the case
of any Infringement Claim against Pfizer (including its Affiliates or Sublicensees) alone or against both Pfizer and BioNTech (including its Affiliates), Pfizer will have the right, but not the obligation, to control the defense of such Infringement
Claim, including control over any related litigation, settlement, appeal or other disposition arising in connection therewith. BioNTech, upon request of Pfizer, agrees to cooperate with Pfizer at Pfizer’s expense. BioNTech will have the right
to consult with Pfizer concerning any Infringement Claim and to participate in and be represented by independent counsel in any associated litigation in which BioNTech is a party at BioNTech’s own expense. If Pfizer elects to control the
defense of any Infringement Claim and BioNTech is obligated under Section 11.3 to indemnify Pfizer (including any Pfizer Indemnified Party) with respect to such Infringement Claim, then (a) Pfizer will bear 50% of its own attorneys’
fees incurred in investigating, preparing or defending such Infringement Claim notwithstanding the provisions of Section 11.3 and (b) BioNTech will otherwise indemnify Pfizer and any applicable Pfizer Indemnified Parties to the full extent
provided for under Section 11.3. In the case of any Infringement Claim against BioNTech alone, Pfizer will have the right to consult with BioNTech concerning such Infringement Claim and Pfizer, upon request of BioNTech, will reasonably
cooperate with BioNTech at BioNTech’s expense. Neither Party will enter into any compromise or settlement in respect of an Infringement Claim admitting or implying that the Development, Manufacture, Commercialization or use of any Candidate or
Product or the practice of any BioNTech Technology or Research Program Technology infringes Third Party patents without the other Party’s written consent. 

7.4. Enforcement of Know-How. 

7.4.1. Notification of Misappropriation. Each Party will promptly notify the other in the event of any actual, potential
or suspected misappropriation of any BioNTech Know-How or Research Program Know-How in the Territory by any Third Party. 

7.4.2. Pfizer Enforcement in the Field. As between Pfizer and BioNTech, Pfizer will have the sole right, but not the
obligation, to institute litigation or take other steps to remedy misappropriation in the Territory in connection with any BioNTech Know-How (excluding BioNTech Know-How
solely owned by Third Parties the subject of a Current Licence in so far as BioNTech has no enforcement rights in respect of the same) or Research Program Know-How in the Field, and any such litigation or
steps will be at Pfizer’s expense including Pfizer indemnifying and holding harmless BioNTech and its Affiliates from and against any adverse cost award, where BioNTech or its Affiliates join any such Enforcement Action upon Pfizer’s
request or where required by Law, subject to BioNTech’s obligation to indemnify Pfizer for such expenses pursuant to Section 11; provided that any infringement recoveries resulting from such litigation or steps relating to a claim
of Third Party misappropriation, after deducting Pfizer’s out of pocket expenses (including counsel fees and expenses including any adverse cost award) in pursuing such claim, will be deemed Net Sales. BioNTech will have no obligation to
cooperate with Pfizer in any such litigation except as set forth in this Section 7.4.2. Pfizer will not, without the prior written consent of BioNTech, enter into any compromise or settlement relating to such litigation or steps that
(a) admits that all or any portion of the BioNTech Know-How or Research Program Know-how is not 

  
 56 

 
protectable under relevant trade secret or confidentiality Laws or (b) requires Pfizer to abandon trade secret protection for any BioNTech Know-How or
Research Program Know-how. In order to establish standing, BioNTech, upon request of Pfizer, agrees to timely commence or to join in any such litigation or steps, at Pfizer’s expense, and in any event to
cooperate with Pfizer in such litigation or steps at Pfizer’s expense. BioNTech will have the right to consult with Pfizer about such litigation or steps and to participate in and be represented by independent counsel in such litigation or
steps at BioNTech’s own expense, and Pfizer shall take into account any reasonable comments provided by BioNTech in such litigation or steps. 

7.4.3. BioNTech Enforcement. As between Pfizer and BioNTech, BioNTech will have the sole right, but not the obligation,
to institute litigation or take other steps to remedy misappropriation in connection with any BioNTech Know-How or Research Program Know-how solely owned by BioNTech
outside the Field, provided that any such Know-how does not lose its confidential status as part of or in consequence of any such litigation or steps, and any such litigation or steps will be at
BioNTech’s expense including BioNTech indemnifying and holding harmless Pfizer and its Affiliates from and against any adverse cost award, where Pfizer or its Affiliates join any such Enforcement Action upon BioNTech’s request or where
required by Law, and Pfizer will have no obligation to cooperate with BioNTech in any such litigation except as set forth in this Section 7.4.3. BioNTech will not, without the prior written consent of Pfizer, enter into any compromise or
settlement relating to such litigation or steps that (a) admits that all or any portion of the BioNTech Know-How or Research Program Know-how is not protectable under relevant trade secret or
confidentiality Laws or (b) requires BioNTech to abandon trade secret protection for any BioNTech Know-How or Research Program Know-How. In order to establish
standing, Pfizer, upon request of BioNTech, agrees to timely commence or to join in any such litigation or steps at BioNTech’s expense, and in any event to cooperate with BioNTech in such litigation or steps at BioNTech’s expense. Pfizer
will have the right to consult with BioNTech about such litigation or steps and to participate in and be represented by independent counsel in such litigation or steps at Pfizer’s own expense, and BioNTech shall take into account any reasonable
comments provided by Pfizer in such litigation or steps. 
 7.4.4. Pfizer
Know-How. Subject to Section 7.4.2, Pfizer will have the sole right, but no obligation, to institute litigation or take other steps to remedy misappropriation in connection with any Know-How that it solely owns including any Pfizer Know-How. 
  

	8.	 CONFIDENTIALITY 

8.1. Confidentiality. Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and for [***]
years thereafter (except to the extent a longer period is required by a Current License applicable for such Confidential Information disclosed pursuant to that Current License), each Party (the “Receiving Party”) receiving any
Confidential Information of the other Party (the “Disclosing Party”) hereunder will: (a) keep the Disclosing Party’s Confidential Information confidential; (b) not disclose, or permit the disclosure of, the Disclosing
Party’s Confidential Information; and (c) not use, or permit to be used, the Disclosing Party’s Confidential Information for any purpose other than as expressly permitted under the terms of this Agreement (including under any license
or right of use granted hereunder). 

  
 57 

 8.2. Authorized Disclosure. 

8.2.1. Disclosure to Party Representatives. Notwithstanding the foregoing provisions of Section 8.1, the Receiving
Party may disclose Confidential Information belonging to the Disclosing Party to the Receiving Party’s Representatives who (a) have a need to know such Confidential Information in connection with the performance of the Receiving
Party’s obligations or the exercise of the Receiving Party’s rights under this Agreement and (b) have agreed in writing to non-disclosure and non-use
provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Section 8. 

8.2.2. Disclosure to Third Parties. Notwithstanding the foregoing provisions of Section 8.1, each Party may
disclose Confidential Information belonging to the other Party to the extent such disclosure is reasonably necessary: 
 (a)
to Governmental Authorities (i), to the extent useful, to obtain or maintain INDs or Regulatory Approvals, in the case of Pfizer or its Affiliates, or any Regulatory Approvals related to the FIH Study, in the case of BioNTech or its Affiliates, for
any Candidate or Product within the Territory, and (ii) in order to respond to inquiries, requests or investigations relating to Candidates or Products or this Agreement; 

(b) to outside consultants (including any professional advisor), potential acquisition partners (including any potential
successors in interest), private investors or financing sources, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent useful to
develop, register or market any Candidate or Product; provided that the Receiving Party will obtain the same confidentiality obligations from such Third Parties as it obtains with respect to its own similar types of confidential information;

 (c) in connection with filing or prosecuting Research Program Patent Rights or Trademark rights as permitted by this
Agreement; 
 (d) in connection with any prosecution or litigation actions or defenses undertaken pursuant to Section 7
or any other litigation directly related to a Candidate or Product in the Field; 
 (e) subject to the provisions of
Section 8.5.2, in connection with or included in scientific presentations and publications relating to Candidates or Products, including abstracts, posters, journal articles and the like, and posting results of and other information about
clinical trials to clinicaltrials.gov or PhRMA websites; 
 (f) subject to the obligations in Section 2. 10. 3, by
Pfizer in respect of Confidential Information belonging to BioNTech (including the terms of the Agreement) to any bona fide or potential sublicensee or manufacturer in respect of any Candidate or Product, or any
co-development or co-promotion partner in the Field , in each case who has agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as restrictive as those set forth in this Section 7.1; and 

(g) to the extent necessary or useful in order to enforce its rights under this Agreement. 

  
 58 

 If a Party deems it reasonably necessary to disclose Confidential Information belonging to
the other Party pursuant to clause (a) or any of clauses (c) through (e) of this Section 8.2.2, then the disclosing Party will to the extent possible give reasonable advance written notice of such disclosure to the other Party and
take such measures to ensure confidential treatment of such information as is reasonably required by the other Party, at the other Party’s expense. 

8.3. SEC Filings and Other Disclosures. Either Party may disclose the terms of this Agreement and make any other public written
disclosure regarding the existence of, or performance under, this Agreement, to the extent required, in the reasonable opinion of such Party’s legal counsel, to comply with (a) applicable Law, including the rules and regulations
promulgated by the United States Securities and Exchange Commission or (b) any equivalent Governmental Authority, securities exchange or securities regulator in any country in the Territory. Before disclosing this Agreement or any of the terms
hereof pursuant to this Section 8.3, the Parties will consult with one another on the terms of this Agreement to be redacted in making any such disclosure, with the Party disclosing pursuant to this Section 8.3 providing as much advance
notice as is feasible under the circumstances, and giving consideration to the comments of the other Party. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 8.3, such Party will, at its own
expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party and limit its disclosure of such Confidential Information to only that required to comply
with applicable Law. 
 8.4. Residual Knowledge Exception. Notwithstanding any provision of this Agreement to the contrary,
Residual Knowledge will not be considered Confidential Information for purposes of this Section 8; provided that, for clarity, a Party’s rights to Residual Knowledge hereunder shall not include the right to practice any Patent Right
owned or Controlled by the other Party that claims such Residual Knowledge unless otherwise expressly granted in another provision of this Agreement or in another agreement between the Parties. 

8.5. Public Announcements; Publications. 

8.5.1. Announcements. Except as may be expressly permitted under Section 8.3, neither Party will make any public
announcement regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement will prevent Pfizer from making any scientific publication or public announcement with respect to any
Candidate or Product under this Agreement; provided, however, that, except as permitted under Section 8.2, Pfizer will not disclose any of BioNTech’s Confidential Information in any such publication or announcement without obtaining
BioNTech’s prior written consent to do so. The Parties agree that the Parties will issue a mutually agreed upon joint press release regarding the signing of this Agreement following the Effective Date, but in any event no later than ten
(10) days after HSR clearance or September 5, 2018 (whichever is later). 
 8.5.2. BioNTech Publications.
During the Term, BioNTech will submit to Pfizer for review and approval any proposed academic, scientific and medical publication or public presentation which contains Confidential Information of Pfizer or its Representatives. In addition, BioNTech
will submit to Pfizer for review and approval any proposed publication or public presentation proposed by BioNTech or its Affiliates or any of their respective Representatives that relates to the activities conducted under this Agreement, including
the Research Plan, or otherwise relating to the BioNTech Technology, the Research Program Technology, the Pfizer Technology or any Candidate or Product in the Field. In both instances, such review and approval will be

  
 59 

 
conducted for the purposes of preserving the value of the BioNTech Technology, the Research Program Technology and the Pfizer Technology and the rights granted or to be granted to Pfizer
hereunder and determining whether any portion of the proposed publication or presentation containing Pfizer’s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required to be
submitted hereunder will be submitted to Pfizer no later than [***] days before submission for publication or presentation (the “Pfizer Review Period”). Pfizer will provide its comments with respect to such publications and
presentations within [***] days of its receipt of such written copy. The Pfizer Review Period may be extended for an additional [***] days in the event Pfizer can, within ten days of receipt of the written copy, demonstrate reasonable need for such
extension including for the preparation and filing of patent applications. BioNTech will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication
governed by this Section 8.5.2, including International Committee of Medical Journal Editors standards regarding authorship and contributions. 

8.5.3. Pfizer Publications. During the Research Term, Pfizer will submit to BioNTech for review and approval any
proposed academic, scientific and medical publication or public presentation which contains Confidential Information of BioNTech or its Representatives. Such review and approval will be conducted for the purposes of determining whether any portion
of the proposed publication or presentation containing Confidential Information of BioNTech or its Representatives should be modified or deleted. Written copies of such proposed publication or presentation required to be submitted hereunder will be
submitted to BioNTech no later than [***] days before submission for publication or presentation (the “BioNTech Review Period”). BioNTech will provide its comments with respect to such publications and presentations within [***]
days of its receipt of such written copy. The BioNTech Review Period may be extended for an additional [***] days in the event BioNTech can, within ten days of receipt of the written copy, demonstrate reasonable need for such extension including for
the preparation and filing of patent applications. Pfizer will comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other parties in any publication governed by this
Section 8.5.3, including International Committee of Medical Journal Editors standards regarding authorship and contributions. 
 8.6.
Obligations in Connection with Change of Control. If a Party is subject to a Change of Control (“Change of Control Party”), such Change of Control Party will, and it will cause its Representatives to, ensure that no
Confidential Information of the other Party is released to (a) any Affiliate of the Change of Control Party that becomes an Affiliate of the Change of Control Party as a result of the Change of Control or (b) any other Representatives of
the Change of Control Party (or of the relevant surviving entity of such Change of Control) who become Representatives of the Change of Control Party as a result of the Change of Control, unless such Affiliate or other Representatives, as
applicable, have signed individual confidentiality agreements which include equivalent obligations to those set out in this Section 8. Upon occurrence of a Change of Control, the Change of Control Party will promptly notify the other Party, share
with the other Party the policies, procedures and technical and organizational measures it plans to implement in order to protect the confidentiality of the other Party’s Confidential Information prior to such implementation and make any
adjustments to such policies and procedures that are reasonably requested by the other Party. 

  
 60 

	9.	 REPRESENTATIONS AND WARRANTIES 

9.1. Mutual Representations and Warranties. Each of BioNTech and Pfizer hereby represents and warrants to the other Party that: 

9.1.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization; 

9.1.2. the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action
under the provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities or voting interests; 

9.1.3. it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder; 

9.1.4. this Agreement has been duly executed and is a legal, valid and binding obligation on each Party, enforceable against
such Party in accordance with its terms; and 
 9.1.5. the execution, delivery and performance by such Party of this
Agreement and its compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Execution Date. 

9.2. Mutual Covenants. In addition to the covenants made by the Parties elsewhere in this Agreement, each of BioNTech and Pfizer hereby
covenants to the other Party that, from the Execution Date until expiration or termination of this Agreement it will perform its obligations under this Agreement in compliance with applicable Laws. 

9.3. Representations and Warranties of BioNTech. BioNTech hereby represents and warrants to Pfizer that, unless otherwise
disclosed in Schedule 9.3 (or otherwise as accepted to have been disclosed between BioNTech’s external counsel and Pfizer’s external counsel other than in writing), and provided that those provisions of the Current Licenses
set forth in Schedule 9.6.3 shall be deemed disclosed against the representations and warranties given by BioNTech at sections 9.3.1, 9.3.2, 9.3.4, 9.3.11 and 9.3.12 of this Agreement: 

9.3.1. as of the Execution Date, except with respect to BioNTech Technology Controlled by BioNTech pursuant to a Current
License, BioNTech or its Affiliates are the sole and exclusive owner of the BioNTech Technology, and all BioNTech Technology is free and clear of any claims, liens, charges or encumbrances; 

9.3.2. as of the Execution Date, BioNTech has, and to its knowledge will have, the full right, power and authority to
(i) grant all of the right, title and interest in the licenses and other rights granted or to be granted to Pfizer, Pfizer’s Affiliates or Pfizer’s Sublicensees under this Agreement and (ii) perform its obligations under this
Agreement; 
 9.3.3. Schedule 9.3.3 sets forth a true and complete list of all Candidates discovered or developed by
BioNTech or its Affiliates on or prior to the Execution Date; 

  
 61 

 9.3.4. as of the Execution Date, (a) Schedule 9.3.4 sets forth a
true and complete list of all Patent Rights (i) owned or otherwise Controlled by BioNTech or its Affiliates or (ii) to which BioNTech or its Affiliates have been granted or otherwise transferred any right to practice under, in each case of
(i) and (ii), that relate to the Candidates, the Products, the BioNTech Technology, or the Parties’ activities in the Research Program, (b) each such Patent Right is in full force and effect, (c) BioNTech or its Affiliates have
timely paid, or caused the appropriate Third Parties to pay, all filing and renewal fees payable with respect to such Patent Rights; and (d) BioNTech Controls all Patent Rights listed in Schedule 9.3.4; 

9.3.5. as of the Execution Date, BioNTech has disclosed to Pfizer all material scientific and technical information and all
information relating to safety and efficacy or suitability for infectious disease arising from the application or use of the BioNTech Technology that are known to it or its Affiliates that relates to the Candidates or Products; 

9.3.6. to BioNTech’s knowledge as of the Execution Date, (a) the BioNTech Patent Rights issued as of the Execution
Date are, valid and enforceable patents, (b) for the inventions that are the subject of BioNTech Patent Rights that are pending Patent Rights as of the Execution Date, there is no prior art or other facts or circumstances that BioNTech believes
would preclude validity or enforceability of any Patent Rights issued from such pending Patent Rights and (c) as of the Execution Date, no Third Party (i) is infringing any BioNTech Patent Right or (ii) has challenged or threatened in
writing to challenge the ownership, scope, validity or enforceability of, or BioNTech’s or any Current Licensor’s rights in or to, any BioNTech Patent Right (including, by way of example, through the institution or written threat of
institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); 

9.3.7. as of the Execution Date, BioNTech and its Affiliates and, to BioNTech’s knowledge, their Representatives and all
Current Licensors have complied with all applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the BioNTech Patent Rights; 

9.3.8. as of the Execution Date, BioNTech has independently developed all BioNTech
Know-How and BioNTech Materials or otherwise has a valid right to use, and to permit Pfizer, Pfizer’s Affiliates and Pfizer’s Sublicensees to use, the BioNTech
Know-How and BioNTech Materials for all permitted purposes under this Agreement; 

9.3.9. except with respect to BioNTech Technology Controlled by BioNTech pursuant to a Current License, BioNTech or its
Affiliates have obtained from all inventors of BioNTech Technology existing as of the Execution Date, valid and enforceable agreements assigning to BioNTech or its Affiliates each such inventor’s entire right, title and interest in and to all
such BioNTech Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech Technology automatically vests in BioNTech or its Affiliates by operation of law); 

9.3.10. in respect of BioNTech Technology solely or jointly owned by BioNTech existing as of the Execution Date, neither
BioNTech nor its Affiliates are subject to any funding agreement with any government or Governmental Authority; 

  
 62 

 9.3.11. neither BioNTech nor any of its Affiliates are party to or otherwise
subject to any agreement or arrangement which limits the ownership or licensed or sublicensed rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide
or provide access or other rights in, to or under, any Intellectual Property Right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such
agreement or arrangement, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement; 

9.3.12. as of the Execution Date (a) there are no BioNTech Third Party Agreements other than the Current Licenses set
forth on Schedule 9.3.12, (b) true and complete copies of each Current License have been provided to Pfizer, (c) except as provided in the Current Licenses, no Third Party has any right, title or interest in or to, or any license under,
any BioNTech Technology in the Field, (d) no rights granted by or to BioNTech or its Affiliates under any Current License conflict with any right or license granted to Pfizer or its Affiliates hereunder and (e) BioNTech and its Affiliates
are in compliance in all material respects with all Current Licenses; 
 9.3.13. as of the Execution Date, to BioNTech’s
knowledge, the use by BioNTech or Pfizer (or their respective Affiliates or Sublicensees) of the BioNTech Technology in accordance with this Agreement, and the Development, Manufacture or Commercialization of those Candidates listed in Schedule
9.3.3 or Products incorporating such Candidates in accordance with this Agreement (a) does not and will not infringe any Patent Right of any Third Party or (b) will not infringe the claims of any published Third Party pending Patent
Right when and if such claims issue; 
 9.3.14. as of the Execution Date, there is no (a) written claim, demand, suit,
proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to BioNTech’s knowledge, made or threatened (irrespective of whether or not in writing) against BioNTech
or any of its Affiliates or (b) judgment or settlement against or owed by BioNTech or any of its Affiliates, in each case in connection with the BioNTech Technology, the Current Licenses, any Candidate or Product or relating to the transactions
contemplated by this Agreement; 
 9.3.15. except with respect to BioNTech Technology Controlled by BioNTech pursuant to a
Current License, BioNTech has valid and enforceable agreements with all Persons acting by or on behalf of BioNTech or its Affiliates under this Agreement which require such Persons to assign to BioNTech their entire right, title and interest in and
to all BioNTech Technology or Research Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech Technology or Research Program Technology automatically vests in BioNTech or its
Affiliates by operation of law); 
 9.3.16. as of the Execution Date, BioNTech and its Affiliates have claimed and
remunerated all employee inventions of their respective employees comprised within the GEIA Technology in accordance with the provisions of the GEIA; 

9.3.17. as of the Execution Date, BioNTech and its Affiliates are entitled to unrestrictedly claim all rights to employee
inventions of their employees comprised within the GEIA Technology; 

  
 63 

 9.3.18. as of the Execution Date, BioNTech has obtained all necessary
assignment documents for the BioNTech Technology or Research Program Technology inventions in its files and maintains written track records of the proper claiming of any inventions made by employees of BioNTech, its Affiliates or Third Parties
included in BioNTech Technology or Research Program Technology by the employer and/or the proper assignment of the inventors of their rights in the invention, including the right to claim priority to said invention, to the employer; 

9.3.19. as of the Execution Date, BioNTech has no knowledge of (a) any inequitable conduct or fraud on any patent office
with respect to any of the BioNTech Patent Rights or (b) any Person (other than Persons identified in the applicable patent applications or patents, as inventors of inventions disclosed in the BioNTech Patent Rights) who claims to be an
inventor of an invention disclosed in the BioNTech Patent Rights; 
 9.3.20. as of the Execution Date, BioNTech and its
Affiliates are not, and to BioNTech’s knowledge, no Current Licensor or Representative of BioNTech (in each case, as applicable) is, debarred by any Regulatory Authority or the subject of debarment proceedings by any Regulatory Authority and,
in the course of the discovery or pre-clinical development of any Candidate or Product, BioNTech and its Affiliates have not and, to the knowledge of BioNTech, no Current Licensor or Representative of BioNTech
(in each case, as applicable) have used any employee or consultant that is debarred by any Regulatory Authority or, to the knowledge of BioNTech, is the subject of debarment proceedings by any Regulatory Authority; 

9.3.21. BioNTech, its Affiliates, and to BioNTech’s knowledge, all third parties and Representatives acting on
BioNTech’s behalf, have and will comply in all material respects with all applicable Law and accepted pharmaceutical industry business practices in connection with this Agreement, including, to the extent applicable, the FD&C Act (21 U.S.C.
§ 301, et seq.), the Anti-Kickback Statute (42 U.S.C. § 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. § 1320a-7a), the False Claims Act (31 U.S.C.
§ 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA, consistent with the ‘Compliance Program Guidance for Pharmaceutical Manufacturers’ published by
the Office of Inspector General, U.S. Department of Health and Human Services; 
 9.3.22. with respect to any Candidates,
Products, or payments or services provided under this Agreement, BioNTech, its Affiliates, and to its knowledge all third parties and Representatives acting on BioNTech’s behalf, have not taken and will not during the Term take any action
directly or indirectly to offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper
advantage, and has not accepted, and will not accept in the future such payment; 
 9.3.23. BioNTech, its Affiliates, and to
its knowledge all third parties and Representatives acting on BioNTech’s behalf, have and will continue to comply with the laws and regulations of the countries where it operates, including anti-bribery and anti-corruption laws, including, to
the extent applicable, the U.S. Foreign Corrupt Practices Act of 1977 and the U.K. Bribery Act 2010, accounting and record keeping laws, and laws relating to interactions with healthcare professionals or healthcare providers (collectively,
“HCPs”) and Government Officials; 

  
 64 

 9.3.24. BioNTech has implemented or will implement within a reasonable
period of time following the Effective Date of this Agreement (but in no event greater than March 30, 2020) policies and procedures, including but not limited to anti-corruption policies and procedures, commensurate with its current risk
profile, and shall review said policies from time to time setting out rules governing interactions with HCPs and Government Officials, engagement of Third Parties, including, where appropriate, due diligence (“Policies”), and its Policies
will mandate a robust set of internal controls, including accounting controls, designed to ensure the making and keeping of fair and accurate books, records and accounts, on its operations around the world and apply worldwide to all its employees,
subsidiaries, and Third Parties acting on its behalf to provide reasonable assurance that BioNTech, its subsidiaries and such Third Parties will comply with Laws, including but not limited to Anti-Corruption Laws to the extent required by such Laws.
BioNTech will reasonably monitor its operations and the operations of its Affiliates with the purpose of ensuring its Policies are effective at the reasonable assurance level and make necessary changes from time to time, in particular as its
business activities expand; 
 9.3.25. BioNTech is, as between the Parties, solely responsible to ensure Compliance by it and
its Affiliates; and 
 9.3.26. the Impf Group does not own or Control any Intellectual Property Rights used by BioNTech or
that BioNTech may reasonably require or be useful to exploitation of any of the RNA Technology. 
 9.4. Accuracy of Representations and
Warranties. 
 9.4.1. BioNTech will take no action which would render any representation or warranty made by BioNTech and
contained in Section 9.1 or Section 9.2 inaccurate or untrue; provided that such covenant shall not apply to representations and warranties expressly given as of the Execution Date; 

9.4.2. BioNTech will promptly notify Pfizer of any lawsuits, claims, administrative actions, regulatory inquiries or
investigations, or other proceedings asserted or commenced against BioNTech or its Representatives involving in any material way the ability of BioNTech to deliver the rights, licenses and sublicenses granted herein; and 

9.4.3. BioNTech will promptly notify Pfizer in writing of any facts or circumstances which come to its attention and which
cause, or through the passage of time may cause, any of the representations and warranties contained in Section 9.1, Section 9.2, Section 12.11 or otherwise in this Agreement to be untrue or misleading in any material respect at any
time during the Term; and in addition to the foregoing, with regard to any of the representations under Section 12.11, BioNTech will suspend all affected activities (including making any related payments) under this Agreement, unless and until
Pfizer determines that such activities may be resumed; provided that such covenant shall not apply to representations and warranties expressly given as of the Execution Date. 

9.5. BioNTech Covenants. In addition to the covenants made by BioNTech elsewhere in this Agreement, BioNTech hereby covenants to
Pfizer that, from the Execution Date until expiration or termination of this Agreement: 

  
 65 

 9.5.1. BioNTech will not, and will cause its Affiliates not to
(a) license, sell or assign (other than in a connection with a permitted assignment of this Agreement by BioNTech pursuant to Section 12.2) or otherwise transfer to any Person (other than Pfizer or its Affiliates or Sublicensees pursuant
to the terms of this Agreement) any BioNTech Technology or Research Program Technology (or agree to do any of the foregoing) or (b) incur or permit to exist, with respect to any BioNTech Technology or Research Program Technology, any lien,
encumbrance, charge, security interest, mortgage, liability, assignment, grant of license or other Binding Obligation, in each case of (a) and (b) that is inconsistent with the licenses and other rights granted (or that may be granted) to
Pfizer or its Affiliates under this Agreement; 
 9.5.2. Except as explicitly permitted under this Agreement, BioNTech will
not (a) take, or omit to take, any action that diminishes the rights under the BioNTech Technology or Research Program Technology granted (or that may be granted) to Pfizer or Pfizer’s Affiliates under this Agreement or (b) take, or
omit to take, any action that is reasonably necessary to avoid diminishing the rights under the BioNTech Technology or Research Program Technology granted (or that may be granted) to Pfizer or Pfizer’s Affiliates under this Agreement (for the
avoidance of doubt, BioNTech shall not be in breach of the covenants set forth in this Section 9.5.2 due to any reasonable act or position taken in connection with the filing, prosecution, maintenance, defense or enforcement of BioNTech
Technology or Research Program Technology as permitted in Section 7); 
 9.5.3. BioNTech will (a) not enter into
any BioNTech Third Party Agreement that adversely affects (i) the rights granted (or that may be granted) to Pfizer, Pfizer’s Affiliates or Sublicensees hereunder or (ii) BioNTech’s ability to fully perform its obligations
hereunder; (b) not amend or otherwise modify any BioNTech Third Party Agreement (including any Current License) or consent or waive rights with respect thereto in any manner that (A) adversely affects the rights granted (or that may be
granted) to Pfizer or Pfizer’s Affiliates or Sublicensees hereunder or (B) BioNTech’s ability to fully perform its obligations hereunder; (c) promptly furnish Pfizer with true and complete copies of all (1) amendments to the
Current Licenses and (2) BioNTech Third Party Agreements and related amendments executed following the Execution Date (in each case with redactions only in respect of sensitive information which is not relevant for the purposes of this
Agreement); (d) remain, and cause its Affiliates to remain, in compliance in all material respects with all BioNTech Third Party Agreements; and (e) furnish Pfizer with copies of all notices received by BioNTech or its Representatives relating
to any alleged breach or default by BioNTech or its Representatives under any BioNTech Third Party Agreement within ten (10) Business Days after receipt thereof (in each case with redactions only in respect of sensitive information which is not
relevant for the purposes of this Agreement); and 
 9.5.4. BioNTech will not enter into or otherwise allow itself or its
Representatives to be subject to any agreement or arrangement, other than the Current Licenses, which limits the ownership or licensed rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a
license, sublicense or access, or provide or provide access or other rights in, to or under, any Intellectual Property Right or material (including any Patent Right, Know-How or other data or information), in
each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned (or that may be licensed or assigned) to Pfizer or its Affiliates pursuant to this Agreement 

  
 66 

 9.5.5. BioNTech and its Affiliates will maintain or obtain valid and
enforceable agreements with or from all inventors of BioNTech Technology or Research Program Technology who are employed by or otherwise acting on behalf of BioNTech or its Affiliates assigning to BioNTech or its Affiliates each such inventor’s
entire right, title and interest in and to all such BioNTech Technology or Research Program Technology (except to the extent applicable Law provides that all right, title and interest in and to such BioNTech Technology or Research Program Technology
automatically vests in BioNTech or its Affiliates by operation of law). 
 9.5.6. BioNTech will unrestrictedly claim and
remunerate (and procure that its Affiliates will unrestrictedly claim and remunerate) all employee inventions of their respective employees comprised within the GEIA Technology in accordance with the provisions of the GEIA. 

9.5.7. In respect of GEIA Technology created after the Effective Date to which Pfizer shall obtain a license hereunder,
BioNTech will use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to conclude agreements with BioNTech employee inventors regarding the respective inventions by which the respective
inventors: (a) waive the employer’s obligation to release the employee invention and to enable the employee inventor upon request to apply for foreign Intellectual Property Rights for such foreign countries in which it does not intend to
apply for Intellectual Property Rights (Sec. 14 GEIA); and (b) waive the employer’s obligation to notify the employee inventor and to transfer the right in the invention to the employee inventor at the latter’s request and expense, if
it does not intend to pursue the application for the grant on an Intellectual Property Right for the invention any further or if it does not want to maintain the Intellectual Property Right granted for the
job-related invention (Sec. 16 GEIA); and (c) waive the employer’s obligation to acknowledge protectability of the invention in case the employer decides not to file a registration, but to keep the
invention secret (Sec. 17 GEIA); 
 9.5.8. To the extent BioNTech Technology or Research Program Technology is created after
the Effective Date by inventors employed by or acting on behalf of BioNTech’s or its Affiliates’ Third Party subcontractors, BioNTech will use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially
Reasonable Efforts) to obtain valid and enforceable agreements with their respective Third Party subcontractors imposing on their Third Party subcontractors the obligation to claim the rights in the invention in accordance with applicable law and to
conclude agreements with its employee inventors assigning to the respective Third Party subcontractor each such inventor’s entire right, title and interest in and to all such BioNTech Technology or Research Program Technology (except to the
extent applicable Law provides that all right, title and interest in and to such BioNTech Technology or Research Program Technology automatically vests in the Third Party subcontractor by operation of law) and, to the extent GEIA applies to such
BioNTech Technology or Research Program Technology, (ii) using Commercially Reasonable Efforts to obtain a waiver of inventor in his rights in Sec. 14, 16 and 17 GEIA; 

9.5.9. with respect to any BioNTech Technology or Research Program Technology to which Pfizer shall obtain a license hereunder
that is made after the Effective Date in the jurisdiction of the GEIA by an inventor on behalf of BioNTech or its Affiliates who is employed by a university pursuant to Sec. 42 GEIA (e.g. university professors, research assistants), BioNTech will
use Commercially Reasonable Efforts (and will procure that its Affiliates use Commercially Reasonable Efforts) to obtain valid and enforceable trifold agreements with such inventor and the 

  
 67 

 
respective university by which the university (a) waives its entire right, title and interest in and to that BioNTech Technology or Research Program Technology made by the inventor,
(b) the inventor assigns its rights, title and interest in and to that BioNTech Technology or Research Program Technology to BioNTech or its Affiliates, (c) the inventor waives its rights pursuant to Sec. 14, 16 and 17 GEIA as well as
(d) waives its negative publication right (Sec. 42 Nr. 2 GEIA) vis-a-vis BioNTech or its Affiliates; 

9.5.10. with respect to animals used in conducting activities under this Agreement, BioNTech will, and will cause its
Affiliates and permitted subcontractors to, comply with Pfizer’s Corporate Policy regarding Animal Care and Use, attached hereto as Exhibit C (except where in conflict with applicable Law); 

9.5.11. with respect to Human Material used, including collection or transfer, by BioNTech, its Affiliates or permitted
subcontractors in conducting activities under this Agreement, (a) such use shall be in accordance with the Research Plan and FIH Studies and shall be within the scope of and consistent with its ethical approval policies, (b) BioNTech will,
and will cause its Affiliates or permitted subcontractors to, handle and use the Human Material in accordance with all applicable Laws and the ICF, which shall permit Pfizer to use the Human Material for the research purposes contemplated by this
Agreement, (c) BioNTech will provide the ICF to Pfizer upon request by Pfizer, (d) the Human Material will be used for research purposes only and not be used for treatment of or administration to humans and (e) if BioNTech procures
any Human Material from a Third Party such as a sample bank, it will ensure that the collection and transfer of the Human Material and the use of the Human Material for purposes of the Research Plan is in accordance with all applicable Laws and
recognized international standards for the protection of human research subjects; and 
 9.5.12. BioNTech has received a copy
of and will comply with Pfizer’s Anti-Bribery and Anti-Corruption Principles attached hereto as Exhibit B. 
 9.6. Pfizer
Covenants. In addition to the covenants made by Pfizer elsewhere in this Agreement, Pfizer hereby covenants to BioNTech that, from the Execution Date until expiration or termination of this Agreement, 

9.6.1. Pfizer and its Affiliates maintain or will obtain valid and enforceable agreements with or from all inventors of Pfizer
Improvements, Research Program Technology, RNA Improvements or Reversion Technology who are employed by or otherwise acting on behalf of Pfizer or its Affiliates valid and enforceable agreements assigning to Pfizer or its Affiliates each such
inventor’s entire right, title and interest in and to all such Pfizer Improvements, Research Program Technology or RNA Improvements (except to the extent applicable Law provides that all right, title and interest in and to such Pfizer
Improvements, Research Program Technology or RNA Improvements automatically vests in Pfizer or its Affiliates by operation of law), and Pfizer and its Affiliates have made or will make any payments owing to any such inventors in respect of any
Pfizer Improvements, Research Program Technology or RNA Improvements or any other Person that is required in connection with the creation or exploitation of or transfer of rights to such Pfizer Improvements, Research Program Technology or RNA
Improvements; 

  
 68 

 9.6.2. with respect to Human Material used, including collection or
transfer, by Pfizer, its Affiliates or permitted subcontractors in conducting activities under this Agreement, (a) such use shall be within the scope of and consistent with its ethical approval policies, (b) Pfizer will, and will cause its
Affiliates or permitted subcontractors to, handle and use the Human Material in accordance with all applicable Laws and the ICF, (c) Pfizer will provide the ICF to BioNTech upon request by BioNTech, (d) the Human Material will be used for
research purposes only and not be used for treatment of or administration to humans and (e) if Pfizer procures any Human Material from a Third Party such as a sample bank, it will ensure that the collection and transfer of the Human Material
and the use of the Human Material for purposes of the Research Plan is in accordance with all applicable Laws and recognized international standards for the protection of human research subjects; and 

9.6.3. Pfizer will comply with the provisions of the Current Licenses set forth in Schedule 9.6.3 in respect of
BioNTech Technology sublicensed to Pfizer under the respective Current Licenses insofar as Pfizer is using such BioNTech Technology. 
 9.7.
Notifications. During the Term, BioNTech will promptly notify Pfizer in writing or orally in the event that it learns of: 

9.7.1. any prior art or other facts that BioNTech believes would result in the invalidity or unenforceability of any of the
claims included in any of the BioNTech Patent Rights or Research Program Patent Rights; or 
 9.7.2. any inequitable conduct
or fraud on the patent office with respect to any of the BioNTech Patent Rights or Research Program Patent Rights; or 

9.7.3. any Person (other than Persons identified as inventors of inventions disclosed in the BioNTech Patent Rights or Research
Program Patent Rights) who claims to be an inventor of an invention disclosed in the BioNTech Patent Rights or Research Program Patent Rights; and 

9.7.4. any lawsuits, claims, administrative actions, government inquiries or investigations, or other proceedings related to
the activities contemplated under this Agreement. 
 9.8. Representation by Legal Counsel. Each Party hereto represents that
it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no
presumption will exist or be implied against the Party which drafted such terms and provisions. 
 9.9. BioNTech’s
knowledge. All references in this Section 9 to BioNTech’s knowledge (or equivalent) shall refer to the actual knowledge after reasonable internal inquiry of BioNTech’s management comprising those individuals set forth in
Schedule 9.9. 
 9.10. Disclaimer. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN LIEU OF ANY OTHER
REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. 

  
 69 

	10.	 GOVERNMENT APPROVALS; TERM AND TERMINATION 

10.1. Antitrust Filing. Each of BioNTech and Pfizer will, within [***] days after the Execution Date (or such later time as may be
agreed to in writing by the Parties) make an appropriate filing under the HSR Act or any Foreign Antitrust Laws (the “Antitrust Filings”) if applicable in the reasonable opinion of either Party with respect to the transactions
contemplated under this Agreement. The Parties will cooperate with one another to the extent necessary in the preparation of any such Antitrust Filings. BioNTech will not agree to any voluntary extension or delay of any statutory waiting period or
withdraw any of its Antitrust Filings pursuant to the HSR Act or any Foreign Antitrust Laws unless Pfizer has given its prior written consent to such extension or delay. Each Party will be responsible for its own costs, expenses, and filing fees
associated with any Antitrust Filing; provided, however, that Pfizer will be solely responsible for any fees (other than penalties that may be incurred as a result of actions or omissions on the part of BioNTech) required to be paid to any
Governmental Authority in connection with submitting any such HSR Filing. 
 10.2. Termination Upon Antitrust Filing Denial. In the
event that the Parties make an Antitrust Filing under Section 10.1, this Agreement will terminate (a) at Pfizer’s option, immediately upon notice to BioNTech, in the event that any Governmental Authority seeks a temporary restraining
order, preliminary or permanent injunction or other legal restraint under the HSR Act or any Foreign Antitrust Laws against BioNTech and Pfizer to enjoin the transactions contemplated by this Agreement, (b) at the election of either Party,
immediately upon notice to the other Party, in the event that any Governmental Authority obtains a temporary restraining order, preliminary or permanent injunction or other legal restraint under the HSR Act or any Foreign Antitrust Laws against
BioNTech or Pfizer to enjoin the transactions contemplated by this Agreement or (c) at the election of either Party, immediately upon notice to the other Party, in the event that the Antitrust Clearance Date will not have occurred on or prior
to 180 days after the effective date of any applicable Antitrust Filings. 
 10.3. Other Government Approvals. Each of
BioNTech and Pfizer will cooperate with the other Party and to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders,
qualifications authorizations, permits and waivers, if any, and to do all other things necessary or useful for the consummation of the transactions as contemplated hereby including the collection of Human Material. 

10.4. Term. Except with respect to the provisions of Sections 10.1 and 10.2 and the provisions of Section 7.1, the term of
this Agreement (the “Term”) will commence on the Effective Date and extend on a country-by-country basis (in the Territory), unless this Agreement is
terminated earlier in accordance with this Section 10, until the last to expire of any Royalty Term for any Product in such country in the Territory. Notwithstanding any provision of this Agreement to the contrary, upon expiration of this Agreement,
Pfizer will retain the fully paid-up, perpetual, irrevocable royalty-free license to each Product as set forth in Section 3.5.2. 

10.5. Termination for Cause by BioNTech. BioNTech may terminate this Agreement for cause, at any time during the Term, by giving
written notice to Pfizer in the event that Pfizer commits a material breach of its obligations under this Agreement and such material breach remains uncured (a) 90 days for a material breach that is a failure of Pfizer to make an undisputed payment
owed to BioNTech under this Agreement and (b) 180 days for all other material breaches, in each case measured from the date written notice of such material breach is given to Pfizer; provided, however, that if any breach is not reasonably
curable within 180 days and if Pfizer is making a bona fide effort/using Commercially Reasonable Efforts to cure such breach, such termination will be delayed for a time period to be agreed by both Parties in order to permit Pfizer a reasonable
period of time to cure such breach. If the alleged material breach relates to non-payment of any amount due under this Agreement, the cure period will be tolled pending resolution of any bona fide dispute
between the Parties as to whether such payment is due. 

  
 70 

 10.6. Termination by Pfizer.  

10.6.1. Termination for Convenience. Upon at least [***] days’ prior written notice to BioNTech, Pfizer may
terminate this Agreement on a Product-by-Product and country-by-country basis, or in its
entirety, without cause, for any or no reason. 
 10.6.2. Termination for Cause. 

(a) General. Pfizer may terminate this Agreement for cause in its entirety, at any time during the Term, by giving
written notice to BioNTech in the event that BioNTech commits a material breach of its obligations under this Agreement and such material breach remains uncured for [***] days, measured from the date written notice of such material breach is given
to BioNTech; provided, however, that if any breach is not reasonably curable within [***] days and if BioNTech is making a bona fide effort/using its Commercially Reasonable Efforts to cure such breach, such termination will be delayed for a
time period to be agreed by both Parties in order to permit BioNTech a reasonable period of time to cure such breach. 
 (b)
Notwithstanding anything to the contrary in this Agreement, Pfizer may terminate this Agreement in whole, immediately and without regard to any cure period, if BioNTech or its Affiliates have committed a violation of Global Trade Control Laws in
connection with this Agreement. Any such termination will be deemed for cause under Section 10.7.1(b) and Pfizer will not be responsible for any payments due relating to such violation of Global Trade Control Laws even if such activities have
already occurred. BioNTech will be responsible for reimbursing Pfizer for any payments made to BioNTech or due to Pfizer under this Agreement that are blocked due to violation of Global Trade Control Laws. 

10.6.3. Termination for Law-related Breach. Pfizer may terminate this Agreement
if BioNTech breaches any of the representations and warranties set forth in Sections 9.3.21 through 9.3.23 or if Pfizer learns that improper payments are being or have been made to Government Officials by BioNTech with respect to services performed
in connection with this Agreement. Further, in the event of such termination BioNTech shall be liable for damages or remedies as provided by Law. 

10.7. Effects of Termination. 

10.7.1. Effect of Termination. 

(a) Termination for Cause by BioNTech; Termination for Convenience by Pfizer. In the event that BioNTech terminates this
Agreement for cause pursuant to Section 10.5 or Pfizer terminates this Agreement for convenience pursuant to Section 10.6.1, the following will apply: 

  
 71 

 (i) Except as otherwise expressly provided herein, all rights and
obligations of each Party hereunder will cease (including all rights and licenses and sublicenses granted by either Party to the other Party hereunder, and all sublicenses granted to Affiliates or Third Parties under the rights granted hereunder).

 (ii) On BioNTech’s written notice to Pfizer, which notice may only be delivered no later [***] days following the
effective date of termination: 
 (A) effective as of receipt of BioNTech’ notice and subject to the remaining
obligations of this Section 10.7.1(a), (1) Pfizer shall grant, and hereby grants, BioNTech a royalty-bearing, non-exclusive, sublicensable license under the Reversion Technology permitting BioNTech to continue
to Develop, Commercialize and Manufacture any Product under this Agreement that is being Developed or Commercialized by Pfizer or its Affiliates at the time of termination, in the form in which such Product then exists (a “Continuation
Product”) and the other provisions of Schedule 10.7.1(a) shall apply; (2) BioNTech shall pay royalties to Pfizer in accordance with paragraphs 6 through 8 of Schedule 10.7.1(a), and (3) BioNTech and its Affiliates shall
release and, upon Pfizer’s receipt of such notice, hereby do release Pfizer, its Affiliates and sublicensees with respect to any and all claims of any nature that BioNTech or its Affiliates may have had against Pfizer relating to this Agreement
that arose on or before the effective date of termination; and 
 (B) the Parties will negotiate in good faith for a period
not to exceed [***] days regarding an agreement (x) governing the further terms of transition of the Continuation Product from Pfizer to BioNTech comprising at minimum the elements set forth in Schedule 10.7.1(a) and (y) for a
license to such Continuation Product under the Pfizer Technology actually used by Pfizer or its Affiliates or Sublicensees before the effective date of termination; provided that if the Parties cannot reach an agreement within such [***] day period,
then the provisions of Section 10.7.1(a)(ii)(C) and (D) shall apply; 
 (C) if the Parties cannot reach an
agreement within such [***] day period set forth in of Section 10.7.1(a)(ii)(B) with respect to the terms of the transition of the Continuation Product or the license described in Section 10.7.1(a)(ii)(B), then the terms of such transition
of the Continuation Product or license shall be determined, taking into account all then-relevant factors, by an independent Third Party expert knowledgeable in pharma licensing to be agreed between the Parties (and if the Parties cannot agree on
such Third Party expert within [***] days of the expiration of the above negotiation period, the Third Party expert shall be independently appointed upon either Party’s request by the International Chamber of Commerce). Each Party shall be
obliged to submit its final proposal for the terms of such transition of or license to the Continuation Product to the Third Party expert, and such proposal shall remain confidential and shall not be disclosed to the other Party. The decision of the
Third Party expert shall be final and binding on both Parties. The costs of the Third Party Expert shall be borne by both Parties at equal shares. 

  
 72 

 (D) for the period between the receipt of BioNTech’ notice until
an agreement is concluded in accordance with Section 10.7.1(a)(ii)(B) and (C) above, Pfizer hereby covenants not to sue (and to procure that its Affiliates will not sue) BioNTech or its Affiliates for infringement of the Pfizer Technology
actually used by Pfizer or its Affiliates or Sublicensees before the effective date of termination. 
 (b) Termination for
Cause by Pfizer. 
 (i) In the event that Pfizer terminates this Agreement pursuant to Section 10.6.2, all rights
and obligations of each Party hereunder shall cease (including all non-perpetual, revocable rights and licenses granted by either Party to the other Party hereunder), except as otherwise expressly provided
herein. 
 (ii) In the event that Pfizer has the right, but elects not, to terminate this Agreement pursuant to
Section 10.7.1(b)(i) (after notice and failure of BioNTech to cure such breach as provided in Section 10.6.2), Pfizer shall notify BioNTech promptly and: (A) Pfizer’s obligations to pay Development Milestones and Sales Milestones and
royalties with respect to Net Sales of such Licensed Products shall be reduced by an amount equal to [***] of the amount that would otherwise have been payable under this Agreement such amount to be paid in accordance with and subject to the other
terms of this Agreement, provided that any such reduction of royalty payments shall not result in any royalty rate that is below the royalty amount which BioNTech or its Affiliates have to pay under any BioNTech Third Party Agreement to Third Party
licensors in connection with the relevant sale of Candidates or Products, and shall be offset against any damage claim of Pfizer in relation to such material breach; and (B) and at Pfizer’s sole discretion Pfizer will have the right to
offset, against any payments due to BioNTech under this Agreement, any damages finally awarded to Pfizer on account of such material breach. If, following Pfizer’s exercise of the rights under this Section 10.7.1(b)(ii), a competent
English court decides through final and binding decision that Pfizer was not entitled to exercise its rights hereunder, BioNTech shall be entitled to terminate this Agreement immediately without any option to cure for Pfizer. 

10.7.2. Accrued Rights. Subject to the release granted pursuant to Section , expiration or termination of this Agreement
for any reason will be without prejudice to any right which will have accrued to the benefit of either Party prior to such termination, including damages arising from any breach under this Agreement. Expiration or termination of this Agreement will
not relieve either Party from any obligation which is expressly indicated to survive such expiration or termination. 

  
 73 

 10.7.3. Survival Period. The following sections, together with any
sections that expressly survive (including any perpetual licenses and sublicenses granted hereunder), will survive expiration or termination of this Agreement for any reason: Sections 1 (Definitions), 3.6.3 (Royalty Statements and Payments) only in
relation to any Calendar Quarter in which sales have occurred prior to the termination, 3.6.7 (Record Keeping), 3.6.8 (Audits), 3.6.9 (Underpayments/Overpayments), 3.6.10 (Confidentiality), 4.6.2 (Title to Pfizer Materials and BioNTech Materials),
4.6.4 (Return of Proprietary Materials), 7.2 (Ownership of Intellectual Property), 7.3.17.3.1(c) (Filing, Prosecution and Maintenance of Joint Patent Rights), 8 (Confidentiality), 10.7 (Effects of Termination), 10.8 (Provision for Insolvency), 11.1
(No Consequential Damages), 11.2 (Indemnification by Pfizer), 11.3 (Indemnification by BioNTech), 11.4 (Procedure), 12 (Miscellaneous)and, to the extent this Agreement expires or is terminated, either in whole or in part, for any reason except by
BioNTech for cause pursuant to Section 10.5 or by Pfizer without cause pursuant to Section 10.6.1, Sections 7.2.4 (Patent Rights) and 7.4 (Enforcement and Defense of Know-How), and to the extent an
Enforcement Action or Infringement Claim is active, live or pending at the time of expiry or termination Sections 7.3.2 or 7.3.6, as applicable. 

10.8. Provision for Insolvency. 

10.8.1. Termination Right. BioNTech will be deemed a “Debtor” under this Agreement if, at any time
during the Term (a) a case is commenced by or against BioNTech under the Bankruptcy Code, (b) BioNTech files for or is subject to the institution of bankruptcy, reorganization, liquidation or receivership proceedings (other than a case
under the Bankruptcy Code), (c) BioNTech assigns all or a substantial portion of its assets for the benefit of creditors, (d) a receiver or custodian is appointed for BioNTech’s business or (e) a substantial portion of BioNTech’s
business is subject to attachment or similar process; provided, however, that in the case of any involuntary case under the Bankruptcy Code, BioNTech will not be deemed a Debtor if the case is dismissed within 60 days after the commencement
thereof. If BioNTech is deemed a Debtor, then Pfizer may terminate this Agreement by providing written notice to BioNTech. If Pfizer terminates this Agreement pursuant this Section 10.8.1, then: (i) all licenses granted to Pfizer under
this Agreement will become irrevocable and perpetual, and Pfizer will have no further obligations to BioNTech under this Agreement other than (A) those obligations that expressly survive termination in accordance with Section 10.7.3 and
(B) an obligation to pay royalties with respect to Net Sales of Products in an amount equal to 100% of the amount that would otherwise have been payable under this Agreement, such amount to be paid in accordance with and subject to the other
terms of this Agreement governing the payment of royalties; (ii) such termination will not be construed to limit BioNTech’s right to receive payments that accrued before the effective date of such termination; (iii) Pfizer will have the
right to offset, against any payment owing to BioNTech as provided for under clause (i), above, any damages found or agreed by the Parties to be owed by BioNTech to Pfizer; and (iv) nothing in this Section 10.8.1 will limit any other
remedy Pfizer may have for any breach by BioNTech of this Agreement. 
 10.8.2. Rights to Intellectual Property. All
rights and licenses now or hereafter granted by BioNTech to Pfizer under or pursuant to any Section of this Agreement, including Sections 2.1, 2.2, 2.3.1, 2.7 and Section 7 hereof, are rights to “intellectual property” (as defined in
the Bankruptcy Code). The Parties hereto acknowledge and agree that the payments provided for under Sections 3.1 through 3.4 and all other payments by Pfizer to BioNTech hereunder, other than royalty payments pursuant to Section 3.5, do not
constitute royalties within the meaning of Section 365(n) of the Bankruptcy Code or relate to licenses of intellectual property hereunder. If (a) a case under the Bankruptcy Code is commenced by or against BioNTech, (b) this Agreement

  
 74 

 
is rejected as provided in the Bankruptcy Code and (c) Pfizer elects to retain its rights hereunder as provided in Section 365(n) of the Bankruptcy Code, then BioNTech (in any capacity,
including debtor-in-possession) and its successors and assigns (including any trustee) will provide to Pfizer all intellectual property licensed hereunder, and agrees to
grant and hereby grants to Pfizer and its Affiliates a right to access and to obtain possession of and to benefit from and, in the case of any chemical or biological material or other tangible item of which there is a fixed or limited quantity, to
obtain a pro rata portion of, each of the following to the extent related to any Candidate or Product, or otherwise related to any right or license granted under or pursuant to this Agreement: (i) copies of
pre-clinical and clinical research data and results; (ii) all of the following (to the extent that any of the following are so related): BioNTech Materials, cell lines, antibodies, assays, reagents and
other biological materials; (iii) samples or Candidates and Products; (iv) BioNTech Technology and RNA Technology, (v) laboratory notes and notebooks; (vi) Candidate and Product data or filings, and (vii) Rights of Reference
in respect of regulatory filings and approvals, all of which constitute “embodiments” of intellectual property pursuant to Section 365(n) of the Bankruptcy Code, and (viii) all other embodiments of such intellectual property,
whether any of the foregoing are in BioNTech’s possession or control or in the possession and control of any Third Party but which BioNTech has the right to access or benefit from and to make available to Pfizer. BioNTech will not interfere
with the exercise by Pfizer or its Affiliates of rights and licenses to intellectual property licensed hereunder and embodiments thereof in accordance with this Agreement and agrees to use Commercially Reasonable Efforts to assist Pfizer and its
Affiliates to obtain such intellectual property and embodiments thereof in the possession or control of Third Parties as reasonably necessary or useful for Pfizer or its Affiliates or Sublicensees to exercise such rights and licenses in accordance
with this Agreement. 
 10.8.3. No Limitation of Rights. All rights, powers and remedies of Pfizer provided in this
Section 10.8 are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at Law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the
Bankruptcy Code involving BioNTech. To the extent equivalent rights exist under the Bankruptcy Code existing from time to time in the jurisdiction where BioNTech is established the foregoing provisions shall be interpreted in accordance with such
equivalent rights, and where such equivalent rights to not exist Pfizer shall be entitled to avail of itself all remedies and rights available to it as a creditor and licensee of Intellectual Property Rights under such local Bankruptcy Code. 

10.9. Change of Control of BioNTech. If a Change of Control of BioNTech by a Specified Person is consummated prior to the date Pfizer
has paid the Development Milestone in row (v) of the table included in Section 3.3 (“Change of Control Term”), then Pfizer shall have the right to terminate the Research Plan (and BioNTech’s involvement in performance
of the Research Plan) in its entirety, as applicable, immediately upon written notice to BioNTech within [***] days after Pfizer receives notice from BioNTech of consummation of such Change of Control of BioNTech and, at Pfizer’s option, it may
request (which BioNTech shall deliver) a technology transfer under the Technology Transfer Plan as soon as reasonably practicable. Such termination of the Research Plan and/or BioNTech’s involvement in its performance (a) shall not
constitute termination of this Agreement, (b) shall not affect the Parties’ rights and obligations under this Agreement other than those relating to such Research Plan including Pfizer’s diligence obligations and (c) shall not
relieve either Party of any obligation that arose prior to such termination. Following termination pursuant to this Section 10.9, Pfizer shall have no further obligations under Section 4.2. 

  
 75 

 10.10. Effects of Change of Control. In the event of a Change of Control of BioNTech
by a Specified Person during the Change of Control Term, the following provisions of this Section 10.10 shall apply: 

10.10.1. BioNTech Intellectual Property. All BioNTech Technology and Research Program Technology, Controlled by BioNTech
immediately prior to such BioNTech Change of Control shall continue to be BioNTech Technology and Research Program Technology licensed to Pfizer for purposes of this Agreement. 

10.10.2. Existing Acquirer Intellectual Property. Patent Rights and Know-How
that were Controlled by the entity acquiring BioNTech or such entity’s Affiliates that were not Affiliates of BioNTech prior to such BioNTech Change of Control (collectively, the “Acquirer”) shall not be included within the
licenses granted to Pfizer hereunder. 
 10.10.3. Independent Intellectual Property. Patent Rights and Know-How that, following such BioNTech Change of Control, are developed, made or otherwise acquired or Controlled by the Acquirer outside of the Research Plan and without use of Pfizer’s Confidential
Information or Research Program Technology, BioNTech Improvements or BioNTech Technology shall not be included within the Research Program Technology or BioNTech Technology or BioNTech Third Party Agreements (it being understood, however, for the
avoidance of doubt, that all BioNTech Technology, Research Program Technology, and Intellectual Property Rights developed by BioNTech or the Acquirer in the course of, or used by BioNTech or the Acquirer under the Research Plan or used in the
Manufacture of the Candidates or Products by BioNTech shall be licensed to Pfizer pursuant to the licenses set forth in this Agreement). 

10.10.4. Research Program Technology. No Research Program Technology Controlled by Pfizer or RNA Improvements or Pfizer
Improvements shall be licensed or sub-licensable to the Acquirer, and no Confidential Information of Pfizer or its Representatives shall be disclosed to the Acquirer, in each case without the prior written
consent of Pfizer. 
 10.11. Effect on Certain Agreement Provisions. From and after the effective date of a BioNTech Change of
Control by a Specified Person, the Acquirer shall not be considered an “Affiliate” for the purposes of this Agreement, provided that the Acquirer does not engage in any activities otherwise restricted under Section 10.10 using any
Research Program Technology, Pfizer Technology, Pfizer Improvements or Confidential Information of Pfizer. 
  

	11.	 LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE 

11.1. No Consequential Damages. Except with respect to liability arising from a breach of Sections 7 or 8, from any willful misconduct
or intentionally wrongful act, or to the extent such Party may be required to indemnify the other Party under this Section 11, in no event will either Party or its Representatives be liable under this Agreement for any special (only as related to
indirect, incidental or consequential damages), indirect, incidental, consequential or punitive damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of indirect profits or revenue suffered by the
other Party or any of its Representatives. Without limiting the generality of the foregoing, “consequential damages” will be deemed to include, and neither Party will be liable to the other Party or any of such other Party’s
Representatives or stockholders for any damages based on or measured by loss of projected or speculative future sales of the Products, any Development Payment due upon any unachieved Development Event under Section 3.3, any Sales Milestone
Payment due upon any unachieved Total Annual Net Sales level under Section 3.4, any unearned royalties under Section 3.5 or any other unearned, speculative or otherwise contingent payments provided for in this Agreement. 

  
 76 

 11.2. Indemnification by Pfizer. Pfizer will indemnify, defend and hold
harmless BioNTech, each of its Affiliates, and each of its and its Affiliates’ employees, officers, directors and agents (each, a “BioNTech Indemnified Party”) from and against any and all claims, causes, or allegations
(whether threatened or pending), judgments, expenses, damages, liabilities, obligations, fees (including the reasonable fees of attorneys and other consulting or testifying professionals), costs and losses (collectively,
“Liabilities”) that the BioNTech Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: 

(a) (a) Development, Manufacture, Commercialization or use of any Product by, on behalf of, or under the authority of, Pfizer
(other than by any BioNTech Indemnified Party), other than (i) claims by Third Parties relating to patent infringement arising out of the exercise of rights under the BioNTech Patent Rights, (ii) claims by Third Parties relating to
misappropriation of trade secrets arising out of the exercise of rights under the BioNTech Know-How or (iii) claims for which BioNTech is required to indemnify Pfizer pursuant to Section 11.3; or

 (b) (b) the material breach by Pfizer of any of its representations, warranties or covenants set forth in
Section 4.6.1, 9.1 or 9.1.1; 
 except, in each case, to the extent caused by the negligence, recklessness or intentional acts of BioNTech or any
BioNTech Indemnified Party. 
 11.3. Indemnification by BioNTech. BioNTech will indemnify, defend and hold harmless Pfizer, its
Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a “Pfizer Indemnified Party”) from and against any and all Liabilities that the Pfizer
Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of (i) the FIH Study, (ii) use of the BioNTech name or logo pursuant to Section 6.4.2, (iii) rights or obligations under the GEIA relating
to inventions made by employees of BioNTech or its Affiliates or Third Party Licensors in relation to BioNTech Technology or Research Program Technology used in any Candidate or Product; or (iv) the material breach by BioNTech or any of its
Representatives of any of its representations, warranties or covenants set forth in Section 9.1, Section 9.1.1, Section 9. 2, Section 9.3, Section 9.4 or Section 9.5 except to the extent caused by the negligence,
recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party. 
 11.4. Procedure. 

11.4.1. Notice. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which
indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the “Indemnified Party”) is
entitled to indemnification hereunder (a “Third Party Claim”), then the Indemnified Party will promptly notify the Party obligated to indemnify the Indemnified Party (the “Indemnifying Party”) thereof; provided,
however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced
thereby. 

  
 77 

 11.4.2. Control. Subject to either Party’s right to control any
actions described in Section 7 (even where the other Party is the Indemnifying Party), the Indemnifying Party will have the right, exercisable by notice to the Indemnified Party within ten Business Days after receipt of notice from the
Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim
solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, in the reasonable judgment of
the Indemnified Party, to satisfy the amount of any adverse monetary judgment that is sought, (b) the Third Party Claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the
Indemnifying Party and the Indemnified Party, the Indemnifying Party will be solely obligated to satisfy and discharge the Third Party Claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the
“Litigation Conditions”). Within ten Business Days after the Indemnifying Party has given notice to the Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party will give notice to the
Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so objects, the Indemnified Party will continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until
such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel
selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party will cooperate, and will cause its
Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings,
hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party’s
intent to defend any Third Party Claim within ten Business Days after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying
Party’s expense (including reasonable, out-of-pocket attorneys’ fees and costs and expenses of enforcement or defense). The Indemnifying Party or the
Indemnified Party, as the case may be, will have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any
Third Party Claim that the other party is defending as provided in this Agreement. 
 11.4.3. Settlement. The
Indemnifying Party will not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party will have the sole
and exclusive right to settle any Third Party Claim, on such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but
will not have the right to settle such Third Party Claim to the extent such Third Party Claim involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party will not
make any admission of liability in respect of any Third Party Claim without the prior written consent of the other party, and the Indemnified Party will use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. 

  
 78 

 11.5. Insurance. Each Party further agrees to obtain and maintain, during the
Term, commercial general liability insurance, including products liability insurance (or clinical trials insurance, if applicable), with minimum “A-” A.M. Best rated insurance carriers to cover its
indemnification obligations under Section 11.2 or Section 11.3, as applicable, in each case with limits of not less than $5,000,000 (Five Million U.S. Dollars) per occurrence and in the aggregate. All deductibles and retentions will be the
responsibility of the named insured. Within [***] days of the Effective Date, BioNTech will amend its existing insurance policies in such a way that (i) Pfizer Inc. and its Affiliates will be indemnified as principal on BioNTech’s
commercial general liability and products liability policies (or clinical trials insurance, if applicable) and (ii) Pfizer Inc. and its Affiliates will be provided a waiver of subrogation on BioNTech’s commercial general liability and products
liability policies (or clinical trials insurance, if applicable). For U.S. exposures, additional insured status on BioNTech’s commercial general liability and products liability policies shall be via form CG20101185 or its equivalent. Products
liability coverage shall be maintained for three years following termination of this Agreement. To the extent of its culpability or negligence, all coverages of BioNTech will be primary and non-contributing
with any similar insurance, carried by Pfizer. Notwithstanding any provision of this Section 11.5 to the contrary, Pfizer may meet its obligations under this Section 11.5 through self-insurance. Neither Party’s insurance will be
construed to create a limit of liability with respect to its indemnification obligations under this Section 11. 
  

	12.	 MISCELLANEOUS 

12.1. BioNTech AG. BioNTech AG and BioNTech RNA shall each be jointly and severally liable to Pfizer with respect to this Agreement and
their obligations hereunder. 
 12.2. Assignment. Neither this Agreement nor any interest hereunder will be assignable by a
Party without the prior written consent of the other Party, except as follows: (a) subject to the provisions of this Agreement in respect of Change of Control, as applicable, a Party may assign its rights and obligations under this Agreement by
way of sale of itself or the sale of the portion of its business to which this Agreement relates, through merger, sale of assets and/or sale of stock or ownership interest, provided that the assignee will expressly agree to be bound by such
Party’s obligations under this Agreement and that such sale is not primarily for the benefit of its creditors, (b) such Party may assign its rights and obligations under this Agreement to any of its Affiliates, provided that the
assignee will expressly agree to be bound by such Party’s obligations under this Agreement and that such Party will remain liable for all of its rights and obligations under this Agreement. In addition, Pfizer may assign its rights and
obligations under this Agreement to a Third Party where Pfizer or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Product in order to comply with Law or the order of any Governmental Authority
as a result of a merger or acquisition, provided that the assignee will expressly agree to be bound by Pfizer’s obligations under this Agreement. Each Party will promptly notify the other Party of any assignment or transfer under the
provisions of this Section 12.2. This Agreement will be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein will be deemed to include the names of such Party’s successors and permitted
assigns to the extent necessary to carry out the intent of this Agreement. Any assignment not in accordance with this Section 12.2 will be void. 

  
 79 

 12.3. Further Actions. Each Party agrees to execute, acknowledge and deliver
such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. 

12.4. Force Majeure. Each Party will be excused from the performance of its obligations under this Agreement to the extent that
such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse will be continued so long as the condition constituting force majeure continues and
the nonperforming Party takes Commercially Reasonable Efforts to remove the condition. For purposes of this Agreement, “force majeure” will include conditions beyond the control of the Parties, including an act of God, voluntary or
involuntary compliance with any regulation, Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers,
destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. 
 12.5. Interpretation.
Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa),
(b) the words “include”, “includes” and “including” will be deemed to be followed by the phrase “without limitation”, (c) the word “will” will be construed to have the same meaning and
effect as the word “shall”, (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended,
supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person’s successors and assigns,
(f) the words “herein”, “hereof” and “hereunder”, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein
to Sections, Exhibits or Schedules will be construed to refer to Sections, Exhibits or Schedules of this Agreement, and references to this Agreement include all Exhibits and Schedules hereto, (h) the word “notice” means notice in
writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder
“agree,” “consent” or “approve” or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (excluding e-mail or instant messaging, but a signed PDF document being acceptable), (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the
then-current amendments thereto or any replacement or successor law, rule or regulation thereof, and (k) the term “or” will be interpreted in the inclusive sense commonly associated with the term “and/or”. 

12.6. Notices. Any notice or notification required or permitted to be provided pursuant to the terms and conditions of this
Agreement (including any notice of force majeure, breach, termination, change of address, etc.) will be in writing and will be deemed given upon receipt if delivered personally or by facsimile transmission (receipt verified), and upon delivery if
mailed by registered or certified mail or courier. Where delivery occurs outside normal working hours, notice will be deemed given at the start of normal working hours on the next Business Day.Notice shall be given to the Parties at the following
addresses or facsimile numbers (or at such other address or facsimile number for a Party as will be specified by like notice, provided, however, that notices of a change of address will be effective only upon receipt thereof): 

  
 80 

 All correspondence to Pfizer will be addressed as follows: 

Pfizer Inc. 
 Notices: R&D
Business Development 
 235 East 42nd Street 

New York, NY 10017 
 Attention:
Attn.: R&DBD Contract Notice 
 Fax:
+1-646-563-9619 

with a copy to: 
 Pfizer Inc. 

Notices: Pfizer Legal Division 

235 East 42nd Street 
 New York,
NY 10017 
 Attn.: Chief Counsel, R&D 

Fax: +1-646-563-9619

 To help expedite Pfizer’s awareness and response, copies of notices may be provided to Pfizer by email but must be supplemented by
one of the following methods: (a) personal delivery, (b) first class certified mail with return receipt requested, or (c) next-day delivery by major international courier, with confirmation of
delivery. Electronic copies may be sent via email to [***]. 
 All correspondence to BioNTech will be addressed as follows: 

BioNTech AG 
 An der Goldgrube 12

 D-55131 

Mainz, Germany 
 Attn: Vice
President, Legal and Intellectual Property 
 Fax: +49-6131-576-270-28 
 12.7.
Amendment. No amendment, modification or supplement of any provision of this Agreement will be valid or effective unless made in writing and signed by a duly authorized officer of each Party. 

12.8. Waiver. No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or
employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party will not be
construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. 
 12.9.
Severability. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same will not affect any other portion of this Agreement, as it is the intent of the Parties that this
Agreement will be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement will be construed as if such clause of portion thereof had never been contained
in this Agreement, and there will be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the fullest extent permitted by applicable Law. 

  
 81 

 12.10. Descriptive Headings. The descriptive headings of this Agreement are
for convenience only and will be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
 12.11.
Global Trade Control Laws. The Parties acknowledge that certain activities covered by or performed under this Agreement may be subject to laws, regulations or orders regarding economic sanctions, import controls or export controls
(“Global Trade Control Laws”). Each of the Parties will perform all activities under this Agreement in compliance with all applicable Global Trade Control Laws. Furthermore, with respect to the activities performed under this
Agreement, each of the Parties represents, warrants and covenants that: 
 12.11.1. Each Party will not, for activities under
this Agreement, (i) engage in any such activities in a Restricted Market; (ii) involve individuals ordinarily resident in a Restricted Market; or (iii) include companies, organizations, or Governmental Authorities from or located in a
Restricted Market. “Restricted Market” for purposes of this Agreement means the Crimean Peninsula, Cuba, the Donbass Region, Iran, North Korea, Sudan, and Syria, or any other country or region sanctioned by the United States or
European Union. 
 12.11.2. Each Party represents and warrants that it is not a Restricted Party and is not owned or
controlled by a Restricted Party. With respect to activities performed under this Agreement, neither Party will engage or delegate to any Restricted Parties for any activities under this Agreement. Each Party will screen all relevant Third Parties
involved by such Party in the activities under this Agreement under the relevant Restricted Party Lists. “Restricted Parties” for purposes of this Agreement means any individual or entity on any of the following “Restricted
Party Lists”: the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals List and the Sectoral Sanctions Identifications List of the U.S. Treasury Department’s Office of Foreign Assets Control; the
U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List of the U.S. Department of Commerce; entities subject to restrictive measures and the Consolidated List of Persons, Groups and Entities Subject to E.U. Financial Sanctions,
as implemented by the E.U. Common Foreign & Security Policy; the List of Excluded Individuals / Entities published by the U.S. Health and Human Services’ Office of Inspector General; any lists of prohibited or debarred parties
established under the U.S. Federal Food Drug and Cosmetic Act; the list of parties suspended or debarred from contracting with the U.S. government; and similar lists of restricted parties maintained by the Governmental Authorities of the countries
that have jurisdiction over the activities conducted under this Agreement. 
 12.11.3. Neither Party will knowingly transfer
to the other Party any goods, software, technology or services that are (i) controlled under the U.S. International Traffic in Arms Regulations or at a level other than EAR99 under the U.S. Export Administration Regulations; or
(ii) specifically identified as an E.U. Dual Use Item or on an applicable export control list of another country. 
 12.12. Dispute
Resolution. If any dispute or disagreement arises between Pfizer and BioNTech in respect of this Agreement, they will follow the following procedures in an attempt to resolve the dispute or disagreement: 

12.12.1. The Party claiming that such a dispute exists will give notice in writing (“Notice of Dispute”) to
the other Party of the nature of the dispute. 

  
 82 

 12.12.2. Within 30 days of receipt of a Notice of Dispute and in advance of
any meeting pursuant to Section 12.12.3, the receiving Party will provide a written response to the other Party’s claims regarding the dispute. 

12.12.3. Within 45 days of receipt of a Notice of Dispute, the Chief Scientific Officer, Vaccine Research and Development of
Pfizer and the Chief Scientific Officer of BioNTech AG will meet at a mutually agreed-upon time and location for the purpose of resolving such dispute to discuss the dispute or disagreement. 

Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate litigation in any court of competent jurisdiction
seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this Section 12.12 will survive for five years from
the date of termination or expiration of this Agreement. 
 12.13. Governing Law. This Agreement is governed by, and all
disputes arising under or in connection with this Agreement shall be resolved in accordance with, laws of England and Wales, without regard to conflict of law principles thereof. 

12.14. Consent to Jurisdiction and Venue. The Parties irrevocably submit to the exclusive jurisdiction of the courts of
England and Wales as regards any claim, dispute or matter (whether contractual or non-contractual) arising out of or in connection with this Agreement (including its formation). Notwithstanding the foregoing,
this clause shall not prevent either Party from being entitled to seek urgent interim or emergency relief (such as a preliminary injunction) before any other court of competent jurisdiction in respect of any claim, dispute or matter (whether
contractual or non-contractual) arising out of or in connection with this Agreement (including its formation). 

12.15. Entire Agreement. This Agreement constitutes and contains the complete, final and exclusive understanding and agreement
of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written, between the Parties respecting the subject matter hereof and thereof, including that certain
Confidential-Disclosure Agreement between the Parties dated [***] which is hereby terminated effective as of the Execution Date, provided that such Confidential Disclosure Agreement will continue to govern the treatment of Confidential
Information disclosed by the Parties prior to the Execution Date in accordance with its terms. 
 12.16. Independent
Contractors. Both Parties are independent contractors under this Agreement. Nothing herein contained will be deemed to create an employment, agency, joint venture or partnership relationship between the Parties hereto or any of their
agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or failure to act of the other Party. Neither Party will have any express or implied power to enter into any contracts or commitments or to
incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any respect whatsoever. 
 12.17.
Counterparts. This Agreement may be executed in two (2) counterparts, each of which will be an original and both of which will constitute together the same document. Counterparts may be signed and delivered by facsimile or digital
(e.g., PDF) file, each of which will be binding when received by the applicable Party. 

  
 83 

 12.18. No Third Party Rights or Obligations. No provision of this Agreement
will be deemed or construed in any way to result in the creation of any rights or obligation in any Person not a Party to this Agreement, and this Agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to
enforce any term of this Agreement. However, Pfizer may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that Pfizer will remain liable hereunder for the
performance by any such Affiliates of any such obligations. 
 (Signature page follows.) 

  
 84 

 IN WITNESS WHEREOF, authorized representatives of the Parties have duly executed this
Agreement as of the Execution Date to be effective as of the Effective Date. 
  

			
	PFIZER INC.	  	BIONTECH RNA
PHARMAECEUTICALS GmbH
		
	 By: [***]
	  	 By: [***]

		
	 Name. [***]
	  	 Name. [***]

		
	 Title: [***]
	  	 Title: [***]

		
		  	BIONTECH AG
		
		  	 By: [***]

		
		  	 Name: [***]

		
		  	 Title: [***]

  
 85 

 Exhibit A 

Research Plan 
  

			
	 Title:
	  	 BioNTech-Pfizer RNA Flu
Vaccine Research Plan

		
	 BioNTech Lead:
	  	[***]
		
	 Pfizer Lead:
	  	[***]

 Brief Rational/Background: 

[***] 
 Objectives, Milestones and Time Frame for Completion:

  
 86 

 Work Plan: 

Detailed descriptions of experiments to be produced jointly by BioNTech and Pfizer during the kick-off meeting after
deal closure and in ongoing consultations, with review of experimental designs by the JSC. 

  
 87 

 Materials: The materials to be transferred are detailed below. 

[***] 
 Equipment and Facilities: 

[***] 
 [***]: 

[***] 
 Human Tissue Samples: 

[***] 
 Subcontractors: 

[***] 

  
 88 

 Work Plan Timeline: 

[***] 

  
 89 

 Three Year Research Budget 

[***] 

  
 90 

 Exhibit B 

PFIZER ANTI-BRIBERY AND ANTI-CORRUPTION PRINCIPLES 

Pfizer has a longstanding corporate policy that prohibits colleagues or anyone acting on our behalf from providing any payment or benefit to any person or
entity in order to improperly influence a government official or to gain an unfair business advantage. Pfizer is committed to performing with integrity, and acting ethically and legally in accordance with all applicable laws and regulations,
including, but not limited to, anti-bribery and anti-corruption laws. We expect the same commitment from the consultants, agents, representatives or other companies and individuals acting on our behalf (“Business Associates”), as well as
those acting on behalf of Business Associates, in connection with work for Pfizer. 
 Bribery of Government Officials 

Most countries have laws that forbid making, offering or promising any payment or anything of value (directly or indirectly) to a government official when the
payment is intended to influence an official act or decision to award or retain business. Under Pfizer’s policies, “government official” is broadly interpreted and includes: (i) any elected or appointed government official (e.g.,
a member of a ministry of health); (ii) any employee or person acting for or on behalf of a government official, agency, or enterprise performing a governmental function; (iii) any political party, candidate for public office, officer,
employee, or person acting for or on behalf of a political party or candidate for public office; or (iv) an employee or person acting for or on behalf of a public international organization (e.g., the United Nations). “Government” is
meant to include all levels and subdivisions of governments (i.e., local, regional, or national and administrative, legislative, or executive). Because this definition of “government official” is so broad, it is likely that Business
Associates will interact with a government official in the ordinary course of their business on behalf of Pfizer. For example, doctors employed by government-owned hospitals would be considered “government officials” under Pfizer’s
policies. 
 The U.S. Foreign Corrupt Practices Act of 1977 (the “FCPA”) prohibits making, promising, or authorizing the making of a payment or
providing anything of value to a non-U.S. government official to improperly or corruptly induce that official to make any governmental act or decision to assist a company in obtaining or retaining business, or
to otherwise obtain an improper advantage. The FCPA also prohibits a company or person from using another company or individual to engage in any of the foregoing activities. As a U.S. company, Pfizer must comply with the FCPA and could be held
liable as a result of acts committed anywhere in the world by a Business Associate. 
 Anti-Bribery and Anti-Corruption Principles Governing Interactions
with Governments and Government Officials 
 Business Associates must communicate and abide by the following principles with regard to their interactions
with governments and government officials: 
  

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or
indirectly make, promise, or authorize the making of a corrupt payment or provide anything of value to any government official to induce that government official to make any governmental act or decision to help Pfizer obtain or retain business.
Business Associates, and those acting on their behalf in connection with work for Pfizer, may never make a payment to or offer a government official any item or benefit, regardless of value, as an improper inducement for such government official to
approve, reimburse, prescribe, or purchase a Pfizer product, to influence the outcome of a clinical trial, or otherwise improperly to benefit Pfizer’s business activities. 

 

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, need to understand
whether local laws, regulations, or operating procedures (including requirements imposed by government entities such as government-owned hospitals or research institutions) impose any limits, restrictions, or disclosure requirements on compensation,
financial support, donations, or gifts that may be provided to government officials. Business Associates, and those acting on their behalf in connection with work for Pfizer, must take into account and comply with any applicable restrictions in
conducting their Pfizer-related activities. If a Business Associate is uncertain as to the meaning or applicability of any identified limits, restrictions, or disclosure requirements with respect to
interactions with government officials, that Business Associate should consult with his or her primary Pfizer contact before undertaking their activities. 

  
 91 

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, are not permitted to
offer facilitation payments. A “facilitation payment” is a nominal, unofficial payment to a government official for the purpose of securing or expediting the performance of a routine,
non-discretionary governmental action. Examples of facilitation payments include payments to expedite the processing of licenses, permits or visas for which all paperwork is in order.In the event that a
Business Associate, or someone acting on their behalf in connection with work for Pfizer, receives or becomes aware of a request or demand for a facilitation payment or bribe in connection with work for Pfizer, the Business Associate shall report
such request or demand promptly to his or her primary Pfizer contact before taking any further action. 

 Commercial Bribery 

Bribery and corruption can also occur in non-government, business to business relationships.Most countries have laws
which prohibit offering, promising, giving, requesting, receiving, accepting, or agreeing to accept money or anything of value in exchange for an improper business advantage. Examples of prohibited conduct could include, but are not limited to, the
provision of inappropriate gifts or hospitality, kickbacks, or investment opportunities offered to improperly induce the purchase of goods or services. Pfizer colleagues are not permitted to offer, give, solicit or accept bribes, and we expect our
Business Associates, and those acting on their behalf in connection with work for Pfizer, to abide by the same principles. 
 Anti-Bribery and
Anti-Corruption Principles Governing Interactions with Private Parties and Pfizer Colleagues 
 Business Associates must communicate and abide by the
following principles with regard to their interactions with private parties and Pfizer colleagues: 
  

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or
indirectly make, promise, or authorize the making of a corrupt payment or provide anything of value to any person to induce that person to provide an unlawful business advantage for Pfizer. 

 

	 	•	 	 Business Associates, and those acting on their behalf in connection with work for Pfizer, may not directly or
indirectly, solicit, agree to accept, or receive a payment or anything of value as an improper inducement in connection with their business activities performed for Pfizer. 

 

	 	•	 	 Pfizer colleagues are not permitted to receive gifts, services, perks, entertainment, or other items of more than
token or nominal monetary value from Business Associates, and those acting on their behalf in connection with work for Pfizer. Moreover, gifts of nominal value are only permitted if they are received on an infrequent basis and only at appropriate
occasions. 

 Reporting Suspected or Actual Violations 

Business Associates, and those acting on behalf in connection with work for Pfizer, are expected to raise concerns related to potential violations of these
International Anti-Bribery and Anti-Corruption Principles or the law. Such reports can be made to a Business Associate’s primary point of contact at Pfizer, or if an Associate prefers, to Pfizer’s Compliance Group, by e-mail at corporate.compliance@pfizer.com or by phone at 1-212-733-3026. 

 

  
 92 

 Exhibit C 

Pfizer’s Corporate Policy regarding Animal Care and Use (v. 1.2, June 18, 2017) 

BACKGROUND 
 Pfizer is dedicated to helping people and
animals live longer, healthier lives through the discovery and development of breakthrough medicines and therapies. Animal-based biomedical research in the pharmaceutical industry remains a vital component of the discovery, evaluation and regulatory
processes, which lead to the development of products that save or improve human lives throughout the world. Pfizer’s Animal Care and Use policy reflects our absolute commitment that all animals used by our business are treated humanely. This
means that any research involving animals is conducted only after appropriate ethical consideration and review. This review ensures that we provide a high level of care to all animals used, and that a scientifically appropriate and validated
alternative to the use of animals is not available. 
 Why We Conduct Animal-based Biomedical Research 

Pfizer is ethically and legally obliged to rigorously evaluate potential new medicines and therapies. Many of these evaluations can be, and are, accomplished
by techniques that do not require the use of animals. However, given the present state of scientific knowledge, testing potential new medicines and therapies in animals is frequently critical to their evaluation, and is required by regulatory
authorities worldwide to ensure the quality, efficacy and safety of the medicines we discover. 
 Pfizer’s Commitment to Ethical and Humane
Treatment of Animals 
 Pfizer accepts its responsibility to use animals in a humane and ethical manner and expects all Colleagues to treat animals with
respect. We approach the use of animals in our business with a high level of humane and ethical concern for those animals. All use is carefully planned and conducted in such a way as to minimize or avoid pain, distress, or discomfort to the animals.
Every proposed use is thoroughly evaluated before being undertaken as the health and well-being of all animals under our care is a primary concern. Similarly, we expect any Third Party organization we engage to conduct animal-based research on our
behalf to adhere to this Policy and to comply with all applicable laws and regulations. 
 Pfizer’s Commitment to Alternatives to Animal-based
Biomedical Research 
 Pfizer is fully committed to the development and use of scientifically validated alternative testing methods that are acceptable
to regulatory authorities and do not compromise patient safety or the effectiveness of our medicines. Pfizer continues to engage and lead cross-industry efforts aimed at developing and refining new in-vitro
testing and predictive informatics-based systems that hold promise for future reduction of animal usage. Pfizer works directly with regulators and through pharmaceutical trade organizations to increase the recognition and acceptance of alternative
models where such alternatives can be used appropriately. 
 POLICY 

For as long as it remains necessary to use animals in the discovery, development,evaluation and production of new medicines, we commit to maintaining high
standards in the humane treatment of these animals. Significantly, we embrace the principles known as the “3Rs” of animal research first proposed in 1959 by Russell and Burch to describe the use of alternatives in animal research. These
are: 
 Replacement of animal experiments with non-animal experiments such as mathematical models, computer
simulations, and in-vitro biological systems wherever appropriate; and where animals must be used; 
 Reduction
of the numbers of animals used in each study, and of the number of studies involving animals, to the absolute minimum necessary to obtain valid results and achieve our research objectives; and 

Refinement of procedures involving animals to minimize the potential for pain and distress. 

  
 93 

 In addition to the 3R’s, and to further assure we maintain high standards for our animals, we have
adopted the following guidelines: 
  

	 	•	 	 When animal experimentation is necessary, great care is taken to choose the most appropriate animal species for
the research and to optimize the study design to ensure that the results will be as meaningful as possible. 

  

	 	•	 	 Non-human primates will only be used when scientifically justified, for
example in cases where other species will not provide sufficiently close analogues to the biological pathways and responses expected in humans. 

  

	 	•	 	 All studies are carefully designed to gain the maximum information from the fewest number of animals possible.

  

	 	•	 	 Each proposed use of animals is reviewed and approved by a panel of objective experts prior to performing any
experiments to ensure that the use of the animals is consistent with sound scientific practices and ethical considerations. 

  

	 	•	 	 Our standards of animal care and welfare meet or exceed those required by applicable local, national, or
international laws and regulations. 

  

	 	•	 	 We regularly monitor our animals for signs of ill health or distress and take prompt action wherever appropriate.
We make veterinary care available to our animals at all times. 

  

	 	•	 	 Our veterinarians and scientists evaluate every proposed animal procedure with an emphasis on eliminating or
minimizing any potential for pain or distress which may be experienced by the animals. 

  

	 	•	 	 We train all Colleagues involved in the care, welfare and use of animals to ensure (a) that they are
competent in the care of the animals and in the procedures required to complete the proposed work; (b) that they are aware of the ethical issues involved in the use of animals; and (c) that they demonstrate respect and humane treatment
towards the animals in their care. 

  

	 	•	 	 We expect our contract research organizations, collaborators and vendors to maintain similar high standards.
Parties conducting animal based research for Pfizer at their facilities are required to adhere to this Policy and to comply with all applicable laws and regulations. We perform welfare audits of Third Party facilities in accordance with our quality
assurance policies. 

  

	 	•	 	 Because respect is a key tenant in our use of animals, we have also established standards regarding the use of
animals in the marketing of Pfizer products. If advertisements featuring animals are used, any animal shown should be healthy and in a natural or appropriate setting. Non-human primates should not be used in
the advertising of Pfizer products, and other wild animals will also not be used unless they are shown in their natural setting or portrayed through animation or computer-generated graphics. 

This Policy represents Pfizer’s commitment to high-quality animal care and welfare throughout our business, and to the replacement, reduction and
refinement of the use of animals in research. We are equally committed to bringing important and safe new medicines to patients. 

  
 94 

 Exhibit D 

Manufacturing Technology Transfer Plan 
  

	
	[***]

  
 95 

 Schedule 1.15 

Pfizer’s CAN Criteria in Effect as of the Effective Date 

[***] 

  
 96 

 Schedule 1.111 

Specified Persons 
 [***] 

  
 97 

 Schedule 3.5.1 

Marginal Royalty Rate Calculation Example 

[***] 

  
 98 

 Schedule 4.2.2 

Approved Subcontractors 

[***] 

  
 99 

 Schedule 5.3 

Supply Agreement Terms 
  

			
	DEFINITIONS
	 [***]

	
	MANUFACTURE OF CLINICAL TRIAL MATERIAL
	 [***]

	
	FINANCIAL TERMS
	 [***]

  
 100 

 Schedule 9.3 

Exceptions to BioNTech’s Representations and Warranties 

[***] 

  
 101 

 Schedule 9.3.3     

Candidates Existing as of the Execution Date 

[***] 

  
 102 

 Schedule 9.3.4     

BioNTech Patent Rights Existing as of the Execution Date 

[***] 

  
 103 

 Schedule 9.3.12 

Current Licenses 
 [***] 

  
 104 

 Schedule 9.6.3 

Certain Terms of Current Licenses 

[***] 

  
 105 

 Schedule 9.9 

BioNTech’s Knowledge 
 [***] 

  
 106 

 Schedule 10.7.1(a) 

Effects of Reversion Rights in case of Termination for Cause by BioNTech or Termination for Convenience by Pfizer 

In the event BioNTech notifies Pfizer pursuant to Section 10.7.1(a)(ii) that it desires a license to the Continuation Product, the following terms and
conditions shall apply: 
  

	 	1.	 Within the time periods set forth in Section 10.7.1(a)(ii), if requested by BioNTech, the Parties will,
subject to the terms of the license described in Section 10.7.1(a)(ii)(C), mutually agree upon a transition plan to effect an orderly and timely transition to BioNTech of all Development, Manufacture and Commercialization activities and
responsibilities with respect to Continuation Products (a “Transition Plan”). Any and all support provided by Pfizer with respect to the Transition Plan shall be at the BioNTech’s cost and expense. 

 

	 	2.	 To the extent permitted by Law and requested by BioNTech, assignment and transfer by Pfizer to BioNTech of all
Regulatory Materials Controlled by Pfizer solely relating to the Continuation Products in the Territory, and not relating to any other product. If Pfizer is restricted from assigning or transferring ownership of any of the foregoing items to
BioNTech, and in respect of Regulatory Materials Controlled by Pfizer and necessary or useful for the Development, Manufacturing or Commercialization of the Continuation Products in the Territory, Pfizer shall use its Commercially Reasonable Efforts
to grant BioNTech (or its designee) a right of reference or use to such item and Pfizer shall take reasonable actions that are reasonably necessary to effect such assignment and transfer or grant of right of reference or use to BioNTech (or its
designee), at BioNTech’s sole expense, including by making such filings as may be reasonably required with Regulatory Authorities in the Territory that may be necessary to record such assignment or effect such transfer and, at BioNTech’s
written request complete any pending regulatory filings with respect to all Continuation Products. For purposes of this Schedule 10.7.1(a), “Regulatory Materials” means all regulatory registrations, applications,
authorizations and approvals (including approvals of BLAs, supplements and amendments, pre- and post-approvals, pricing and Third Party reimbursement approvals, and labeling approvals), Regulatory Approvals or
other submissions made to or with any Regulatory Authority necessary for the Development (including the conduct of clinical studies), Manufacture or Commercialization of a Continuation Product in a regulatory jurisdiction, together with all related
correspondence to or from any Regulatory Authority and all documents referenced in the complete regulatory chronology for each BLA, including all INDs, clinical trial applications and foreign equivalents of any of the foregoing.

  

	 	3.	 Upon BioNTech’s written request, assignment and transfer by Pfizer to BioNTech of its entire right, title,
and interest in and to all pharmacological, toxicological and clinical test data and results, research data, reports and batch records, safety data and all other data Controlled by Pfizer and reasonably in its possession as of the effective date of
termination and generated in the Development, Manufacture or Commercialization of Continuation Products, at BioNTech’s sole expense, subject to a retained non-exclusive right by Pfizer to use such data
for research purposes and to continue prosecution of any Patent Rights Controlled by Pfizer and its Affiliates in the course of conducting its activities under this Agreement. 

 

	 	4.	 Any supply agreement entered into by the Parties pursuant to the Agreement shall terminate. If Pfizer has, at
such time of termination, established its own supply and is capable of supplying the Continuation Product without breaching applicable Law and to the extent not prevented by technical or force majeure

  
 107 

	 	
(as defined in Section 12.4 of the Agreement) conditions, and if BioNTech so requests, the Parties shall negotiate in good faith as soon as reasonably possible (with a target date of [***]
days from the termination effective date) a supply agreement under which Pfizer would supply BioNTech with transitional supply of such Continuation Product at [***] and on commercially reasonable terms for a commercially reasonable period of time of
up to [***]months. During the negotiation period, Pfizer will provide a continued supply of the Continuation Product to BioNTech for BioNTech’s demand of Continuation Product for BioNTech’s or its Affiliates Development or
Commercialization of the Product at [***] (provided that such demand does not exceed Pfizer’s anticipated forecasts (prior to termination of this Agreement). The transfer of the applicable Manufacturing process from Pfizer to BioNTech or its
designee will be part of the transition planning pursuant to Section 1 above. 

  

	 	5.	 BioNTech shall have the first right to file, prosecute, maintain, defend and enforce any Product Patent Rights
included in the Reversion Technology; provided, however, that if Pfizer requests, Pfizer shall be granted the right to review and comment on such Product Patent Rights. 

 

	 	6.	 Pfizer shall receive the following percentage of the royalties set forth in the table in Section 3.5.1 of
the Agreement in respect of Continuation Product Net Sales during the Continuation Product Royalty Term: 

  

			
	[***]	  	

  

	 	(A)	 “Continuation Product Net Sales” shall be on the same basis as if BioNTech was Pfizer in the
definition of Net Sales. 

  

	 	(B)	 “Continuation Product Royalty Term” shall be on the same basis as if BioNTech was Pfizer in
the definition of Royalty Term (or defined terms used in that definition). 

  

	 	7.	 Pfizer shall have the same reporting, audit and other rights with respect to the royalties to be paid by
BioNTech to Pfizer under this Schedule 10.7.1(a) as are afforded by Pfizer to BioNTech under the Agreement. 

  

	 	8.	 Section 3.5.3 of the Agreement would apply mutatis mutandis to BioNTech with respect to the
Continuation Product, provided, however that: 

  

	 	(A)	 BioNTech shall maintain its books and records in accordance with IFRS, as consistently applied by BioNTech with
respect to sales of the Product, rather than GAAP; 

  

	 	(B)	 Pfizer shall not be obliged to share or be responsible for any payments to any Third Party in respect of the
Candidates or Products under any royalty stacking provisions or Third Party Patents, and BioNTech shall be responsible for all Third Party payment obligations and responsibilities concerning Third Party Patents; and 

  
 108 

	 	(C)	 BioNTech shall be responsible for and indemnify Pfizer for any breach or liability arising under any agreement
between Pfizer and a Third Party concerning Patent Rights licensed in by Pfizer in connection with any Candidate or Product. 

  
 109EX-10.19

Table of Contents

 Exhibit 10.19 

THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 

COLLABORATION & LICENSE AGREEMENT 

DATED AS OF OCTOBER 9th, 2018 

BY AND BETWEEN 
 THE
TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 
 AND 

BIONTECH RNA PHARMACEUTICALS GMBH 

Table of Contents

 TABLE OF CONTENTS 

 

									
	 	  	Page	 
	 ARTICLE 1 Definitions
	  	 	1	 
		
	 ARTICLE 2 Collaboration Programs; Governance
	  	 	11	 
				
		 	2.1	  	Overall Project.	  	 	11	 
		 	2.2	  	Research.	  	 	11	 
		 	2.3	  	Funding of the Research Program	  	 	12	 
	            	 	2.4	  	Unavailability of Dr. Drew Weissman	  	 	13	 
		 	2.5	  	Transfer of Materials	  	 	13	 
		 	2.6	  	Governance.	  	 	13	 
		 	2.7	  	Licensed Indication Election	  	 	15	 
		
	 ARTICLE 3 Licenses and other Rights
	  	 	16	 
				
		 	3.1	  	Grant of License to Licensee.	  	 	16	 
		 	3.2	  	Retained Rights and Grant of License to Penn.	  	 	16	 
		 	3.3	  	U.S. Government Rights.	  	 	16	 
		 	3.4	  	Grant of Sublicense by Licensee	  	 	17	 
		 	3.5	  	No Implied License	  	 	18	 
		 	3.6	  	Additional Weissman Patent Rights.	  	 	18	 
		 	3.7	  	Covenants of Penn.	  	 	18	 
		 	3.8	  	Time-Limited Option.	  	 	18	 
		
	 ARTICLE 4 Financial Provisions
	  	 	18	 
				
		 	4.1	  	Research Funding	  	 	18	 
		 	4.2	  	Alliance Management Fee.	  	 	18	 
		 	4.3	  	Milestone Payments.	  	 	19	 
		 	4.4	  	Royalties.	  	 	20	 
		 	4.5	  	Penn Sublicense Income.	  	 	21	 
		 	4.6	  	Mode of Payment and Currency.	  	 	22	 
		 	4.7	  	Royalty and Sublicense Income Reports.	  	 	23	 
		 	4.8	  	Late Payments	  	 	24	 
		 	4.9	  	Accounting	  	 	24	 
		 	4.10	  	Books and Records.	  	 	24	 
		 	4.11	  	Audits	  	 	24	 
		 	4.12	  	Withholdings	  	 	25	 
		
	 ARTICLE 5 Manufacturing, Clinical Development, Regulatory Affairs;
Commercialization
	  	 	26	 
				
		 	5.1	  	Clinical Development.	  	 	26	 
		 	5.2	  	Commercialization.	  	 	26	 
		 	5.3	  	Manufacturing	  	 	26	 
		 	5.4	  	Regulatory	  	 	26	 
		 	5.5	  	General Diligence.	  	 	27	 
		 	5.6	  	Progress Reports.	  	 	28	 
		
	 ARTICLE 6 Intellectual Property
	  	 	28	 
				
		 	6.1	  	Ownership and Inventorship.	  	 	28	 

  
 -i- 

Table of Contents

 TABLE OF CONTENTS 

(continued) 
  

									
	 	  	Page	 
	            	 	6.2	  	Patent Filing Prosecution and Maintenance	  	 	29	 
		 	6.3	  	Patent Costs	  	 	30	 
		 	6.4	  	Infringement	  	 	31	 
		 	6.5	  	Patent Marking	  	 	32	 
		
	 ARTICLE 7 Confidentiality& Publication
	  	 	33	 
				
		 	7.1	  	Confidential Information.	  	 	33	 
		 	7.2	  	Exceptions to Confidentiality.	  	 	33	 
		 	7.3	  	Penn Intellectual Property	  	 	34	 
		 	7.4	  	Publications	  	 	34	 
		 	7.5	  	Other Permitted Disclosures.	  	 	34	 
		
	 ARTICLE 8 Representations, Warranties and Covenants
	  	 	35	 
				
		 	8.1	  	Mutual Representations and Warranties.	  	 	35	 
		 	8.2	  	Penn Representations.	  	 	35	 
		 	8.3	  	Disclaimer of Representations and Warranties	  	 	35	 
		 	8.4	  	Mutual Covenants.	  	 	36	 
		
	 ARTICLE 9 Indemnification; Insurance and Limitation of Liability
	  	 	36	 
				
		 	9.1	  	Indemnification.	  	 	36	 
		 	9.2	  	Insurance.	  	 	37	 
		 	9.3	  	Limitation of Liability	  	 	38	 
		
	 ARTICLE 10 Term and Termination
	  	 	38	 
				
		 	10.1	  	Term	  	 	38	 
		 	10.2	  	Termination of the Agreement for Convenience.	  	 	38	 
		 	10.3	  	Termination For Cause.	  	 	38	 
		 	10.4	  	Effects of Termination.	  	 	39	 
		 	10.5	  	Tolling	  	 	40	 
		
	 ARTICLE 11 ADDITIONAL PROVISIONS
	  	 	40	 
				
		 	11.1	  	Relationship of the Parties.	  	 	40	 
		 	11.2	  	Expenses.	  	 	40	 
		 	11.3	  	Third Party Beneficiary	  	 	40	 
		 	11.4	  	Use of Names	  	 	40	 
		 	11.5	  	No Discrimination	  	 	41	 
		 	11.6	  	Successors and Assignment.	  	 	41	 
		 	11.7	  	Further Actions.	  	 	41	 
		 	11.8	  	Entire Agreement of the Parties; Amendments.	  	 	41	 
		 	11.9	  	Governing Law.	  	 	42	 
		 	11.10	  	Dispute Resolution	  	 	42	 
		 	11.11	  	Injunctive Relief	  	 	42	 
		 	11.12	  	Notices and Deliveries.	  	 	42	 
		 	11.13	  	Waiver	  	 	43	 
		 	11.14	  	Severability.	  	 	43	 
		 	11.15	  	Interpretation	  	 	43	 
		 	11.16	  	Counterparts	  	 	43	 
		 	11.17	  	Force Majeure.	  	 	44	 

  
 -ii- 

Table of Contents

 COLLABORATION & LICENSE AGREEMENT 

This Collaboration & License Agreement (this “Agreement”) is dated as of October 9th 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and BioNTech RNA
Pharmaceuticals GmbH, a German corporation having its principal office at An der Goldgrube 12, 55131 Mainz, Germany (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as
“Parties”. 
 RECITALS: 

WHEREAS, Licensee is a biopharmaceutical company with expertise in the development, manufacture and commercialization of mRNA vaccines,
including RNA synthesis, formulation and GMP manufacturing; 
 WHEREAS, Penn, through Dr. Drew Weissman and the Weissman
Laboratory, have technology and expertise in RNA synthesis and purification, immunogen discovery and development, and the use of mRNA as prophylactic vaccines against infectious diseases; and 

WHEREAS, the Research Program contemplated by this Agreement is of mutual interest to Licensee and Penn and furthers the educational,
scholarship and research objectives of Penn as a nonprofit, tax-exempt, educational institution, and may benefit Licensee and Penn through the creation or discovery of new inventions and the development and
commercialization of Products (as defined below). 
 NOW, THEREFORE, in consideration of the various promises and undertakings set
forth herein, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Unless otherwise
specifically provided herein, the following terms shall have the following meanings: 
  

	1.1	 “Acceptance Criteria” means the target criteria set forth in the Research Plan with respect to
the development of any Product; provided that on an Indication-by-Indication basis these criteria shall be deemed to have been achieved no later than upon completion of
an IND-ready data package for such Product for such Indication. 

  

	1.2	 “Accounting Standards” means the United States generally accepted accounting principles
applied on a consistent basis (GAAP) or the International Financial Reporting Standards (IFRS). 

  

	1.3	 “Affiliate” means a Person that controls, is controlled by or is under common control with a
Party, but only for so long as such control exists. For the purposes of this Section 1.2, the word “control” (including, with correlative meaning, the terms “controlled by” or “under the common control with”) means
the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such Person or entity, whether by the ownership of more than fifty percent (50%) of the voting securities of such entity, or
by contract or otherwise. 

  

	1.4	 “Arbitration Rules” has the meaning as set forth in Section 11.10(b).

  

	1.5	 “BioNTech Background IP” means the BioNTech Background Patents and the BioNTech Background Know-How. 

Table of Contents

	1.6	 “BioNTech Background Know-How” means Know-How that (i) is Controlled by Licensee and/or its Affiliates as of the Effective Date or thereafter during the Research Term and (ii) is necessary or reasonably useful for the research, development,
manufacturing, use or exploitation of any Product. 

  

	1.7	 “BioNTech Background Patents” means the Patent Rights that are listed on Exhibit A, and
any Patent Rights issuing therefrom. 

  

	1.8	 “BioNTech Foreground IP” means the BioNTech Foreground Patents and the BioNTech Foreground Know-How. 

  

	1.9	 “BioNTech Foreground Patents” means any Patent Rights solely conceived or conceived and
reduced to practice by Licensee or its subcontractors under the Research Program. 

  

	1.10	 “BioNTech Foreground Know-How” means Know-How solely developed by Licensee or its subcontractors under the Research Program. 

  

	1.11	 “BioNTech Materials” means any biological or chemical materials Controlled by Licensee
and provided to Penn under this Agreement. 

  

	1.12	 “BioNTech Patent Family” means Patent Rights that (i) are related to each other through
priority claims, (ii) claim or cover one or more Licensed Product or the manufacturing or use thereof, (iii) are Controlled by Licensee and (iv) excludes Penn Patent Rights. 

 

	1.13	 “BLA” means an application submitted to a Regulatory Authority for marketing approval of a
product, including (a) a Biologics License Application or New Drug Application submitted to the FDA, (b) a Marketing Authorization Application (“MAA”) in the European Union, (c) any equivalent or comparable
application, registration or certification in any other country or region, or (d) any successor applications or procedures, supplements or amendments that may be submitted with respect to the foregoing. 

 

	1.14	 “Calendar Quarter” mean the respective periods of three (3) consecutive calendar months
ending on March 31, June 30, September 30 and December 31 of each Calendar Year. 

  

	1.15	 “Calendar Year” means each successive period of twelve (12) months commencing on
January 1 and ending on December 31. 

  

	1.16	 “cGLP” means the current good laboratory practice regulations promulgated by the FDA,
published at 21 C.F.R. § 58, and all applicable FDA rules, regulations, orders and guidances and equivalent or comparable non-United States regulations, rules, orders, guidances and standards in the
Territory, as applicable, as such current laboratory practices, rules, regulations, orders, guidances and standards may be amended from time to time. 

  

	1.17	 “cGMP” means those current good manufacturing practices promulgated by the FDA, published at
21 C.F.R §§ 210 and 211, and all applicable FDA rules, regulations, orders and guidances, and the requirements with respect to current good manufacturing practices prescribed by the European Community under provisions of “The Rules
Governing Medicinal Products in the European Community, Volume 4, Good Manufacturing Practices, Annex 13, Manufacture of Investigational Medicinal Products, July 2003”, as such practices, rules, orders, guidances, guidelines, regulations and
standards may be amended from time to time. 

  

	1.18	 “Clinical Trial” means a human clinical trial conducted on human subjects that is designed to
(a) evaluate whether a pharmaceutical product is reasonably safe for continued testing, (b) investigate the safety and efficacy of the pharmaceutical product for its intended use, and to define warnings, precautions and adverse reactions
that may be associated with the pharmaceutical product in the dosage range to be prescribed or (c) support Regulatory Approval of such pharmaceutical product or label expansion of such pharmaceutical product. 

  
 2 

Table of Contents

	1.19	 “Combination Product” means any Product containing a) at least one Licensed Product and b) at
least one additional therapeutically active ingredient that is not a Product; in each case where the foregoing is co-formulated, co-packaged or sold under one price
(whether payment of such price is paid to the same or more than one seller). For the avoidance of doubt, adjuvants, including molecular adjuvants or lipid nanoparticles, are not considered therapeutically active ingredients for the purposes of this
definition regardless of whether or not such adjuvant or lipid nanoparticle is co-packaged with a Licensed Product. 

  

	1.20	 “Commercially Reasonable Efforts” means the efforts and resources that a similarly situated
biopharmaceutical company or research institution, as applicable, would use for its own internally discovered technology of similar commercial potential and similar stage of development, taking into consideration the likely timing of the
technology’s entry into the market, any patent and other proprietary position and issues of safety and efficacy. For clarity, Commercially Reasonable Efforts will not mean that a Party guarantees that it will actually accomplish the applicable
task or objective. 

  

	1.21	 “Companion Diagnostic” means an ex vivo medical test used as a companion to a Licensed
Product in the Field for diagnosis, screening, or evaluation of a disease, or the progress of, or response to, treatment in the Field. 

  

	1.22	 “Controlled” means, with respect to intellectual property rights, that a Party or one of its
Affiliates owns or has a license or sublicense to such intellectual property rights and has the ability to provide to, grant a license or sublicense to, or assign its right, title and interest in and to, such intellectual property rights as provided
for in this Agreement without violating the terms of any agreement or other arrangement with any Third Party. 

  

	1.23	 “Development Candidate” means any Product developed under the Research Plan that meets the
Acceptance Criteria, and/or for which Licensee decides to enter into the clinical development and file an IND. 

  

	1.24	 “Distributor” means any Third Party that: [***]. 

 

	1.25	 “Distributor Fees” means, with respect to a Licensed Product, any consideration received by
Licensee or its Affiliates or Sublicensees from a Distributor that is allocable to such Licensed Product [***]. 

  

	1.26	 “EMA” means the European Medicines Agency and any successor entity thereto.

  

	1.27	 “FDA” means the United States Food and Drug Administration and any successor entity thereto.

  

	1.28	 “FD&C Act” means the United States Federal Food, Drug and Cosmetic Act, as amended.

  

	1.29	 “Field” means mRNA vaccines and mRNA diagnostics for the diagnosis, detection, evaluation,
prophylaxis and treatment of infectious diseases in humans and animals. 

  

	1.30	 “First Commercial Sale” means, on a country-by-country basis, the first Sale of a Licensed Product in such country to a Third Party by Licensee, or any of its Affiliates or Sublicensees, in each case, after all Governmental Approvals have been
obtained for such country. 

  

	1.31	 “Foreground IP” means the BioNTech Foreground IP, the Joint Foreground IP, the Penn Foreground
IP, and all Research Results. 

  
 3 

Table of Contents

	1.32	 “Foreground Patents” means any Patent Rights covering any Foreground IP.

  

	1.33	 “Governmental Approval” means, with respect to a Licensed Product in a country or region, all
approvals, licenses, registrations and authorizations of the relevant Governmental Body, if applicable, required for the commercialization of such Licensed Product in such country. 

 

	1.34	 “Governmental Body” means any: (a) nation, principality, state, commonwealth, province,
territory, county, municipality, district or other jurisdiction of any nature; (b) federal, provincial, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority of any nature (including any
governmental division, subdivision, department, agency, bureau, branch, office, commission, council, board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi-national
or supranational organization or body; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative, judicial, administrative, regulatory, police, military or taxing authority or power of any nature.

  

	1.35	 “IND” means an Investigational New Drug Application as defined in the FD&C Act and the
regulations promulgated thereunder, or (b) the equivalent application to the equivalent regulatory authority in any other regulatory jurisdiction, including a Clinical Trial Authorization (“CTA”) to the European Medicines
Agency, the filing of which is necessary to initiate or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction. 

  

	1.36	 “Indication” means, with respect to the Field, a distinct disease or disorder; in each case
regardless of the severity, frequency or route of any treatment. One Indication shall be distinguished from another Indication by reference to the then current World Health Organization (WHO) International Classification of Diseases at the time such
Indication is selected for inclusion in the Research Program, as agreed upon by the Parties. Indication consists of Licensed Indications and Research Indications, which shall be listed in Exhibits D and E. 

 

	1.37	 “Joint Foreground IP” means the Joint Foreground Patents and the Joint Foreground Know-How. 

  

	1.38	 “Joint Foreground Know-How” means Know-How that is Controlled by the Parties and developed jointly by Licensee and Penn in the Weissman Laboratory during the Research Term under the Research Program. 

 

	1.39	 “Joint Foreground Patents” means any Patent Rights Controlled by the Parties and conceived or
conceived and reduced to practice jointly by Licensee and Penn (or their relevant subcontractors) under the Research Program. 

  

	1.40	 “Know-How” means proprietary and confidential
intellectual property, data, results, pre-clinical and clinical protocols and study data, chemical structures, chemical sequences, information, inventions, formulas, trade secrets, techniques, methods,
processes, procedures and developments, and regulatory documentation, whether or not patentable; except that “Know-How” does not include Patent Rights claiming any of the foregoing (for as long as
such Patent Rights exist). 

  

	1.41	 “Law” or “Laws” means all applicable laws, statutes, rules, regulations,
ordinances and other pronouncements having the binding effect of law of any Governmental Body. 

  

	1.42	 “Licensed Indication” means an Indication for which a Product has achieved the Acceptance
Criteria as determined by the JSC and/or formal notice is provided to Penn as set forth in Section 2.7. Licensed Indications shall be listed in Exhibit D, which exhibit shall be updated by the Parties as new Licensed Indications are
added or removed. 

  
 4 

Table of Contents

	1.43	 “Licensed Product” means any Product for an Indication covered by a Valid Penn Claim or
whose manufacture, import, use, offer for sale or sale would, absent the License, constitute an infringement, inducement of infringement or contributory infringement of any Valid Penn Claim. 

 

	1.44	 “MHLW” means the Ministry of Health, Labor and Welfare of Japan. 

 

	1.45	 “Net Revenue” means the gross monetary consideration received by Penn for a sublicense to a
Product developed under this Agreement directed against a terminated Licensed Indication in accordance with the provisions of Section 5.5.4 of this Agreement that would meet the definition of Product if licensed to Licensee under this Agreement
less (a) payments made to Penn under sponsored research agreements or research awards, grants and contracts, (b) accrued interest, (c) reimbursement for intellectual property or legal expenses, and (d) reimbursement for research
and development costs [***]. 

  

	1.46	 “Net Sales” means the gross consideration invoiced or received by Licensee or any of its
Affiliates or Sublicensees for Sales of Licensed Product (including any cash amounts plus the fair market value of any other forms of consideration), less the following deductions (to the extent included in and not already deducted from the gross
amounts invoiced or otherwise charged) to the extent reasonable and customary and solely related to the sale of the Licensed Product: 

  

	 	(a)	 trade discounts, including trade, cash and quantity discounts or rebates, credits or refunds;

  

	 	(b)	 allowances or credits granted upon claims, returns or rejections of products, including recalls, regardless of
the party requesting such recall; 

  

	 	(c)	 charges included in the gross sales price for freight, insurance, transportation, postage, handling and any
other charges relating to the sale, transportation, delivery or return of such Licensed Product; 

  

	 	(d)	 customs duties, sales, excise and use taxes and any other governmental charges (including value added tax)
actually paid in connection with the transportation, distribution, use or sale of such Licensed Product (but excluding what is commonly known as income taxes); 

 

	 	(e)	 rebates and chargebacks or retroactive price reductions made to federal, state or local governments (or their
agencies), or any Third Party payor, administrator or contractor, including managed health organizations; and 

  

	 	(f)	 payments required by law to be made under Medicaid, Medicare or other government special medical assistance
programs (including, but not limited to, payments made under the new “Medicare Part D Coverage Gap Discount Program” and the “Annual Fee on Branded Pharmaceutical Manufacturers”, specific to the Licensed Product for which the
deduction is taken). 

 Even if there is overlap between any of deductions described above, each individual item shall only
be deducted once in the overall Net Sales calculation. Each of the above deductions to Net Sales shall be calculated in accordance with the Accounting Standards (with the applicable Accounting Standard used clearly indicated on any reports). 

In the event that the Licensed Product is sold as a Combination Product, Net Sales will be determined by multiplying Net Sales of such
Combination Product by the fraction A/(A+B), where A is the invoice price of the Licensed Product, when sold separately, and B is the invoice 

  
 5 

Table of Contents

 
price of any other therapeutically active ingredient(s) in the combination, when sold separately, in each case in the same country and similar class, purity and dosage as in the Combination
Product. If, on a country-by-country basis, the Licensed Product or the other therapeutically active ingredient that is not a Product in the Combination Product is/are
not sold separately in such country, Net Sales shall be determined by multiplying actual Net Sales of such Combination Product by the fraction C/(C+D), where C is the fair market value of the Licensed Product portion of such combination and D is the
fair market value of the other therapeutically active ingredient that is not a Product (such fair market value is to be determined by mutual agreement of the Parties or, in the absence of such mutual agreement, by a neutral Third Party). 

 

	1.47	 “Option Patents” means the Patent Rights Controlled by Penn that are listed on Exhibit
F, and any Patent Rights issuing therefrom. 

  

	1.48	 “Patent Rights” means patents and patent applications, together with any unlisted patents and
patent applications claiming priority thereto, and any continuations, continuations-in-part (to the extent related directly to the subject matter of the parent
application or containing new information developed pursuant to the Research Program), reissues, reexamination certificates, substitutions, divisionals, supplementary protection certificates, renewals, registrations, extensions including all
confirmations, revalidations, patents of addition, PCTs, and pediatric exclusivity periods and all foreign counterparts thereof, and any patents issued or issuing with respect to any of the foregoing. 

 

	1.49	 “Penn Background IP” means the Penn Background Patents and the Penn Background Know-How. 

  

	1.50	 “Penn Background Know-How” means Know-How that (i) is Controlled by Penn and a) existing in the Weissman Laboratory as of the Effective Date or b) developed by Penn in the Weissman Laboratory thereafter during the Research Term but outside of
the Research Program and (ii) is necessary or reasonably useful for the research, development, manufacturing, use or exploitation of any Product in the Field (excluding Penn Foreground Know-How).

  

	1.51	 “Penn Background Patents” means the Patent Rights Controlled by Penn that are listed on
Exhibit B, and any Patent Rights issuing therefrom. 

  

	1.52	 “Penn Foreground IP” means the Penn Foreground Patents and the Penn Foreground Know How.

  

	1.53	 “Penn Foreground Know-How” means Know-How that (i) is Controlled by Penn and developed by Penn in the Weissman Laboratory during the Research Term under the Research Program and (ii) is necessary or reasonably useful for the research,
development, manufacturing, use or exploitation of any Product in the Field. 

  

	1.54	 “Penn Foreground Patents” means any Patent Rights Controlled by Penn and solely conceived or
conceived and reduced to practice by Penn or its subcontractors under the Research Program. 

  

	1.55	 “Penn Know-How” means (a) the Penn Background Know-How, (b) the Penn Foreground Know-How, and (c) Penn’s interest in the Joint Foreground Know-How.

  

	1.56	 “Penn Materials” means any biological or chemical materials Controlled by Penn and
provided to Licensee under this Agreement, including any progeny or unmodified derivatives thereof, including without limitation, portions and sequence information, made, used or developed by or on behalf of Licensee. 

  
 6 

Table of Contents

	1.57	 “Penn Patent Family” means Penn Patent Rights that (i) are related to each other through
priority claims, and (ii) claim or cover one or more Licensed Product or the manufacturing or use thereof. 

  

	1.58	 “Penn Patent Rights” means (a) the Penn Background Patents, (b) the Penn Foreground
Patents, (c) the Joint Foreground Patents and (d) Third Party Patents. 

  

	1.59	 “Person” means any natural person, corporation, firm, business trust, joint venture,
association, organization, company, partnership or other business entity, or any government or agency or political subdivision thereof. 

  

	1.60	 “Phase 1 Study” means a Clinical Trial of a Licensed Product in patients with the primary
objective of characterizing its safety, tolerability, and pharmacokinetics and identifying a recommended dose and regimen for future studies as described in 21 C.F.R. § 312.21(a), or a comparable Clinical Trial prescribed by the relevant
regulatory authority in a country other than the United States. The Licensed Product can be administered to patients as a single agent or in combination with other investigational or marketed agents. 

 

	1.61	 “Phase 1/2 Study” means a Clinical Trial of a Licensed Product in diseased patients that
satisfies the requirements of a Phase 1 Study and a Phase 2 Study. 

  

	1.62	 “Phase 2 Study” means a Clinical Trial of a Licensed Product in patients with the primary
objective of characterizing its activity in a specific disease state as well as generating more detailed safety, tolerability, and pharmacokinetics information as described in 21 C.F.R. § 312.21(b), or a comparable Clinical Trial prescribed by
the relevant regulatory authority in a country other than the United States including a human Clinical Trial that is also designed to satisfy the requirements of 21 C.F.R. § 312.21(a) or corresponding foreign regulations and is subsequently
optimized or expanded to satisfy the requirements of 21 C.F.R. § 312.21(b) (or corresponding foreign regulations) or otherwise to enable a Phase 3 Study (e.g., a phase 1/2 trial). The relevant Licensed Product may be administered to patients as
a single agent or in combination with other investigational or marketed agents. 

  

	1.63	 “Phase 2/3 Study” means a Clinical Trial of a Licensed Product in diseased patients that
satisfies the requirements of a Phase 2 Study and a Phase 3 Study. 

  

	1.64	 “Phase 3 Study” means a Clinical Trial of a Licensed Product in patients that incorporates
accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain regulatory approval in any country as described in 21 C.F.R. § 312.21(c), or a comparable Clinical Trial prescribed by the relevant
regulatory authority in a country other than the United States. The relevant Licensed Product may be administered to patients as a single agent or in combination with other investigational or marketed agents. 

 

	1.65	 “Product” means any article, composition, substance, or any other material identified,
discovered or developed under the Research Program that incorporates, consists of, is made through use of, or otherwise uses a formulated mRNA or a defined combination of formulated mRNAs encoding one or more immunogens for applications in the
Field. 

  

	1.66	 “Program Data” means the data resulting from the performance of the Research Program.

  

	1.67	 “Regulatory Approval” means, with respect to a product in any regulatory jurisdiction,
approval from the applicable Regulatory Authority sufficient for the manufacture, commercialization, use, marketing and sale of such pharmaceutical product in such jurisdiction in accordance with Laws. “Regulatory Approval” does not
include authorization by a Regulatory Authority to conduct named patient, compassionate use or other similar activities. 

  
 7 

Table of Contents

	1.68	 “Regulatory Authority” means any Governmental Authority, including the FDA, EMA or MHLW, or
any successor agency thereto, that has responsibility for granting any licenses or approvals or granting pricing or reimbursement approvals necessary for the marketing and sale of a pharmaceutical product in any country. 

 

	1.69	 “Research Indication” means an Indication for which Products are being developed under
the Research Program prior to achievement of the Acceptance Criteria. The initial Research Indications are listed in Exhibit E attached hereto, which shall be updated by the Parties as Research Indications are added or removed.

  

	1.70	 “Research Plan” means the research plan setting forth the Parties’ roles and
responsibilities for the Research Program as set forth in Exhibit C hereto, respectively, and as may be agreed upon by the JSC and amended from time to time by the JSC. 

 

	1.71	 “Research Program” means the research and development program of Products in the Field funded
by Licensee and to be conducted by the Parties hereunder in accordance with the Research Plan. 

  

	1.72	 “Research Results” means all any and all information, inventions, developments,
animate and inanimate materials, including live animals, discoveries, software, know-how, methods, techniques, formulae, data, software, processes, methodologies, techniques, biological materials, software and
works of authorship, whether patentable or copyrightable, that are first conceived, discovered, developed or reduced to practice, or generated in the performance of the Research Program, including any unpatentable inventions discovered, developed or
conceived in the conduct of the Research Program. Research Results expressly exclude any Foreground Patents. 

  

	1.73	 “Sale” means any transaction for which consideration is received or expected by Licensee, its
Affiliates or Sublicensees for sale, use, lease, transfer or other disposition of a Licensed Product to or for the benefit of a third party. For clarity, sale, use, lease, transfer or other disposition of a Licensed Product by Licensee or any of its
Affiliates or Sublicensees to another of these entities for resale by such entity to a third party shall not be deemed a Sale. For the avoidance of doubt, the provision of a Licensed Product for clinical studies, named patient or similar programs or
compassionate use prior to the grant of a Governmental Approval shall not be regarded as First Commercial Sale. 

  

	1.74	 “Sublicense” means any sublicense granted by Licensee to another Person, in whole or in part,
under its rights received under the License, as permitted under Section 3.4, but excluding any Person acting solely as a contract manufacturer or contract research organization on behalf of Licensee or its Affiliates or Sublicensees and for
clarity not marketing or selling Licensed Product. The term Sublicense shall include any grant of rights under the License by a Sublicensee to any downstream Third Party, and such applicable downstream Third Party shall be considered a Sublicensee
for purposes of this Agreement. 

  

	1.75	 “Sublicensee” means a Person (including any Affiliate) to which a Sublicense is granted
pursuant to the terms of Section 3.4. 

  

	1.76	 “Sublicense Documents” means any and all agreements, amendments or written understandings
entered into with a Sublicensee or any of its Affiliates pertaining to a Sublicense. 

  

	1.77	 “Sublicense Income” means income received by Licensee or its Affiliates in consideration for a
Sublicense granted to a Third Party. Sublicense Income includes income received from a Third Party Sublicensee in the form of license issue fees, milestone payments and the like but specifically excludes [***]. 

  
 8 

Table of Contents

	1.78	 “Tax” means all taxes, duties, fees, premiums, assessments, imposts, levies, rates,
withholdings, dues, government contributions and other charges of any kind whatsoever, whether direct or indirect, together with all interest, penalties, fines, additions to tax or other additional amounts, imposed by any Governmental Body.

  

	1.79	 “Territory” means worldwide. 

 

	1.80	 “Third Party” means any Person other than Penn, Licensee or any of their respective
Affiliates. 

  

	1.81	 “Third Party Patents” means Third Party Patent Rights in the Field directly related to the
Research Program or any Licensed Product that are in-licensed by Penn pursuant to Section 2.2.7 during the Research Term, to the extent Controlled by Penn and added to the Agreement as
Exhibit K. For clarity, Third Party Patent Rights under this Agreement does not include any Patent Rights that are jointly owned by Penn and a Third Party. 

 

	1.82	 “United States” or “US” means the United States of America, its territories
and possessions. 

  

	1.83	 “USD” or “$” means the lawful currency of the United States of America.

  

	1.84	 “Valid Claim” means a claim of (i) a good faith patent application pending for less than
[***] from the filing date of such patent application, or (ii) an issued patent, in each case of (i) and (ii) which has not expired or lapsed, or been cancelled, abandoned or dedicated to the public and which has not been disclaimed,
cancelled, or held invalid or unenforceable by a court or administrative agency of competent jurisdiction from which no further appeal can be taken or was timely taken. 

 

	1.85	 “Valid Penn Claim” means a Valid Claim in any of the Penn Patent Rights but excluding a Valid
Claim in a Third Party Patent. 

  

	1.86	 “Weissman Laboratory” means all individuals within the Weissman Laboratory at Penn that report
directly to or are under the direct supervision or control of Drew Weissman, MD or any successor. 

  

	1.87	 Other Terms. The definition of each of the following terms is set forth in the section of the Agreement
indicated below: 

  

			
	 Defined Term
	  	 Section

	 Advance Payment
	  	6.3.3
	 Agreement
	  	Introductory Clause
	 Alliance Management Fee
	  	4.2
	 Arbitration Rules
	  	11.10
	 BioNTech/mRT License
	  	4.3.1
	 Cellscript
	  	4.3.1
	 Commercial Milestone
	  	4.3.3(a)
	 Commercial Milestone Payment
	  	4.3.3(a)
	 Confidential Information
	  	7.1
	 CTA
	  	1.35
	 Development Milestone
	  	4.3.2(a)
	 Development Milestone Payment
	  	4.3.2(a)

  
 9 

Table of Contents

			
	 Disclosing Party
	  	7.1
	 Effective Date
	  	Introductory Clause
	 Infringement Notice
	  	6.4.1
	 Joint IP Sub-Committee
	  	2.6.2
	 Joint Steering Committee (“JSC”)
	  	2.6.1(a)
	 License
	  	3.1
	 License Fee Report
	  	4.7
	 Licensee
	  	Introductory Clause
	 MAA
	  	1.13
	 mRT
	  	4.3.1
	 mRT Offset
	  	4.3.1
	 mRT Payment
	  	4.3.1
	 Observer Period
	  	5.4.2
	 Ongoing Patent Costs
	  	6.3.2
	 Party or Parties
	  	Introductory Clause
	 Patent Costs
	  	6.3.1
	 Penn
	  	Introductory Clause
	 Penn/mRT License
	  	4.3.1
	 Penn Patent Counsel
	  	6.2.1(a)
	 Penn Indemnitees
	  	9.1.1
	 Penn Sublicense Income Share
	  	4.5.3
	 Permitted Assignment
	  	11.6.2
	 Progress Report
	  	5.6.1
	 Quarterly Budget Amount
	  	2.3.2
	 Quarterly Financial Report
	  	2.3.3
	 Receiving Party
	  	7.1
	 Reduction License
	  	4.4.4
	 Representative
	  	7.5
	 Research Funding Commitment
	  	2.3.1
	 Research Term
	  	2.2.2
	 Royalty
	  	4.4.1
	 Royalty Term
	  	4.4.2
	 SDR Report
	  	3.4.4
	 Sublicense Income A
	  	4.5.1
	 Sublicense Income B
	  	4.5.2
	 Term
	  	10.1
	 Third Party License
	  	2.2.7

  
 10 

Table of Contents

 ARTICLE 2 

COLLABORATION PROGRAMS; GOVERNANCE 
  

	2.1	 Overall Project. The Parties desire to collaborate with respect to the research and development of
Products, as set forth in more detail in this Article 2, within the Field, with the goal of identifying one or more Development Candidates for clinical development and commercialization in the Field. 

 

	2.2	 Research. 

  

	 	2.2.1	 Under the Research Program, the Parties will use Commercially Reasonable Efforts to develop Products that meet
the Acceptance Criteria for up to ten (10) Indications in the Field. The Research Program will be performed in accordance with the Research Plan and the other terms and conditions of this Agreement. Unless otherwise agreed in the Research Plan,
Penn will be responsible for the conduct of the Research Plan for the research and development work up to completion of IND enabling studies, including animal model development, and IND supporting preclinical work (toxicology and pharmacokinetics)
of Products within the Field, and Licensee shall be responsible for the manufacture of mRNA amounts in excess [***] to support pre-clinical studies and IND-enabling
studies. 

  

	 	2.2.2	 The Research Program shall begin on the Effective Date and continue for a period of [***] years, unless
otherwise mutually agreed by the Parties (“Research Term”). Notwithstanding the foregoing, the Research Term shall end immediately upon termination or conclusion of funding provided by Licensee to Penn to conduct the Research
Program. 

  

	 	2.2.3	 All personnel, contractors and others who participate in the conduct of the Research Program on behalf of
either Party shall be bound by confidentiality obligations that are at least as restrictive as the confidentiality obligations set forth in this Agreement and are consistent with the intellectual property assignment provisions set forth in this
Agreement during the Research Term. For all researchers working on the Research Program in the Weissman Laboratory, such confidentiality obligations shall be agreed in writing. 

 

	 	2.2.4	 The JSC shall review the Research Plan (i) within [***] of the Effective Date, and (ii) thereafter at
least once per Calendar Year or upon request by either Party in accordance with Section 2.3.1. The JSC may discuss and approve amendments the Research Plan at any time, including amendments to include further activities, including corresponding
revisions to the budget. 

  

	 	2.2.5	 Each Party shall maintain records of its activities and any results obtained under the Research Program in
sufficient detail and in good scientific manner appropriate for patent and regulatory purposes to properly reflect all work done and results achieved. Upon reasonable request of Licensee during the Research Term and [***] thereafter, Penn shall
provide to Licensee copies of any such records or results (including nonclinical data (in vitro and in vivo) and mRNA development data and results) generated or obtained under the Research Program. Notwithstanding the above, within
[***] days after the conclusion of each year of the Research Program, Penn will provide Licensee with a written report setting forth the research conducted and results obtained. For a period of [***] months after delivery of such written report, and
at Licensee’s sole cost and expense, Penn shall, through the Weissman Laboratory, provide reasonable technical assistance as Licensee may reasonably request to assist Licensee 

  
 11 

Table of Contents

	 	
in connection with questions arising from such written report; provided, however, that such assistance shall not include performance of any additional activities that are not set forth in the
Research Plan. 

  

	 	2.2.6	 Through the JSC, during the performance of activities under the applicable Research Plan, the Parties will
discuss potential Development Candidates arising out of the applicable Research Program. 

  

	 	2.2.7	 In addition to the Research Plan, Penn shall provide to Licensee through the JSC the proposed constructs for a
Product such that the Parties may consider known freedom-to-operate issues related thereto. For clarity, this Section 2.2.7 will not change the governance of the
Research Program and does not require that Penn engage in a freedom-to-operate analysis with respect to any technology or intellectual property relating to a Product or
Penn’s performance of the Research Plan. If the Parties identify additional intellectual property owned or controlled by a Third Party that is necessary to develop Products, the JSC will decide which Party, if any, will enter into a license
with such Third Party (the “Third Party License”). If the Parties agree that the Third Party License shall be concluded by Penn and sublicensed to Licensee hereunder, Licensee shall reimburse to Penn all costs which relate to the
license rights sublicensed to Licensee hereunder, provided that Licensee has given its prior written consent to such costs. In all other cases, Licensee will bear all Third Party License costs necessary to achieve freedom-to-operate for any Product. If the Parties cannot agree on which Party shall enter into a Third Party License, Licensee shall have the first right to enter into such Third Party License.

  

	 	2.2.8	 The Parties hereby acknowledge that there are inherent uncertainties involved in the research and development
of Products and such uncertainties form part of the business risk involved in undertaking the Research Program. Accordingly, in the event that, at any time during the Research Term and on an Indication-by-Indication basis, the JSC determines that the Parties are not able to develop or identify a suitable Product to propose as a Development Candidate in such Indication, then the JSC may decide to
terminate the Research Program with respect to such Indication and such Indication shall immediately be excluded from the license grants to Licensee set forth in Section 3.1 of this Agreement. 

 

	 	2.2.9	 Each Party will have the right to engage Third Party subcontractors to perform certain of its obligations under
this Agreement; provided that Penn’s right to engage commercial Third Party subcontractors is subject to Licensee’s prior written consent, which shall not be unreasonably withheld. Any subcontractor to be engaged by either Party to perform
a Party’s obligations set forth in this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity and will enter into such Party’s
standard agreement for such activity consistent with such Party’s standard practices, subject to modifications to ensure that such agreement shall be as least as protective as the nondisclosure obligations and consistent with the assignment of
intellectual property rights set forth herein. Any Party engaging a subcontractor hereunder will remain responsible and obligated for such activities and will not grant rights to such subcontractor that interfere with the rights of the other Party
under this Agreement. 

  

	2.3	 Funding of the Research Program.  

 

	 	2.3.1	 During the initial Research Term, Licensee intends to provide funding of Twenty Million United States Dollars
($20,000,000) to Penn as a research funding commitment to fund research activities under the Research Program (the “Research Funding 

  
 12 

Table of Contents

	 	
Commitment”). The activities to be performed by Penn under the Research Program shall be funded in their entirety by Licensee. All such activities shall be charged at cost. [***]

  

	 	2.3.2	 On the Effective Date, Licensee shall pay to Penn an upfront one-time non-refundable research payment of Five Million United States Dollars ($5,000,000) to start work on the initial development programs under the Research Plan selected by the JSC. Prior to the beginning of each
Calendar Year, the Parties, via the JSC, shall estimate, on a per Calendar Quarter basis, what additional funds are required for Penn to perform its activities planned such Calendar Year under the Research Plan (each such amount a “Quarterly
Budget Amount”). [***] 

  

	 	2.3.3	 Penn shall maintain records of the use of the funds provided by Licensee under this Agreement and shall make
such records available to Licensee in accordance with the terms of this Agreement including Section 4.10.2. In addition, within [***] days following the end of each Calendar Quarter, Penn shall provide to Licensee a detailed report of all costs
incurred by Penn under the Research Plan in the respective previous Calendar Quarter (each such report a “Quarterly Financial Report”). [***]. 

 

	 	2.3.4	 Unless otherwise determined by the JSC, title to any equipment, laboratory animals, or any other tangible
materials made or acquired (in whole or in part) with funds provided under this Agreement will vest in Penn, and such equipment, animals, or tangible materials will remain the property of Penn following termination or expiration of this Agreement
(but subject to any license grants to Licensee hereunder). 

  

	 	2.3.5	 Licensee will be responsible, at its sole cost and expense, for the manufacture of mRNA in amounts in excess of
[***]. 

  

	2.4	 Unavailability of Dr. Drew Weissman. If Drew Weissman, MD becomes unavailable to
oversee and support the performance of the activities under the Research Plan for any reason, Penn may propose another member of its faculty to oversee the performance of the Research Program whom Licensee may accept nor not in its sole discretion.
If a substitute faculty member acceptable to Licensee has not been agreed upon within [***] days after Drew Weissman, MD is no longer available to oversee and support the performance of the Research Plan, Licensee may terminate this Agreement upon
written notice thereof to Penn, subject to the provisions of Article 10. 

  

	2.5	 Transfer of Materials. Upon reasonable request of Licensee, Penn shall transfer to Licensee a
portion or sample of any materials generated or obtained under the Research Program. All Penn Materials and BioNTech Materials shall be transferred by the Parties pursuant to a material transfer protocol to be executed by both Parties and the terms
set forth in this Agreement and the terms of material transfer set forth on Exhibit H. The use of such Penn Materials shall be limited to the rights granted to Licensee herein and in Exhibit H and the use of such BioNTech Materials shall be
limited to Penn’s performance of the Research Program. 

  

	2.6	 Governance. 

  

	 	2.6.1	 Joint Steering Committee. 

 

	 	(a)	 Formation; Composition. Within [***] days of the Effective Date, the Parties will establish a joint
steering committee (the “Joint Steering Committee” or “JSC”) comprised of a minimum of two (2) representatives from each Party with sufficient

  
 13 

Table of Contents

	 	
seniority within the applicable Party to make decisions arising within the scope of the JSC’s responsibilities. The Penn JSC will include a representative from the Penn Center for Innovation
and the Penn principal investigator. The JSC may change its size from time to time by mutual consent of its members, provided that the JSC will consist at all times of an equal number of representatives of each of Penn and Licensee. Each Party may
replace its JSC representatives at any time upon written notice to the other Party. 

  

	 	(b)	 Specific Responsibilities. The JSC will: 

 

	 	(i)	 oversee the Research Program; 

 

	 	(ii)	 determine the Acceptance Criteria; 

 

	 	(iii)	 determine whether a Product for an Indication satisfies the Acceptance Criteria for such Indication;

  

	 	(iv)	 determine whether the development of Products in relation to a specific Research Indication shall be terminated
in accordance with Section 2.2.8; 

  

	 	(v)	 review freedom-to-operate
issues related to proposed constructs of Products; 

  

	 	(vi)	 on or before October 1 of each year, approve an updated budget, including capital expenditures, in
accordance with Section 2.3.1; 

  

	 	(vii)	 determine and monitor the Quarterly Budget Amounts in accordance with Section 2.3.2,

  

	 	(viii)	 consider and decide on any amendments to the Research Plan; 

 

	 	(ix)	 resolve any disagreement between the Parties relating to the Research Program or Research Plan;

  

	 	(x)	 discuss and decide on the use of any Patent Rights in connection with the Research Program or any Product
(including any Penn Patent Rights); 

  

	 	(xi)	 designate patent representatives from each Party to consider, and resolve as necessary to the extent possible,
any intellectual property matters; 

  

	 	(xii)	 oversee, manage, coordinate and integrate the activities of the Parties under the Research Plan;

  

	 	(xiii)	 make key decisions during the progress of the Research Plan; 

 

	 	(xiv)	 address any issues identified by Licensee with respect to Third Party intellectual property rights necessary
for the performance of the Research Program, including Licensee’s analysis of whether a license is required from such Third Party for the exploitation of a Product; 

 

	 	(xv)	 decide which Party, if any, will enter into a license with a Third Party to secure rights necessary to develop
Products; 

  

	 	(xvi)	 establish such additional subcommittees as it deems necessary to achieve the objectives and intent of the
Research Program; and 

  

	 	(xvii)	 perform such other functions as appropriate, and as agreed in writing by the parties. 

  
 14 

Table of Contents

	 	(c)	 Reporting. Each Party shall keep the JSC informed on the progress of the activities under the Research
Program then currently ongoing under the Research Plan, including delivering quarterly written updates of its progress under the Research Plan to the JSC at least one (1) week in advance of each JSC meeting. 

 

	 	(d)	 Meetings. During the performance of the Research Plan, the JSC will meet quarterly. Following the
completion of the performance under the Research Plan, the Parties may agree to meet to discuss items previously addressed by the JSC. The JSC may meet in person, by videoconference or by teleconference. Notwithstanding the foregoing, at least two
(2) meetings per Calendar Year will be in person unless the parties mutually agree in writing to waive such requirement. In-person JSC meetings will be held at locations alternately selected by Penn and
by Licensee. Meetings of the JSC will be effective only if all representatives of each Party are present or participating in such meeting, and each Party shall use Commercially Reasonable Efforts to ensure that all representatives of each Party are
present and participate in every meeting. The JSC shall keep accurate minutes of its deliberations which shall record all proposed decisions and all actions recommended or taken. The secretary of the JSC (as appointed by the Licensee) shall be
responsible for the preparation of draft minutes. Draft minutes shall be sent to all members of the JSC within [***] working days after each meeting and shall be approved, if appropriate, at the next meeting. All records of the JSC shall at all
times be available to both Penn and Licensee. 

  

	 	(e)	 Decision-Making. The representatives from each Party on the JSC will have, collectively, one
(1) vote on behalf of that Party, and all decision making will be by unanimous consent of both Parties. If the JSC is unable to reach agreement on any issue or matter for which it is responsible, such disputed matter will be escalated to
Licensee’s Chief Executive Officer and Penn’s Associate Vice Provost for Research or his/her designee, for discussion in good faith. In the event that after escalation the Parties are unable to reach agreement with respect to the disputed
matter within [***] days, then Licensee shall have the final decision-making authority; provided that Penn and the Weissman Laboratory cannot be forced to conduct work or other activities that it believes to be unsafe or not legally permissible.
[***] 

  

	 	2.6.2	 Joint IP Sub-Committee. The Parties will establish a joint
intellectual property sub-committee (the “Joint IP Sub-Committee”) consisting of an equal number of members from each Party, and such Joint IP Sub-Committee will oversee and steer intellectual property filings, prosecution, management and freedom-to-operate analysis; however,
the Joint IP Sub-Committee shall have no authority to make financial decisions. The representatives from each Party on the Joint IP Sub-Committee will have,
collectively, one (1) vote on behalf of that Party, and all decision making will be by unanimous consent by the Parties. Disputes at the Joint IP Sub-Committee will be referred to the JSC for resolution.

  

	2.7	 Licensed Indication Election. During the Research Term, on a Research Indication-by-Research Indication basis, the JSC shall determine if the Acceptance Criteria have been achieved for a Product for such Research Indication. Upon achievement of the Acceptance Criteria for a
Product for a specific Research Indication, Licensee may elect, by providing Penn with formal written notice, to convert such Research Indication to a Licensed Indication within [***], provided, however, that Licensee shall not be obligated to make
an election decision for more than one (1) Research Indication in any [***] time period following the achievement of the Acceptance Criteria for the first Product as determined by the JSC [***]. 

  
 15 

Table of Contents

 ARTICLE 3 

LICENSES AND OTHER RIGHTS 
  

	3.1	 Grant of License to Licensee. Subject to the terms and conditions of this Agreement, Penn hereby grants
to Licensee and its Affiliates (the “License”): 

  

	 	3.1.1	 an exclusive (even as to Penn but subject to Section 3.2), worldwide, royalty-bearing right and license
(with the right to sublicense (through multiple tiers) as provided in, and subject to, the provisions of Section 3.4) under Penn’s interest in the Penn Patent Rights which are necessary or useful, to research, develop, make, have made,
use, sell, offer for sale, commercialize and import Products in the Field in the Territory for the Licensed Indications during the Term; 

  

	 	3.1.2	 a non-exclusive, worldwide, royalty-bearing right and license (with the
right to sublicense (through multiple tiers) as provided in, and subject to, the provisions of Section 3.4) under Penn Know-How and Penn Materials to the extent necessary or useful to research, develop,
make, have made, use, sell, offer for sale, commercialize and import Products in the Field in the Territory for the Licensed Indications during the Term; and 

  

	 	3.1.3	 an exclusive (even as to Penn but subject to Section 3.2), worldwide right and license (without the right
to sublicense) under Penn’s interest in the Penn Patent Rights and a non-exclusive, worldwide right and license (without the right to sublicense) under Penn
Know-How and Penn Materials, in each case which are necessary or useful, to research and develop Products in the Field in the Territory for the Research Indications during the Research Term.

  

	3.2	 Retained Rights and Grant of License to Penn. Notwithstanding the License set forth in Section 3.1,
Penn retains the right under the Penn Patent Rights and the Foreground IP (including Penn Materials which have been generated under the Research Program) to: (a) conduct educational, research and patient care activities itself and
(b) authorize non-commercial Third Parties to conduct educational, research and patient care activities. For clarity, the foregoing retained rights of Penn are in all fields (including the Field).
Licensee hereby grants to Penn a non-exclusive license to Licensee’s interest in BioNTech Foreground IP and Joint Foreground IP to conduct educational, research and patient care activities at Penn.
Notwithstanding anything in this Section 3.2 to the contrary, the foregoing patient care activities shall not include the use of any Product in the Field outside the conduct of the Research Program. 

 

	3.3	 U.S. Government Rights. The License is expressly subject to all applicable provisions of any license to
the United States Government executed by Penn and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. §§200-212 or applicable governmental implementing
regulations or guidelines, including the requirement that products that result from intellectual property funded by the United States Federal Government that are sold in the United States be substantially manufactured in the United States. In the
event that Licensee believes in good faith that substantial manufacture of such product is not commercially feasible in the United States and makes a request to Penn in writing to assist in obtaining a waiver of such requirement from the United
States Government, then Penn shall, at the expense of Licensee with respect to Penn’s documented out-of-pocket expenses, use reasonable efforts to assist in
obtaining such waiver. 

  
 16 

Table of Contents

	3.4	 Grant of Sublicense by Licensee. 

 

	 	3.4.1	 Penn grants to Licensee the right to grant Sublicenses (through multiple tiers), in whole or in part, under the
License in Sections 3.1.1 and 3.1.2 subject to the terms and conditions of this Agreement and specifically this Section 3.4. 

  

	 	3.4.2	 All Sublicenses will be (a) issued in writing, (b) to the extent applicable, include all of the
retained rights of Penn and the U.S. Government pursuant to Section 3.2 and 3.3 and (c) shall explicitly list all Products, and include no less than the following terms and conditions, and in each such instance shall be consistent with the
provisions applicable to Licensee under this Agreement: 

  

	 	(i)	 Reasonable record keeping, audit and reporting obligations sufficient to enable Licensee to reasonably verify
the payments due to Licensee under such Sublicense and to reasonably monitor such Sublicensee’s progress in developing and/or commercializing Product, provided that such obligations shall be no less stringent that those provided in this
Agreement for Licensee. 

  

	 	(ii)	 Infringement and enforcement provisions that do not conflict with the restrictions and procedural requirements
imposed on Licensee and do not provide greater rights to Sublicensee than as provided in Section 6.4. 

  

	 	(iii)	 Confidentiality provisions with respect to Confidential Information of Penn consistent with the restrictions on
Licensee in Article 7 of this Agreement. 

  

	 	(iv)	 Covenants by Sublicensee that are equivalent to those made by Licensee in Section 8.3.

  

	 	(v)	 A requirement of indemnification of Penn by Sublicensee that is equivalent to the indemnification of Penn by
Licensee under Section 9.1 of this Agreement. 

  

	 	(vi)	 A requirement of obtaining and maintaining commercially reasonable insurance by Sublicensee.

  

	 	(vii)	 Restriction on use of Penn’s names etc. consistent with Section 11.4 of this Agreement.

 Any Sublicense that does not include all of the terms and conditions set forth in this Section 3.4.2 or which is
not issued in accordance with the terms and conditions set forth in this Section 3.4, shall be considered null and void with no further notice from Penn. 
  

	 	3.4.3	 Within [***] after the execution of a Sublicense Document, Licensee shall provide a complete and accurate copy
of such Sublicense Document to Penn (which copy may be redacted solely to remove confidential information of Licensee that is not applicable to determining compliance with this Agreement and confidential information of such Sublicensee), in the
English Language, and such copies will be the Confidential Information of Licensee and may only be used to determine Licensee’s compliance with this Agreement. Penn’s receipt of a Sublicense Document, however, will constitute neither an
approval nor disapproval of the Sublicense Document nor a waiver of any right of Penn or obligation of Licensee under this Agreement. In the event Penn cannot, in its reasonable discretion, interpret the Sublicense Document due to the redacted
information, Penn may request, and Licensee shall be obligated to provide to Penn counsel a copy of the unredacted Sublicense Document (other than any research and development plans included as an exhibit to such Sublicense Document).

  
 17 

Table of Contents

	 	3.4.4	 Licensee shall provide an annual Sublicense Development Report on or before December 1 of each year during
the Term (“SDR Report”), which shall contain the information set forth on Exhibit I attached hereto. 

  

	3.5	 No Implied License. Each Party acknowledges that the rights and licenses granted in this
Agreement are limited to the scope expressly granted. Accordingly, except for the rights expressly granted under this Agreement, no right, title, or interest of any nature whatsoever is granted whether by implication, estoppel, reliance, or
otherwise, by either Party to the other Party. All rights with respect to any know-how, patent or other intellectual property right rights that are not specifically granted herein are reserved to the owner
thereof. 

  

	3.6	 Additional Weissman Patent Rights. [***]. 

 

	3.7	 Covenants of Penn. 

 

	 	3.7.1	 During the Research Term, Penn shall not directly (or indirectly through license grant from Penn to a non-commercial Third Party that is sub-licensable or transferrable to a commercial Third Party) grant a license to any commercial Third Party to use any Penn Foreground IP or
Joint Foreground IP for development, manufacture, use or exploitation of any Product in the Field without the prior written permission of Licensee. [***]. 

  

	 	3.7.2	 [***]. 

  

	 	3.7.3	 [***]. 

  

	 	3.7.4	 [***]. 

  

	3.8	 Time-Limited Option. Subject to the terms and conditions of this Agreement, Penn hereby grants an option
to Licensee for [***] months after the Effective Date, exercisable through written notice to Penn, to obtain a license under Penn’s interest in the Option Patent Rights set forth in Exhibit F to research, develop, make, have made,
use, sell, offer for sale, commercialize and import Products in the Field in the Territory for the Licensed Indications during the Term (the “Option”). Upon exercise of such Option, the Option Patents shall become Penn Background
Patents under this Agreement. During the term of the Option, Licensee shall be responsible for reimbursing Penn for Historical and Ongoing Patent Costs associated with the Option Patents in accordance with Sections 6.3.1 and 6.3.2 of this Agreement.
The Option shall terminate immediately if the Agreement is terminated for any reason prior to Licensee’s exercise of such Option. 

ARTICLE 4 
 FINANCIAL
PROVISIONS 
  

	4.1	 Research Funding. The research funding to be provided by Licensee to Penn in connection with the
performance of the Research Program is set forth in Section 2.3. 

  

	4.2	 Alliance Management Fee. During the Research Term, Licensee shall pay Penn an active alliance
management fee of [***] to cover all alliance management activities at the Penn Center for Innovation related to managing and overseeing the intellectual property and contractual obligations of Penn under this Agreement (including managing permitted
subcontractors and 

  
 18 

Table of Contents

	 	
attending JSC meetings) (“Alliance Management Fee”). Such Alliance Management Fee shall be payable to Penn in advance on the Effective Date and each one year anniversary
thereafter during the Research Term per contract year to cover all alliance management activities at the Penn Center for Innovation related to managing and overseeing the intellectual property and contractual obligations of Penn under this Agreement
(including managing permitted subcontractors and attending JSC meetings). For the avoidance of doubt, the Alliance Management Fee shall be in addition to, and shall not reduce, the Research Funding Commitment. [***] of all Alliance Management Fees
paid by Licensee shall be [***]. 

  

	4.3	 Milestone Payments. 

 

	 	4.3.1	 [***]  

  

	 	4.3.2	 Development Milestones. 

 

	 	(a)	 As consideration for the License, [***] Licensee will pay Penn each of the following milestone payments
(each, a “Development Milestone Payment”) upon the first, second and third achievement of the corresponding milestone by any Licensed Product (assessed on a
milestone-by-milestone basis) irrespective of the Licensed Product for which such milestone has been achieved (each, a “Development Milestone”), whether
achieved by Licensee or an Affiliate or Sublicensee. For the avoidance of doubt, no Development Milestone Payment shall be due upon the fourth, fifth or any subsequent achievement of any of the below milestones in this Section 4.3.2(a).
Licensee shall promptly notify Penn in writing of the achievement of any such Development Milestone and Licensee shall pay Penn in full the corresponding Development Milestone Payment within forty-five (45) days of such achievement. For
clarity, each Development Milestone Payment is non-refundable, is not an advance against Royalties due to Penn or any other amounts due to Penn. For further clarity, the maximum cumulative amount of
Development Milestone Payments potentially payable under this Agreement is [***]. 

  

									
	 Development Milestone
	  	Milestone Payment
(in U.S. dollars,
each payable up to
three (3) times)	 	 	Maximum mRT
Offset	 
	 Initiation of Phase 1 Study (as defined by the enrollment of the 3rd patient)
	  	 	[	***] 	 	 	[	***] 
	 Initiation of Phase 2 or Phase 1/2 Study (as defined by the enrollment of the 5th patient)
	  	 	[	***] 	 	 	[	***] 
	 Initiation of Phase 3 or Phase 2/3 Study (as defined by the enrollment of the 5th patient)
	  	 	[	***] 	 	 	[	***] 
	 Approval of first BLA
	  	 	[	***] 	 	 	[	***] 
	 Approval of second BLA
	  	 	[	***] 	 	 	[	***] 
	 Approval of third BLA
	  	 	[	***] 	 	 	[	***] 

  

	 	(b)	 Each time a Development Milestone is achieved for any Licensed Product, then any other Development Milestone
Payments with respect to earlier Development Milestones for the same Licensed Product that have not yet been paid will be due and payable together with the Development Milestone Payment for the Development Milestone that is achieved.

  
 19 

Table of Contents

	 	(c)	 Each Development Milestone in the Table above will be payable for the first three (3) Licensed Products to
achieve such Development Milestone and for no Licensed Product thereafter. 

  

	 	4.3.3	 Commercial Milestone Payments. 

 

	 	(a)	 As additional consideration for the License [***] Licensee will pay Penn the following commercial
milestone payments (each, a “Commercial Milestone Payment”) on a Licensed Product-per-Licensed Product basis upon the achievement of the corresponding
milestone (each, a “Commercial Milestone”), whether achieved by Licensee or an Affiliate, or a combination of Licensee and/or an Affiliate. Licensee shall promptly notify Penn in writing of the achievement of any such Commercial
Milestone and Licensee shall pay Penn in full the corresponding Commercial Milestone Payment within forty-five (45) days of such achievement. For clarity, each Commercial Milestone Payment is
non-refundable and is not an advance against Royalties due to Penn or any other amounts due to Penn. 

  

									
	 Commercial Milestone Event
	  	Milestone
Payment
(U.S. Dollars,
each payable once
per Licensed
Product)	 	 	Maximum mRT
Offset	 
	 Worldwide annual Net Sales of a Licensed Product by Licensee and/or Affiliates equal or exceed
[***] US Dollars
	  	 	[	***] 	 	 	[	***] 
	 Worldwide annual Net Sales of a Licensed Product by Licensee and/or Affiliates equal or exceed
[***] US Dollars
	  	 	[	***] 	 	 	[	***] 
	 Worldwide annual Net Sales of a Licensed Product by Licensee and/or Affiliates equal or exceed
[***] US Dollars
	  	 	[	***] 	 	 	[	***] 

  

	 	(b)	 For clarity, each of the foregoing Commercial Milestone Payments shall only be due once per Licensed Product
and Net Sales made by any Third Party Sublicensee shall be disregarded in the calculation of the Commercial Milestone event. 

  

	4.4	 Royalties. 

  

	 	4.4.1	 Royalty. As further consideration for the License [***] during the Royalty Term, Licensee shall
pay to Penn a non-refundable, non-creditable royalty of [***] on worldwide annual Net Sales for all Licensed Products sold by Licensee, its Affiliates, or
Sublicensees (“Royalty”). 

  

	 	4.4.2	 Royalty Term. Licensee’s obligations to pay Penn the Royalty will continue on a country-by country and Licensed Product-by-Licensed Product basis from the date of the First Commercial Sale of such Licensed Product
in such country until the expiration or abandonment of the last Valid Penn Claim within the Penn Patent Rights in the country in which such Licensed Product is made, used, imported, or sold (such term, the “Royalty Term”).

  
 20 

Table of Contents

	 	4.4.3	 Licensed Products for Animal Health, Diagnostics and Companion Diagnostics. 

 

	 	(a)	 Licensed Products developed and sold solely (i) for animal health applications or (ii) as diagnostic
tests shall not be subject to the Development Milestones and Commercial Milestones set forth in Section 4.3 and shall only be subject to the Royalty payment to Penn as set forth in Section 4.4.1 above. 

 

	 	(b)	 Licensed Products that are developed and sold solely as Companion Diagnostics shall not be subject to
Development Milestones, Commercial Milestones or Royalty payments. 

  

	 	4.4.4	 Reductions for Third Party Licenses. If Licensee determines upon the advice of independent
intellectual property counsel that a license to Patent Rights from a Third Party is necessary to develop, make, have made, use, sell, offer for sale, commercialize or import a Licensed Product, Licensee may obtain such a Third Party license to such
Patent Rights. Licensee may deduct from any Royalty payments due to Penn under Section 4.4.1 of this Agreement an amount equal to [***] of any royalty paid by Licensee to a Third Party on Sales of a particular Licensed Product in a particular
country under a Third Party license obtained by Licensee pursuant to this Section 4.4.4 (“Reduction License”); provided that the royalty deductions shall not reduce the Royalty payable to Penn to less than [***].

  

	 	4.4.5	 Distributor Fees. With respect to any Distributor Fees received by Licensee or its Affiliates or
Sublicensees with respect to a Licensed Product in any Calendar Quarter, Licensee shall pay to Penn [***] of all such Distributor Fee [***]. 

  

	 	4.4.7	 Calculations. Licensee must pay Royalties owed to Penn on a Calendar Quarter basis on or before the
following dates: 

  

	 	(a)	 February 28 for any Sales that took place on or before the last day of the Calendar Quarter ending
December 31, of the prior year; 

  

	 	(b)	 May 31 for any Sales that took place on or before the last day of the Calendar Quarter ending
March 31 of such calendar year; 

  

	 	(c)	 August 31 for any Sales that took place on or before the last day of the Calendar Quarter ending
June 30 of such calendar year; and 

  

	 	(d)	 November 30 for any Sales that took place on or before the last day of the Calendar Quarter ending
September 30 of such calendar year; or 

  

	 	(e)	 In case of Royalties on Sublicense Income, on or before the dates specified in Section 4.5.5.

  

	4.5	 Penn Sublicense Income. 

 

	 	4.5.1	 Sublicense Income A. As further consideration for the License, Penn will receive a percentage of all
Sublicense Income assessed on a Licensed Product-by-Licensed Product basis for the [***] Licensed Products sublicensed to any Third Party Sublicensee (including, for
clarity, commercial sales milestones), tiered according to the schedule set forth in Section 4.5.3 below (“Sublicense Income A”). [***]. Any payments made by Licensee to Penn under Section 4.5.1 shall be credited towards
future Development Milestone payments under Section 4.3.2. [***]. 

  
 21 

Table of Contents

	 	4.5.2	 Sublicense Income B. As further consideration for the License, Penn will receive a percentage of
Sublicense Income from commercial sales milestones assessed on a Licensed Product-by-Licensed Product basis for the [***] Licensed Product sublicensed to any Third Party
Sublicensee, tiered according to Section 4.5.3 below (“Sublicense Income B”). [***]. 

  

	 	4.5.3	 Subject to the respective caps and other stipulations in Sections 4.5.1 and 4.5.2 above, Licensee will pay to
Penn the following percentage of Sublicense Income A and Sublicense Income B received by Licensee (the “Penn Sublicense Income Share”), on a Licensed
Product-by-Licensed Product basis: 

  

			
	[***]	  	

  

	 	4.5.4	 When multiple products are being licensed under a Sublicense, [***], the relative value of the
sublicensed products will be based on the stage of development of each product at the time of Sublicensing, and weighted in accordance with the following chart: 

 

			
	[***]	  	

  

	 	4.5.5	 Licensee will make such payment to Penn on or before the following dates: 

 

	 	(a)	 February 28 for any Sublicense Income received by Licensee on or before the last day of the Calendar
Quarter ending December 31, of the prior year; 

  

	 	(b)	 May 31 for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter
ending March 31 of such calendar year; 

  

	 	(c)	 August 31 for any Sublicense Income received by Licensee on or before the last day of the Calendar Quarter
ending June 30 of such calendar year; and 

  

	 	(d)	 November 30 for any Sublicense Income received by Licensee on or before the last day of the Calendar
Quarter ending September 30 of such calendar year. 

  

	4.6	 Mode of Payment and Currency. All payments to Penn hereunder shall be made by deposit of USD in the
requisite amount to the “The Trustees of the University of Pennsylvania” and will be made by delivery to any one of the following: 

  
 22 

Table of Contents

 For funding of the performance of the Research Program by Penn: 

 

	
	 By ACH/Wire:

	 [***]

 For all other payments to Penn under this Agreement: 

 

			
	 By ACH/Wire:
	  	By Check (lockbox):
	 [***]
	  	[***]

 All payments owed to Penn by Licensee will be invoiced by Penn in the format provided in Exhibit L.
Payments under this Agreement shall be made in USD. All Royalties, Commercial Milestones, and Penn Sublicense Income Share payable shall be calculated first in the currency of the jurisdiction in which payment was made, and if not in the United
States, then converted into USD. The exchange rate for such conversion shall be the average of the rate quoted in The Wall Street Journal for the last business day of each month in the Calendar Quarter for such Royalty payment made. 

 

	4.7	 Royalty and Sublicense Income Reports. Within sixty (60) days after the end of each Calendar
Quarter, Licensee shall deliver to Penn a report (“License Fee Report”) setting out all details necessary to calculate the Royalty and the Penn Sublicense Income Share due under this Article 4 for such Calendar Quarter, including:

  

	 	4.7.1	 Number of the Licensed Products Sold by Licensee, its Affiliates and Sublicensees in each country and the
corresponding name of each such Licensed Product; 

  

	 	4.7.2	 Gross sales, Net Sales of each Licensed Product made by Licensee, its Affiliates and Sublicensees;

  

	 	4.7.3	 Royalties (including calculation of any applicable mRT Offset) or (only if applicable) the [***].

  

	 	4.7.4	 Distributor Fees for Licensed Product; 

 

	 	4.7.5	 Sublicense Income and the calculation of the Penn Sublicense Income Share broken down by Sublicense Income A
and Sublicense Income B, the respective caps on such Sublicense Income and any credits being applied to unpaid Development Milestones based on the Penn Sublicense Income Share paid to Penn; 

  
 23 

Table of Contents

	 	4.7.6	 The method and currency exchange rates (if any) used to calculate the Royalties and the Penn Sublicense Income
Share; 

  

	 	4.7.7	 A specification of all deductions and their dollar value that were taken to calculate Net Sales;

  

	 	4.7.8	 A list of all countries in which Licensed Product is being manufactured (on a product by product basis); and

  

	 	4.7.9	 Date of First Commercial Sale in the United States (this needs only to be reported in the first royalty report
following such First Commercial Sale in the United States). 

 Each License Fee Report shall be substantially in the form
of the sample report attached hereto as Exhibit J. 
  

	4.8	 Late Payments. In addition to any other remedies available to Penn, including the right to terminate
this Agreement, any failure by Licensee to make an undisputed (in good faith) payment within [***] days after the date when due shall obligate Licensee to pay computed interest, the interest period commencing on the due date and ending on the actual
payment date, to Penn at a rate per annum equal to [***]. 

  

	4.9	 Accounting. Each Party shall calculate all amounts, and perform other accounting procedures required,
under this Agreement and applicable to it in accordance with Accounting Standards. 

  

	4.10	 Books and Records. 

 

	 	4.10.1	 Licensee will keep accurate books and records of all Licensed Products developed, manufactured or sold and all
Sublicenses entered into by Licensee that involve Penn Patent Rights. Licensee will preserve these books and records for at least [***] years from the date to which they pertain. 

 

	 	4.10.2	 Penn will keep accurate books and records of all work performed under the Research Program. Penn will preserve
these books and records for at least [***] from the date to which they pertain. 

  

	4.11	 Audits. 

  

	 	4.11.1	 Penn, at its own cost, through an independent auditor reasonably acceptable to Licensee (and who has executed
an appropriate confidentiality agreement reasonably acceptable to Licensee that requires the auditor to keep any information learned by it confidential except as needed to report its audit conclusions to Penn), may inspect and audit only the
relevant records of Licensee pertaining to the calculation of any Milestones, Royalties and Penn Sublicense Income Share due to Penn under this Agreement. Licensee shall provide such auditors with reasonable access to the records during reasonable
business hours and at mutually agreed upon times. Such access need not be given to any such set of records more often than once each year, not more frequently than once with respect to records covering any specific period of time and not more than
[***] years after the date of any report to be audited. Penn shall provide Licensee 

  
 24 

Table of Contents

	 	
with written notice of its election to inspect and audit the records related to the Milestones, Royalties and Penn Sublicense Income Share due hereunder not less than [***] days prior to the
proposed date of review of Licensee’s records by Penn’s auditors. Should the auditor find any underpayment of Milestones, Royalties or Penn Sublicense Income Share by Licensee, Licensee shall (a) promptly pay Penn the amount of such
underpayment; and (b) reimburse Penn for the cost of the audit, if such underpayment equals or exceeds [***] of the total Milestones, Royalties and Penn Sublicense Income Share paid during the time period audited. If the auditor finds
overpayment by Licensee, then Licensee shall have the right to deduct the overpayment from any future Milestones, Royalties or Penn Sublicense Income Share due to Penn by Licensee or, if no such future Milestones, Royalties or Penn Sublicense Income
Share are payable, then Penn shall refund the overpayment to Licensee within [***] days after Penn receives the audit report. Licensee may designate competitively sensitive information which such auditor may see and review but which it may not
disclose to Penn; provided, however, that such designation shall not restrict the auditor’s investigation or conclusions. 

  

	 	4.11.2	 Licensee, at its own cost, through an independent auditor reasonably acceptable to Penn (and who has executed
an appropriate confidentiality agreement reasonably acceptable to Penn that requires the auditor to keep any information learned by it confidential except as needed to report its audit conclusions to Licensee), may inspect and audit only the
relevant records of Penn pertaining to the costs and expenses incurred by and reduction of Royalties due to Penn under this Agreement. Penn shall provide such auditors with reasonable access to the records during reasonable business hours at
mutually agreed upon times. Such access need not be given to any such set of records more often than once each year, not more frequently than once with respect to records covering any specific period of time and not more than [***] years after the
date of any report to be audited. Licensee shall provide Penn with written notice of its election to inspect and audit such records not less than [***] days prior to the proposed date of review of Penn’s records by Licensee’s auditors.
Should the auditor find any over reporting of costs and expenses or underreporting of reduction of Royalties, then Penn shall promptly issue to Licensee a credit against future payments due or, in the case that no future payments are expected, issue
a refund, in each case, in the amount of such overpayment. If the auditor finds underpayment by Licensee to Penn, then Licensee shall pay the difference between the underpayment and the actual payment made for the relevant time period to Penn within
[***] days after Licensee receives the audit report. Penn may designate competitively sensitive information which such auditor may see and review but which it may not disclose to Licensee; provided, however, that such designation shall not restrict
the auditor’s investigation or conclusions. 

  

	4.12	 Withholdings. 

 

	 	4.12.1	 Licensee may withhold from payments due to Penn amounts for payment of any withholding tax that is required by
Law to be paid to any taxing authority with respect to such payments. Licensee will provide Penn all relevant documents and correspondence, and will also provide to Penn any other cooperation or assistance on a reasonable basis as may be necessary
to enable Penn to claim exemption from such withholding taxes and to receive a refund of such withholding tax or claim a foreign tax credit. Licensee will give proper evidence from time to time as to the payment of any such tax. The Parties will
cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. 

  
 25 

Table of Contents

	 	4.12.2	 Apart from any such permitted withholding and those deductions expressly included in the definition of Net
Sales, the amounts payable hereunder will not be reduced on account of any taxes, charges, duties or other levies. 

ARTICLE 5 
 MANUFACTURING,
CLINICAL DEVELOPMENT, REGULATORY AFFAIRS; COMMERCIALIZATION 
  

	5.1	 Clinical Development. Licensee will have sole responsibility for and sole decision making over the
clinical development of any Product arising from the Research Program in the Field. Notwithstanding the foregoing, if Licensee wishes to conduct clinical development of a Development Candidate at Penn and Penn has the clinical expertise, interest
and ability to run such a trial as assessed at Penn’s sole discretion, such a study will be conducted under a separate Clinical Trial Agreement to be negotiated by the Parties prior to initiation of such study. Such separate clinical trial
agreement will include a detailed clinical development plan, including costs and time lines for conducting the Clinical Trial. 

  

	5.2	 Commercialization. Licensee will have sole responsibility for and sole decision making over all
commercialization activities of Products arising from the Research Program in the Field, and will be solely responsible for the associated costs of such commercialization activities. 

 

	5.3	 Manufacturing. Except as otherwise provided in this Agreement or in the Research Plan,
Licensee will be responsible for all manufacturing activities and associated costs to support the clinical development (including GMP manufacturing for Clinical Trials) of the Products developed under the Research Program, and commercialization of
the Products for Licensed Indications arising from the Research Program. Any transfer of materials in support of the manufacturing activities will be managed in accordance with Section 2.5 of this Agreement. Any manufacturing activities
conducted under this Agreement (including manufacturing activities conducted by or on behalf of Licensee, or Licensee’s fully-owned Affiliate, BioNTech Innovative Manufacturing Services GmbH) will be done at Licensee’s sole cost and
expense. 

  

	5.4	 Regulatory. 

 

	 	5.4.1	 It is anticipated that Licensee (or any Sublicensee) will be the regulatory sponsor for Clinical Trials, and in
such instance Licensee (or any Sublicensee) will: (a) have responsibility for all regulatory activities for the Products arising from the Research Program in the Field; (b) have the right to conduct all communications with Regulatory
Authorities, including all meetings, conferences and discussions (including advisory committee meetings), with regard to Products arising from the Research Program in the Field; (c) lead and have control over preparing and submitting all
regulatory filings related to the Products arising from the Research Program in the Field, including all applications for Regulatory Approval (provided, however, that Licensee shall provide Penn with copies of all such applications made by Licensee
prior to submission; for the avoidance of doubt, this bracket shall not apply to applications made by Sublicensees); and (d) own any and all applications for Regulatory Approvals (including INDs), Regulatory Approvals, and other regulatory
filings related to the Product arising from the Research Program in the Field which will be held in the name of Licensee or its designees. Notwithstanding any of the foregoing, for Clinical Trials conducted at and solely by Penn, the JSC may decide
that the applications for Regulatory Approvals (including INDs), Regulatory Approvals, and other regulatory filings related to the Product arising from the Research Program will be owned by, and held in the name of, Penn. 

  
 26 

Table of Contents

	 	5.4.2	 At the discretion of Licensee, Penn shall have the right to participate as an observer in all material
meetings, conferences, and discussions by Licensee with Regulatory Authorities pertaining to Development of the corresponding Products and Regulatory Approvals, provided that such right shall expire with respect to each Product upon the submission
of an IND for such Product (the period of time during which Penn may participate in such meetings, conferences and discussions, the “Observer Period”). During the Observer Period, Licensee shall provide Penn with reasonable advance
notice of all such meetings and other contact and shall provide advance copies of all related documents and other relevant information relating to such meetings or other contact, including any documents that Licensee proposes to submit to any
Regulatory Authority. During any meetings with Regulatory Authorities, which shall be at Licensee’s expense, Penn shall not initiate any interactions with any Regulatory Authority and will only communicate with a Regulatory Authority if
(a) such Regulatory Authority asks a question of Penn or (b) Licensee instructs Penn to communicate with such Regulatory Authority. For the avoidance of doubt, this Section 5.4.2 shall not apply to any regulatory activities of any
Sublicensee. 

  

	5.5	 General Diligence.  

 

	 	5.5.1	 General Diligence. Licensee will use Commercially Reasonable Efforts to clinically develop, obtain
Regulatory Approval and commercialize at least one (1) Product for each Licensed Indication selected by Licensee pursuant to Section 2.7 (“General Diligence”). 

 

	 	5.5.2	 Diligence Events. Licensee, itself and/or through its Affiliates, Sublicensees or Third Party
subcontractors, shall achieve each Diligence Event set forth in the table below by the corresponding Achievement Date (each a “Diligence Event”) for the first Product for each Licensed Indication. [***] 

 

			
	 Diligence Event for each Licensed Indication, on a Licensed Indication-by-Licensed Indication basis
	  	Achievement Date
	[***]	  	[***]

  

	 	5.5.3	 Penn’s sole and exclusive remedy with respect to Licensee’s failure to comply with its obligations
under this Section 5.5 shall be its right to terminate this Agreement on an Indication-by-Indication basis with respect to the Licensed Indication for which a
Diligence Event or General Diligence has not been achieved, upon written notice to Licensee. 

  

	 	5.5.4	 Returned Indications 

 

	 	(a)	 [***] 

  

	 	(b)	 If Licensee exercises its option to enter into such collaboration and/or license with Penn, the financial terms
of this Agreement shall apply to such collaboration or license, provided that each Development Milestone in Section 4.3.2 shall be increased by [***]. In addition, the Royalty under Section 4.4.1 shall be increased by [***]provided that at
least [***] patients have been dosed in a Phase 1 Study that has been initiated for the Product. In addition, Licensee shall pay Penn [***]of the development costs for the 

  
 27 

Table of Contents

	 	
development of the Product for the Indication incurred by Penn since the termination of the license for such Indication pursuant to Section 5.5.3 or the decision by Licensee not to elect
such Indication as a Licensed Indication pursuant to Section 2.7. 

  

	 	(c)	 If Licensee does not exercise its option, Penn shall be free to enter into any agreement with a Third Party
regarding such Product for the Indication. For agreements entered into by Penn within the first [***] after an Indication becomes a Returned Indication, Penn will pay Licensee [***]of the Net Revenue Penn receives in such sublicensing transaction
for any Product for such Returned Indication. 

  

	5.6	 Progress Reports. 

 

	 	5.6.1	 Licensee, on an annual basis, but in no event later than December 1st of each Calendar Year, shall submit to Penn a progress report (each, a “Progress Report”) covering Licensee’s (and any Affiliates’ and Sublicensees’) activities
related to the development of all Products and the obtaining of Governmental Approvals necessary for commercialization of Products. 

  

	 	5.6.2	 Each Progress Report must include all of the following for each annual period: 

 

	 	(a)	 Summary of work completed; 

 

	 	(b)	 Summary of work in progress; 

 

	 	(c)	 Current schedule of anticipated events or milestones; 

 

	 	(d)	 An updated SDR report listing of any and all Third Party Sublicenses granted by Licensee; and

  

	 	(e)	 The names and addresses of all Sublicensees, and a current and valid phone number and e-mail address for a principal point of contact at each such Sublicensee who is responsible for administering the Sublicensee. 

ARTICLE 6 
 INTELLECTUAL
PROPERTY 
  

	6.1	 Ownership and Inventorship. 

 

	 	6.1.1	 Penn Intellectual Property. Penn will be the sole owner of all Penn Foreground IP and will retain all
right, title and interest in and to the Penn Background IP, Penn Foreground IP and Penn Materials, subject to the rights and licenses granted to Licensee set forth herein. 

 

	 	6.1.2	 Licensee Intellectual Property. Licensee will be the sole owner of all BioNTech Foreground IP and will
retain all right, title and interest in and to all BioNTech Background IP, BioNTech Foreground IP and BioNTech Materials, subject to the rights and licenses granted to Penn set forth herein. 

 

	 	6.1.3	 Joint Intellectual Property. All Joint Foreground IP will be jointly owned by the Parties.

  
 28 

Table of Contents

	 	6.1.4	 Inventorship. Inventorship shall be determined in accordance with United States patent laws with
ownership following inventorship. 

  

	6.2	 Patent Filing Prosecution and Maintenance. 

 

	 	6.2.1	 Penn Background Patents and Penn Foreground Patents. Penn Background Patents and Penn Foreground Patents
will be held in the name of Penn. Penn shall have the first right, but not the obligation, to control the preparation, filing, prosecution and maintenance of Penn Background Patents and Penn Foreground Patents subject to the provisions of this
Section 6.2.1: 

  

	 	(a)	 The filing, prosecution and maintenance of any Penn Background Patents and Penn Foreground Patents shall be
made by a qualified patent counsel selected by Penn and reasonably acceptable to Licensee, taking also the costs into account (“Penn Patent Counsel”). 

 

	 	(b)	 Penn shall (through the Penn Patent Counsel) (i) provide Licensee with written notice as early as possible
in advance of undertaking to prepare, file, prosecute and maintain any Patent Rights for any Penn Background Patents or Penn Foreground Patents, (ii) provide Licensee with any draft patent application to be filed by Penn as early as reasonably
possible in advance of filing and use reasonable efforts to incorporate all reasonable comments by Licensee thereon; (iii) provide Licensee with any patent application filed by Penn after such filing; (iv) provide Licensee with copies of
all substantive communications received from or filed in patent office(s) with respect to such filings and use reasonable efforts to incorporate all reasonable comments by Licensee thereon; (v) notify Licensee of any interference, opposition,
reexamination request, nullity proceeding, appeal or other interparty action, review it with Licensee as reasonably requested, and use reasonable efforts to incorporate all reasonable comments by Licensee thereon; and (vi) provide Licensee with
written notice at least [***] days prior to abandoning or forfeiting any such Patent Rights, to permit Licensee to undertake such filing, prosecution and/or maintenance without a loss of rights. 

 

	 	(c)	 In the event that Penn provides Licensee with the written notice described in
sub-section (b)(vi) above, prior to abandoning or forfeiting any such Patent Rights, Licensee shall have the option, exercisable by delivery to Penn of written notice thereof within [***] days thereafter, to
assume the right (but not the obligation), at its sole expense and sole discretion, to control the preparation, filing, prosecution and maintenance of such Patent Rights. If Licensee timely exercises such option, then with respect to such Patent
Rights, (i) Licensee shall thereafter assume the rights and obligations attributed to Penn under sub-section (b) above, and (ii) Penn shall thereafter assume the rights and obligations
attributed to Licensee under sub-section (b) above. 

  

	 	6.2.2	 Joint Foreground Patents. Licensee shall have the first right, but not the obligation, to control the
preparation, filing, prosecution and maintenance of any Joint Foreground Patents subject to the provisions of this Section 6.2.2: 

  

	 	(a)	 The filing, prosecution and maintenance of any Joint Foreground Patents shall be made by a qualified patent
counsel selected by Licensee and reasonably acceptable to Penn (“Licensee Patent Counsel”). 

  

	 	(b)	 Licensee shall (through Licensee Patent Counsel) (i) provide Penn with written notice as early as possible
in advance of undertaking to prepare, file, prosecute and maintain any Patent Rights for any Joint Foreground Patents, (ii) provide Penn with any draft of patent application to be filed by Licensee as early as reasonably possible in advance of

  
 29 

Table of Contents

	 	
filing and incorporate all reasonable comments by Penn thereon; (iii) provide Penn with any patent application filed by Licensee after such filing; (iv) provide Penn with copies of all
substantive communications received from or filed in patent office(s) with respect to such filings and incorporate all reasonable comments by Penn thereon; (v) notify Penn of any interference, opposition, reexamination request, nullity
proceeding, appeal or other interparty action, review it with Penn as reasonably requested, and incorporate all reasonable comments by Penn thereon; and (vi) provide Penn with written notice at least [***] days prior to abandoning or forfeiting
such Patent Rights, sufficiently in advance to permit Penn to undertake such filing, prosecution and/or maintenance without a loss of rights. 

  

	 	(c)	 In the event that Licensee provides Penn with the written notice described in
sub-section (b)(vi) above, prior to abandoning, or forfeiting any such Patent Rights, Penn shall have the option, exercisable by delivery to Licensee of written notice thereof within thirty (30) days
thereafter, to assume the right (but not the obligation), at its sole expense and sole discretion, to control the preparation, filing, prosecution and maintenance of such Patent Rights. If Penn timely exercises such option, then with respect to such
Patent Rights, the License to such Patent Rights will terminate, and Licensee shall have no rights, and Penn shall have no obligations, with respect to such Patent Rights. 

 

	 	6.2.3	 BioNTech Background Patents and BioNTech Foreground Patents. Licensee shall have the sole right, but not
the obligation, to control the preparation, filing, prosecution and maintenance of BioNTech Background Patents and BioNTech Foreground Patents at its sole cost and expense and at its sole discretion. 

 

	 	6.2.4	 Clarification. For the purposes of Section 6.2.1 to 6.2.3, “maintenance” of Patent Rights
includes interference proceedings, re-examinations, inter parties patent review proceedings before the USPTO or a similar patent administration outside the US (including opposition proceedings at the EPO). For
further clarity, validity challenges raised in infringement litigation will be handled per Section 6.4. 

  

	 	6.2.5	 Patent Term Extensions. Penn will have the exclusive right to decide whether to elect and file for
patent term restoration or extension, supplemental protection certificate or any of their equivalents with respect to Penn Background Patents and Penn Foreground Patents in the Territory where Licensee is not the only licensee for such Penn
Background Patents or Penn Foreground Patents, and Licensee will have the exclusive right to decide whether to elect and file for patent term restoration or extension, supplemental protection certificate or any of their equivalents with respect to
Penn Background Patents and Penn Foreground Patents in the Territory where Licensee is the only licensee for such Penn Patent Rights as well as any Joint Foreground Patents and shall, if required, direct Penn regarding such filings with respect to
such Patent Rights. Penn will cooperate and follow all instructions received from Licensee with respect to electing and filing for such restoration or extension, supplemental protection certificate or the equivalent of any of the foregoing for Penn
Background Patents and Penn Foreground Patents where Licensee is the only licensee as well as any Joint Foreground Patents. 

  

	6.3	 Patent Costs. 

 

	 	6.3.1	 Historic Patent Costs. Within [***] days of the Effective Date, Licensee will reimburse Penn an amount
of [***] all unreimbursed out-of pocket costs for the filing, prosecution and maintenance of Penn Background Patents and Option Patents, including all accrued attorney fees, expenses, official and filing fees
(“Patent Costs”) 

  
 30 

Table of Contents

	 	
incurred prior to the Effective Date; provided, however, that if the Parties agree to include any additional Patent Rights to Exhibit B after the Effective Date, Licensee will reimburse Penn for
all unreimbursed Patent Costs that have been incurred by Penn as of the date that such additional Patent Rights are added to Exhibit B. If additional Penn Background Patents are added at a later time during the Term, Licensee will reimburse Penn for
Patent Costs incurred by Penn prior to the date such additional Background Patents are added to the Agreement. 

  

	 	6.3.2	 Ongoing Patent Costs. During the Term of this Agreement, Licensee will bear all Patent Costs incurred by
either Penn or Licensee in connection with the preparation, filing, maintenance or prosecution of any Patent Rights under Section 6.2 and the Option Patents except for the Patent Costs incurred by Penn after Licensee has notified Penn of its
abandonment or forfeiture of such Penn Foreground Patent or Joint Foreground Patent and the [***] day notice period has expired pursuant to Section 6.2.2(b)(vi) or Patent Costs incurred by Penn after expiration of the term of an unexercised
Option for the Option Patents (“Ongoing Patent Costs”). Licensee will reimburse Penn for all Ongoing Patent Costs incurred by Penn in relation to Penn Background Patents and Penn Foreground Patents pursuant to Section 6.2.1
within [***] days of receipt of an invoice for such costs. In the event that Penn licenses any Penn Patent Right in a field separate from the Field to a Third Party, then, upon execution of such Third Party license agreement, Licensee’s Ongoing
Patent Costs obligation will be a pro-rata portion of such Ongoing Patent Costs. 

  

	 	6.3.3	 Advance Payments. At any time, at Penn’s request, Licensee shall pay in advance the Penn Patent
Counsel’s estimated costs for undertaking material patent actions in relation to Penn Background Patents and Penn Foreground Patents before Penn authorizes the Penn Patent Counsel to proceed (“Advance Payment”). Notwithstanding
whether Licensee makes an Advance Payment for any patent action, Licensee shall bear all Ongoing Patent Costs incurred during the Term in accordance with Section 6.3.2. 

 

	 	6.3.4	 [***]. 

  

	6.4	 Infringement. 

 

	 	6.4.1	 Infringement Notice. If either Party believes that an infringement by a Third Party with respect to any
Penn Background Patents or any Foreground Patents is occurring or may potentially occur, the knowledgeable Party will provide the other Party with (a) written notice of such infringement or potential infringement (if enforcement action is
intended, reasonably in advance of taking such enforcement action), and (b) evidence of such infringement or potential infringement (the “Infringement Notice”). 

 

	 	6.4.2	 Enforcement in the Field. As between the Parties, Licensee will have the first right, under its sole
control and at its sole expense, to institute suit against an infringer asserting patent infringement of any Penn Background Patent, any Penn Foreground Patents and any Joint Foreground Patents in the Field, provided that Penn has been appropriately
notified in advance, and Penn has determined that Licensee is the sole licensee for such Patent Rights at the time when such enforcement action is to be initiated. If required by Law, Penn will permit any action under this Section 6.4.2 to be
brought in its name, including being joined as a party-plaintiff, provided that Licensee will reimburse Penn for its documented out-of-pocket costs incurred in
connection with such action. Licensee will have the right to settle any such action with Penn’s consent (such consent not to be unreasonably withheld or delayed). In the event that Penn provides an Infringement Notice to Licensee regarding an
infringement of a Penn 

  
 31 

Table of Contents

	 	
Background Patent or Penn Foreground Patent in the Field and Licensee does not within [***] days of receipt of such notice abate the infringement or file suit to enforce such Penn Background
Patent or Penn Foreground Patent, then Penn shall have the right to take any action reasonably appropriate to enforce such Penn Background Patent or Penn Foreground Patent, provided that (i) all such actions shall be closely coordinated with
Licensee and (ii) Penn shall have no enforcement step-in right with respect to such Penn Background Patent or Penn Foreground Patent in the event that Licensee notifies Penn in advance of such enforcement
action that Licensee does not wish to enforce such Penn Background Patent or Penn Foreground Patent for strategic reasons. If Penn has determined that Licensee is not the sole licensee for such Patent Rights at the time when such enforcement action
is to be initiated, Penn shall have the first right, under its sole control and at its sole expense, to institute suit against an infringer asserting patent infringement of such Patent Rights, provided that all such enforcement actions shall be
closely coordinated with Licensee. 

  

	 	6.4.3	 Enforcement of Penn Background Patents and Penn Foreground Patents outside the Field. As between the
Parties, Penn will have the first right, under its sole control and at its sole expense, to institute suit against an infringer asserting patent infringement of any Penn Background Patent and any Penn Foreground Patent outside the Field, provided
that Licensee has been appropriately notified in advance and Licensee’s reasonable comments have been taken into account by Penn. All such enforcement actions shall be reasonably coordinated with Licensee. 

 

	 	6.4.4	 Recoveries. Any recovery or settlement received in connection with any suit will first be shared by Penn
and Licensee equally to cover any litigation costs each incurred and next shall be paid to Penn or Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other. Any remaining recoveries shall be allocated as
follows: 

  

	 	(a)	 for any suit that is initiated by Licensee with respect to infringement of any Penn Patent Right in the Field,
Penn shall receive [***] (other than amounts attributable to enhanced damages for willful infringement) and the Licensee shall receive the remainder; 

  

	 	(b)	 for any suit that is initiated by Penn with respect to infringement of any Penn Patent Right, Penn shall
receive [***] of the recovery; and 

  

	 	(c)	 for any portion of the recovery or settlement paid as enhanced damages for willful infringement, (a) for a
suit that is initiated by a Party and the other Party voluntarily joins such suit, then the Parties shall share equally the enhanced damages, and (b) for any suit that is initiated by Licensee and Penn is not a party to the litigation, Penn
shall receive [***] and Licensee shall receive the remainder. 

  

	 	6.4.5	 Cooperation. Each Party will reasonably cooperate and assist with the other in litigation proceedings
instituted hereunder but the Party who initiated the suit shall reimburse the cooperating Party for documented out-of-pocket expenses with respect to such cooperation.
For clarity, such requirement does not require a Party to join a suit unless otherwise specifically required under this Agreement. If Penn is subjected to third party discovery related to the Penn Patent Rights or Licensed Products, Licensee will
pay Penn’s reasonable, documented out-of-pocket expenses with respect to same. 

 

	6.5	 Patent Marking. Licensee shall place in a conspicuous location on any Licensed Product (or its packaging
where appropriate and practicable) made or sold under this Agreement a patent notice in accordance with the Laws concerning the marking of patented articles where such Licensed Product is made or sold, as applicable. 

  
 32 

Table of Contents

 ARTICLE 7 

CONFIDENTIALITY& PUBLICATION 
  

	7.1	 Confidential Information. Each Party shall use reasonable efforts to limit the disclosure of
Confidential Information hereunder to the information that is required to be disclosed pursuant to the terms of this Agreement and that is reasonably necessary for either Party to fulfill its obligations and exercise its rights under this Agreement.
Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that, during the Term and for [***] years thereafter, the receiving Party (the “Receiving Party”) and its Affiliates will
keep confidential and will not publish or otherwise disclose or use for any purpose, other than as necessary to satisfy obligations or exercise rights under this Agreement, any confidential or proprietary information or materials, patentable or
otherwise, in any form (written, oral, photographic, electronic, magnetic, or otherwise), including trade secrets, Know-How, inventions or discoveries, proprietary information, formulae, processes, techniques
and information relating to the past, present and future marketing, financial, and research and development activities of any product or potential product or useful technology of the Disclosing Party or its Affiliates and the pricing thereof
(collectively, “Confidential Information”), which is disclosed by or on behalf of such Party (the “Disclosing Party”) to the Receiving Party or its Affiliates or otherwise received or accessed by a Receiving Party
in the course of performing its obligations or exercising its rights under this Agreement. The Parties agree that all Research Results generated under the Research Program solely by Licensee shall be regarded as Confidential Information of Licensee
and treated by Penn accordingly. All other Research Results shall be treated as confidential by Penn and Licensee until publication in accordance with Section 7.4 below. 

 

	7.2	 Exceptions to Confidentiality. “Confidential Information” does not include information that
the Receiving Party can show (a) was in the lawful knowledge and possession of the Receiving Party or its Affiliates prior to the time it was disclosed to, or learned by, the Receiving Party or its Affiliates, or was otherwise developed
independently by the Receiving Party or its Affiliates, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party or its Affiliates; (b) was generally available to
the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party or its Affiliates, as evidenced by written records of the Receiving Party or its Affiliates; (c) became generally available to the public or
otherwise part of the public domain after its disclosure and other than through any act or omission of the Receiving Party or its Affiliates in breach of this Agreement; or (d) was disclosed to the Receiving Party or its Affiliates, other than
under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party or its Affiliates not to disclose such information to others. In the event a Party is required to make a disclosure under Law or regulation, the
order of a court of competent jurisdiction, or the rules of the U.S. Securities and Exchange Commission or any foreign equivalent (including by reason of any securities offering by Licensee), any stock exchange or listing entity, the Receiving Party
shall be entitled to make such disclosure, provided that it provides prompt prior written notice to the Disclosing Party and takes all reasonable steps (including cooperating with the Disclosing Party in seeking to secure confidential treatment of,
or otherwise limit, such Confidential Information required to be disclosed) to limit the extent of the disclosure and obtain confidential treatment for any remaining required disclosure. 

  
 33 

Table of Contents

	7.3	 Penn Intellectual Property. In order to preserve the patentability of intellectual property and to
preserve Penn’s publication rights, each Party shall maintain Penn Patent Rights Foreground IP, BioNTech Background IP, Penn Background IP, Research Results and information provided pursuant to the Research Program (whether oral or written) as
confidential and shall not disclose such information to any Third Party until the earlier of (i) publication of such information pursuant to the terms of this Agreement or (ii) with respect to intellectual property or Patent Rights
Controlled by a Party pursuant to the terms of this Agreement, such Party’s written confirmation that all desirable patentable inventions relating to such information have been protected. 

 

	7.4	 Publications.  

 

	 	7.4.1	 Alignment of Publications in JSC. The Parties will use commercially reasonable efforts to agree upon
publications of Research Results or other information and material resulting from the Research Program in the JSC. 

  

	 	7.4.2	 Coordination of Publications. Notwithstanding the above, Penn shall have the first right to publish
Research Results generated by Penn. If either Party wishes to publish, present or otherwise disclose Research Results or other information and material resulting from the Research Program for any purpose, such Party shall furnish the other Party
with a copy of any proposed publication, presentation or other disclosure at least [***] days in advance of the date of such presentation or disclosure or the submission of said proposed publication in order for the other Party to review and comment
on said proposed publication, disclosure or presentation to (a) determine whether such contains any Confidential Information of the other Party and (b) enable the other Party to identify any intellectual property that it wishes to file
patent applications on or to seek other intellectual property protection for. If within the [***] day review period (i) the other Party notifies publishing Party that it requires deletion from the publication, disclosure or presentation of its
Confidential Information, the Parties will cooperate to modify the disclosure to ensure that Confidential Information of the other Party is not disclosed or (ii) if the other Party requests that publication or presentation be delayed to allow
for patent filings or other intellectual property protection on certain items in the proposed publication, disclosure or presentation, the publishing Party shall delay the publication or presentation for up to [***] days, subject to reasonable
extension as mutually agreed upon by the Parties, to allow for the filing of patent applications or other intellectual property protection. 

  

	 	7.4.3	 Naming of Other Party. Either Party shall name the other Party as collaboration partner in accordance
with good scientific practice in all of its publications, presentations or other disclosures relating to any Research Results or other information and material resulting from the Research Program. 

 

	7.5	 Other Permitted Disclosures. Notwithstanding anything herein to the contrary, either Party may
disclose Confidential Information of the other Party to (a) its Affiliates, and to its and their directors, employees, consultants, agents, licensees, sublicensees, collaborators, subcontractors, potential or actual investors, acquirers or
merger partners (each a “Representative”) in each case who have a need to know such Confidential Information, are bound by commercially reasonable obligations of confidentiality and such Party remains liable for any breach by
such Representative of the non-disclosure and restrictions on use set forth in this Agreement and (b) the extent such disclosure is required to file or prosecute patent applications, prosecute or defend
litigation, or to submit filings to Regulatory Authorities, provided, however, that in each case in this subsection (b), the prosecuting or filing Party shall provide to the other Party prior written notice of such disclosure. 

  
 34 

Table of Contents

 ARTICLE 8 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	8.1	 Mutual Representations and Warranties. Each Party represents and warrants to the other Party that, as of
the Effective Date: 

  

	 	8.1.1	 such Party is duly organized and validly existing under the Laws of the jurisdiction of its incorporation or
organization; 

  

	 	8.1.2	 such Party has taken all action necessary to authorize the execution and delivery of this Agreement and the
performance of its obligations under this Agreement; 

  

	 	8.1.3	 this Agreement is a legal and valid obligation of such Party, binding upon such Party and enforceable against
such Party in accordance with the terms of this Agreement, except as enforcement may be limited by applicable bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights
generally and by general equitable principles; and 

  

	 	8.1.4	 such Party has all right, power and authority to enter into this Agreement and to perform its obligations under
this Agreement without violating any prior agreements or legal obligations. 

  

	8.2	 Penn Representations. Penn represents to Licensee that, as of the Effective Date: 

 

	 	8.2.1	 it has not granted any commercial license to any Third Party under any of the Penn Background Patents in the
Field; 

  

	 	8.2.2	 to the knowledge of the current staff of the Penn Center for Innovation, Penn has not received any claim in
writing from any Third Party contesting the validity, enforceability, licensability, use, or ownership of any Penn Background Patents; 

  

	 	8.2.3	 [***]; and 

  

	 	8.2.4	 [***]. 

  

	8.3	 Disclaimer of Representations and Warranties. 

 

	 	8.3.1	 Other than the representations and warranties provided in Sections 8.1 and 8.2 above, NEITHER PENN NOR LICENSEE
MAKES ANY REPRESENTATIONS OR WARRANTIES, WHETHER EXPRESS OR IMPLIED, AND PENN AND LICENSEE EACH EXPLICITLY DISCLAIMS ANY REPRESENTATION AND WARRANTY, INCLUDING WITH RESPECT TO ANY ACCURACY, COMPLETENESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, COMMERCIAL UTILITY, NON-INFRINGEMENT OR TITLE FOR THE INTELLECTUAL PROPERTY, PATENT RIGHTS, LICENSE AND ANY LICENSED PRODUCT. 

 

	 	8.3.2	 Furthermore, nothing in this Agreement will be construed as: 

 

	 	(a)	 A representation or warranty by Penn as to the validity or scope of any Penn Patent Right;

  
 35 

Table of Contents

	 	(b)	 A representation or warranty that anything made, used, sold or otherwise disposed of under the License is or
will be free from infringement of patents, copyrights, trademarks or any other forms of intellectual property rights or tangible property rights of Third Parties; 

 

	 	(c)	 Obligating Penn to bring or prosecute actions or suits against Third Parties for patent, copyright or trademark
infringement; and 

  

	 	(d)	 Conferring by implication, estoppel or otherwise any license or rights under any Patent Rights of Penn other
than Penn Patent Rights as defined herein, regardless of whether such Patent Rights are dominant or subordinate to Penn Patent Rights. 

  

	8.4	 Mutual Covenants. 

 

	 	8.4.1	 Licensee and its Affiliates will not, directly or indirectly (including where such is done by a Third Party on
behalf of Licensee or its Affiliates, at the urging of Licensee or its Affiliates or with the assistance of the Licensee or its Affiliates) challenge the validity, scope, or enforceability of or otherwise oppose any Penn Patent Right, [***].

  

	 	8.4.2	 Both Parties will comply with all Laws that apply to its activities or obligations under this Agreement. For
example, both Parties will comply with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the applicable agency of the United States government and/or written
assurances by the relevant Party that such Party will not export data or commodities to certain foreign countries without prior approval of the agency. 

  

	 	8.4.3	 Licensee will not grant a security interest in the License or this Agreement without Penn’s prior written
consent. [***]. 

 ARTICLE 9 

INDEMNIFICATION; INSURANCE AND LIMITATION OF LIABILITY 
  

	9.1	 Indemnification. 

 

	 	9.1.1	 Indemnification by Licensee. Licensee shall defend, indemnify and hold Penn and its respective trustees,
officers, faculty, students, employees, contractors and agents (the “Penn Indemnitees”) harmless from and against any and all liability, damage, loss, cost or expense (including reasonable attorneys’ fees), including, without
limitation, bodily injury, risk of bodily injury, death and property damage to the extent arising out of Third Party claims or suits related to: 

  

	 	(a)	 the gross negligence, recklessness or wrongful intentional acts or omissions of Licensee, its Affiliates or
Sublicensees and its or their respective directors, officers, employees and agents, in connection with Licensee’s performance of its obligations or exercise of its rights under this Agreement; 

 

	 	(b)	 any breach of this Agreement by Licensee (including violation of the representations and warranties set forth
in Section 8.1); or 

  

	 	(c)	 any violation of Law by Licensee or its Affiliates or Sublicensees; or 

  
 36 

Table of Contents

	 	(d)	 the development, manufacturing or commercialization (including commercial manufacturing, packaging and labeling
of Products, and all product liability losses) of a Product by or on behalf of Licensee or its Affiliates or Sublicensees; or 

  

	 	(e)	 the use of licensed Penn Know-How or Penn Materials in the development,
manufacturing or commercialization (including commercial manufacturing, packaging and labeling of Products) by or on behalf of Licensee or its Affiliates or Sublicensees; or 

 

	 	(f)	 the use of BioNTech Background IP, Penn Background IP, any Foreground IP or Research Results by or on behalf of
Licensee or its Affiliates or Sublicensees; or 

  

	 	(g)	 any enforcement action or suit brought by Licensee against a Third Party for infringement of Penn Patent Rights
or any Joint Foreground Patent; 

 provided that Licensee’s obligations pursuant to this Section 9.1 shall not
apply to the extent such claims or suits result from the gross negligence or willful misconduct of any of Penn Indemnitees. 
  

	 	9.1.2	 As a condition to a Penn Indemnitee’s right to receive indemnification under this Section 9.1, Penn
shall: (a) promptly notify Licensee as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) reasonably cooperate, and cause the individual Penn Indemnitees to reasonably cooperate, with
Licensee in the defense, settlement or compromise of such claim or suit; and (c) permit the Licensee to control the defense, settlement or compromise of such claim or suit, including the right to select defense counsel. In no event, however,
may Licensee compromise or settle any claim or suit in a manner which (i) admits fault or negligence on the part of Penn or any other Penn Indemnitee; (ii) commits Penn or any other Penn Indemnitee to take, or forbear to take, any action,
without the prior written consent of Penn, or (iii) grant any rights under the Penn Patent Rights except for Sublicenses permitted under Article 3. Penn shall reasonably cooperate with Licensee and its counsel in the course of the defense of
any such suit, claim or demand, such cooperation to include without limitation using reasonable efforts to provide or make available documents, information and witnesses. 

 

	 	9.1.3	 Notwithstanding Section 9.1.2 above, in the event that Penn believes in good faith that a bona fide
conflict exists between Licensee and Penn or any other Penn Indemnitee with respect to a claim or suit subject to indemnification hereunder, then Penn or any other Penn Indemnitee shall have the right to defend against any such claim or suit itself
at its own expense, including by selecting its own counsel. 

  

	9.2	 Insurance.  

 

	 	9.2.1	 Licensee, at its sole cost and expense, must insure its activities in connection with the exercise of its
rights under this Agreement and obtain, and keep in force and maintain Commercial Form General Liability Insurance (contractual liability included) with limits as follows: 

 

	 	(a)	 Each occurrence     [***] 

 

	 	(b)	 General aggregate  [***] 

Prior to the commencement of Clinical Trials, if applicable, involving Product: 

  
 37 

Table of Contents

	 	(c)	 Clinical trials liability insurance [***] 

Prior to the First Commercial Sale of a Product: 
  

	 	(d)	 Products liability insurance [***] 

The Parties may review periodically the adequacy of the minimum amounts of insurance for each coverage required by this Section 9.2.1, and
adjust the limits in the Parties’ reasonable discretion but in no event will Licensee be required to increase such limits beyond the limits of insurance carried by similarly-situated companies. 

 

	 	9.2.2	 Licensee expressly understands that the coverages and limits in Section 9.2.1 do not in any way limit
Licensee’s liability of indemnification obligations. 

  

	 	9.2.3	 Upon request by Penn but not to exceed once per year, Licensee must furnish to Penn with valid certificate of
insurance evidencing compliance with all requirements of this Agreement. 

  

	9.3	 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES BE LIABLE TO THE OTHER
PARTY OR ANY OF ITS AFFILIATES FOR SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES, INCLUDING LOSS OF PROFITS, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS
AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY’S INDEMNIFICATION OBLIGATIONS UNDER SECTION 9.1 ABOVE. 

ARTICLE 10 
 TERM AND
TERMINATION 
  

	10.1	 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date and,
unless terminated sooner as provided below, shall continue in full force and effect until the expiration or abandonment of the last Penn Patent Right covering any Development Candidate or Licensed Product in the Field. [***]. 

 

	10.2	 Termination of the Agreement for Convenience. At any time during the Term beginning [***] months after
the Effective Date, Licensee may, at its convenience, terminate this Agreement, entirely or in relation to one or more Indications only, upon providing at least [***] days prior written notice to Penn of such intention to terminate, and provided
that Licensee ceases using the License or making, using, or selling Products in relation to the Indications that have been terminated. 

  

	10.3	 Termination For Cause. 

 

	 	10.3.1	 If either Party materially breaches any of its material obligations under this Agreement, the non-breaching Party may give to the breaching Party a written notice specifying the nature of the default, requiring the breaching Party to cure such breach, and stating the
non-breaching Party’s intention to terminate this Agreement. If such breach is not cured within ninety (90) days of such notice, such termination shall become effective with respect to the relevant
Indication(s) upon a notice of termination by the terminating Party thereafter. 

  
 38 

Table of Contents

	 	10.3.2	 Either Party may terminate this Agreement, upon written notice, with immediate effect if, at any time, the
other Party is unable to pay its debts, including any debts related to exclusive sublicensees, when they come due, or files in any court or agency pursuant to any statute or regulation of any state, country or jurisdiction, a petition in bankruptcy
or insolvency or for reorganization or for an arrangement or for the appointment of a receiver or trustee of the other Party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the
other Party is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not dismissed within ninety (90) days after the filing thereof, or if the other Party proposes or is a party to any
dissolution or liquidation, or if the other Party makes an assignment for the benefit of its creditors of all or substantially all its assets. 

  

	10.4	 Effects of Termination. 

 

	 	10.4.1	 In the event of any expiration of this Agreement pursuant to Section 10.1, the following provisions shall
survive: [***] All other provisions set forth in this Agreement shall terminate upon expiration of this Agreement. 

  

	 	10.4.2	 In the event of any termination by Licensee pursuant to Section 10.2 or by Penn pursuant to
Section 10.3, the following provisions shall survive: [***] All other provisions set forth in this Agreement shall terminate upon termination of this Agreement. 

 

	 	10.4.3	 In the event of any termination of this Agreement by Licensee pursuant to Section 10.3, the following
provisions shall survive: Sections [***] All other provisions set forth in this Agreement shall terminate upon termination of this Agreement. 

  

	 	10.4.4	 Termination or expiration of this Agreement shall not relieve the Parties of any obligation or liability that,
at the time of termination or expiration, has already accrued hereunder, or which is attributable to a period prior to the effective date of such termination or expiration. Termination or expiration of this Agreement shall not preclude either Party
from pursuing all rights and remedies it may have hereunder or at Law or in equity with respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. 

 

	 	10.4.5	 If this Agreement is terminated for any reason, all outstanding Sublicenses (including all Sublicense Documents
for each Sublicense) not in default will be assigned by Licensee to Penn, and such assignment will be accepted by Penn. Each assigned Sublicense will remain in full force and effect with Penn as the licensor or sublicensor instead of Licensee, but
the duties and obligations of Penn under the assigned Sublicenses will not be greater than the duties of Penn under this Agreement, and the rights of Penn under the assigned Sublicenses will not be less than the rights of Penn under this Agreement,
including all financial consideration and other rights of Penn. Penn may, at its sole discretion, amend such outstanding Sublicenses to contain the terms and conditions found in this Agreement. 

 

	 	10.4.6	 Within [***] days of termination of this Agreement by Licensee pursuant to pursuant to Section 10.2 with
respect to any Indication(s), Licensee shall pay Penn all costs not previously paid and attributable solely to the terminated Indication(s) through the effective termination date per the budget of the Research Plan for
services performed by, or on behalf of, Penn, as well as all commitments related to the performance of the 

  
 39 

Table of Contents

	 	
Research Plan for such Indication(s) that are reflected in the budget (i.e., all costs or non-cancellable commitments incurred prior to the receipt, or
issuance, by Penn of the notice of termination, and the cost of each employee, student and faculty member supported under the Research Plan for such Indication until the earlier of (a) [***] days of termination of this Agreement and
(b) reassignment of such employee, student and faculty member supported under the Research Plan; and subject to Penn’s written notification to Licensee and Licensee’s acknowledgement of all costs and
non-cancellable commitments as they arise) incurred by Penn under this Agreement for the terminated Indication(s), as applicable. 

 

	 	10.4.7	 Upon termination pursuant to Section 10.2 or Section 10.3, Licensee and its Affiliates will promptly
cease selling the Product(s) in the Indications subject to such termination. Each Party will return (or destroy, as directed by the other Party) all data, files, records and other materials containing or comprising the other Party’s
Confidential Information with respect to Product(s) in the Indications subject to such termination, except to the extent such Confidential Information is necessary or useful to conduct activities in connection with surviving portions of this
Agreement. Notwithstanding the foregoing, the Parties will be permitted to retain one copy of such data, files, records, and other materials for archival and legal compliance purposes. 

 

	10.5	 Tolling. [***]. 

ARTICLE 11 
 ADDITIONAL
PROVISIONS 
  

	11.1	 Relationship of the Parties. Nothing in this Agreement is intended or shall be deemed, for financial,
tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. The Parties are independent contractors and at no time will either Party make commitments or incur any charges or
expenses for or on behalf of the other Party. 

  

	11.2	 Expenses. Except as otherwise provided in this Agreement, each Party shall pay its own expenses and
costs incidental to the preparation of this Agreement and to the consummation of the transactions contemplated hereby 

  

	11.3	 Third Party Beneficiary. The Parties agree that each Sublicensee is a third party beneficiary of this
Agreement with respect to Section 10.4.4. 

  

	11.4	 Use of Names. 

 

	 	11.4.1	 Licensee, its Affiliates and Sublicensees may not use the name, logo, seal, trademark, or service mark
(including any adaptation of them) of Penn or any Penn school, organization, employee, student or representative, without the prior written consent of Penn. Notwithstanding the foregoing, Licensee may use the name of Penn in a non-misleading and factual manner solely in (a) executive summaries, business plans, offering memoranda and other similar documents used by Licensee for the purpose of raising financing for the operations of
Licensee, or entering into commercial contracts with Third Parties, but in such case only to the extent necessary to inform a reader that the Penn Patent Rights have been licensed by Licensee from Penn, and to inform a

  
 40 

Table of Contents

	 	
reader of the identity and published credentials of inventors of intellectual property, and (b) any securities reports required to be filed with the US Securities and Exchange Commission or
any foreign equivalent. 

  

	 	11.4.2	 Penn will not use Licensee’s name without Licensee’s prior written consent except that Penn may
(a) acknowledge Licensee’s funding of the Research Program, (b) use Licensee’s name in connection with any scientific contributions in scientific publications and in listings of sponsored research projects as well as required
under Section 7.4.3, (c) use Licensee’s name as required by Law, and (d) use Licensee’s name in connection with institutional compliance policies; provided that, Penn shall not use Licensee’s name for publicity purposes
without Licensee’s prior written consent. 

  

	11.5	 No Discrimination. Neither Penn nor Licensee will discriminate against any employee or applicant for
employment because of race, color, sex, sexual or affectional preference, age, religion, national or ethnic origin, handicap, or veteran status. 

  

	11.6	 Successors and Assignment. 

 

	 	11.6.1	 The terms and provisions hereof shall inure to the benefit of, and be binding upon, the Parties and their
respective successors and permitted assigns. 

  

	 	11.6.2	 Neither Party may not assign or transfer this Agreement or any of its rights or obligations created hereunder,
by operation of law or otherwise, without the prior written consent of the other Party, provided that the other Party shall not unreasonably withhold, condition or delay its consent; provided, however, that each Party may assign this Agreement to
any Affiliate of such Party or to any entity with which such Party merges or consolidates, or to which it sells or transfers all of its stock or all or substantially all of its assets to which this Agreement relates without the other Party’s
consent (“Permitted Assignment”). For any Permitted Assignment, the assigning Party will provide the other Party with notice of such assignment containing at minimum the contact information of the assignee within [***]
days after closing of such Permitted Assignment, and such Permitted Assignment shall be in accordance with this Section 11.6. 

  

	 	11.6.3	 Any assignment not in accordance with this Section 11.6 shall be void. 

 

	11.7	 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments and to
do all such other acts as may be necessary in order to carry out the purposes and intent of this Agreement. 

  

	11.8	 Entire Agreement of the Parties; Amendments. This Agreement and the Exhibits and Appendices or Schedules
hereto constitute and contain the entire understanding and agreement of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties,
whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer
of each Party. 

  
 41 

Table of Contents

	11.9	 Governing Law. This Agreement shall be governed by and interpreted in accordance with the laws of the
[***], excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the [***]. 

  

	11.10	 Dispute Resolution. If a dispute arises between the Parties concerning this Agreement, then the Parties
will confer, as soon as practicable, in an attempt to resolve the dispute. 

  

	 	(a)	 The Parties shall attempt in good faith to resolve any dispute arising out of or relating to this Agreement
promptly by negotiation between senior individuals who have the authority to settle the controversy. Either Party may give the other Party written notice of a dispute not resolved in the normal course of business. If the matter has not been resolved
by these persons within [***] days of a disputing Party’s notice, the dispute shall be referred to a more senior individual of the Parties with the decision-making authority for resolution. If the dispute is not resolved within [***] days from
the referral to a more senior individual the parties will have no further obligation under this Section 11.10(a). 

  

	 	(b)	 With respect to any claim or controversy that has not been resolved under 11.10(a), the Parties will consider
in good faith whether to enter into an agreement to resolve any such claim or controversy by mediation under the International Institute for Conflict Prevention & Resolution (“CPR”) Mediation Procedure then currently in effect.
Unless otherwise mutually agreed, any such mediation shall be held in New York City. Such agreement may provide that (a) the mediator would be selected from the CPR Panels of Distinguished Neutrals and (b) if any such claim or controversy
remains unresolved [***] days after the appointment of a mediator or [***] days after good faith efforts by either Party to proceed to mediation, the Parties shall discuss in good faith whether to submit the dispute to binding arbitration in
accordance with the arbitration rules of the International Chamber of Commerce (ICC) (“Arbitration Rules”). In such case, the arbitration shall be conducted in the English language in London, United Kingdom, by one arbitrator
appointed in accordance with the Arbitration Rules. The arbitrator, by accepting appointment, undertakes to exert their best efforts to conduct the process so as to issue an award within [***] of the appointment of the arbitrator. The arbitrator
shall decide the dispute in accordance with the law governing this Agreement. The procedural rules of the seat of the arbitration tribunal shall not apply; no discovery proceedings shall take place, unless the Parties otherwise agree in writing.

  

	 	(c)	 However, absent a separate agreement concerning mediation and/or an agreement of the Parties to submit any
dispute to binding arbitration, each Party shall remain free to enforce its rights in a court of law, and the Parties agree that such dispute shall be litigated in the United States District Court for the Southern District of New York, or in the
state courts of the State of New York, New York County, and each Party hereby irrevocably submits to the exclusive jurisdiction of such courts for all purposes with respect to any such legal action or proceeding in connection with this Agreement and
subject to this Section 11.10. 

  

	11.11	 Injunctive Relief. Notwithstanding anything herein to the contrary, in the event of an actual or
threatened breach of this Agreement, the aggrieved Party may seek provisional equitable relief (including restraining orders, specific performance or other injunctive relief). 

 

	11.12	 Notices and Deliveries. Any notice, request, approval or consent required or permitted to be given under
this Agreement shall be in writing and directed to a Party at its address shown below or such other address as such Party shall have last given by notice to the other Party. A 

  
 42 

Table of Contents

	 	
notice will be deemed received: if delivered personally, on the date of delivery; if mailed, five (5) days after deposit in the United States mail or if sent via courier, one
(1) business day after deposit with the courier service. 

  

			
	 For Penn
	  	 with a copy to:

	 [***]
	  	 [***]

  

	11.13	 Waiver. A waiver by either Party of any of the terms and conditions of this Agreement in any instance
shall not be deemed or construed to be a waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and
none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party. 

  

	11.14	 Severability. When possible, each provision of this Agreement will be interpreted in such manner as to
be effective and valid under law, but if any provision of this Agreement is held to be prohibited by or invalid under law, such provision will be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of
this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision. 

 

	11.15	 Interpretation. The words “include,” “includes” and “including” shall be
deemed to be followed by the phrase “without limitation”. All references herein to Articles, Sections, Schedules and Exhibits shall be deemed references to Articles and Sections of, Schedules and Exhibits to, this Agreement unless the
context shall otherwise require. “Herein,” “hereby,” “hereunder,” “hereof” and other equivalent words refer to this Agreement as an entirety and not solely to the particular portion of this Agreement in which
any such word is used. The term “or” means “and/or” hereunder. All definitions set forth herein will be deemed applicable whether the words defined are used herein in the singular or the plural. Except as otherwise expressly
provided herein, all terms of an accounting or financial nature shall be construed in accordance with Accounting Standards, as in effect from time to time. Unless the context otherwise requires, countries shall include territories. References to any
specific Law or article, section or other division thereof, shall be deemed to include the then-current amendments or any replacement Law thereto. 

  

	11.16	 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original,
and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original. 

  
 43 

Table of Contents

	11.17	 Force Majeure. Neither Party will be liable for any failure to perform as required by this Agreement to
the extent such failure to perform is due to circumstances reasonably beyond such Party’s control, including, without limitation, labor disturbances or labor disputes of any kind, accidents, failure of any governmental approval required for
full performance, civil disorders or commotions, terrorism, acts of aggression, acts of God, energy or other conservation measures imposed by law or regulation, explosions, failure of utilities, mechanical breakdowns, material shortages, disease, or
other such occurrences. 

 [SIGNATURE PAGE FOLLOWS] 

  
 44 

Table of Contents

 IN WITNESS WHEREOF, duly authorized representatives of the Parties have executed this
Agreement as of the Effective Date. 
  

					
	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	 		 	BIONTECH RNA PHARMACEUTICALS GmbH
			
	By:             [***]	 		 	By: [***]
	Name:        [***]	 		 	Name: [***]
	Title:          [***]	 		 	Title: [***]

 Read and Acknowledged by 

Dr. Drew Weissman: 

[***]                         
            
 [Signature Page to Collaboration & License Agreement]

Table of Contents

 Exhibit A 

BioNTech Background Patents 
 [***] 

Table of Contents

 Exhibit B 

Penn Background Patents 

[***] 

Table of Contents

 Exhibit C 

Research Program 
 Penn-BioNTech Vaccine
Development Alliance Program 
 Initial Research Plan 

General points that should be considered in plans: 
  

	 	•	 	 I am assuming that all vaccines will pass through toxicity testing without incident, based on macaque studies,
use of similar lipids in Phase 3 trials, and physiologic nature of mRNA. 

  

	 	•	 	 We do not know the optimal dosing interval. This may need to be incorporated into each macaque study or could be
done as a single study, whose results are used for all vaccines. Potentially, some of the vaccines could be a single injection. 

  

	 	•	 	 All of the Year 1 studies are underfunded, due to the limitation of 5 million dollars total, but all are
currently ongoing with good potential to move into clinical trials. We would not want to delay any of them. 

  

	 	•	 	 The remaining 4 vaccines have not been selected. Discussions with BioNTech scientists and business advisors, as
well as, the potential addition of a pharmaceutical partner, are needed. 

  

	 	•	 	 I believe a human experimental phase 1 clinical trial of LNPs, 3-5, empty
or poly(C) containing, should be part of the selection criteria for LNPs to use for vaccination for all vaccine studies. While expensive, it would likely increase the success and reduce the toxicity observed in all vaccine trials that follow.

Table of Contents

 Estimated timeline for vaccine development 

[***] 
  

	*	 Potential pathogens for vaccine development but not included in initial Research Indications.

Table of Contents

 [***] 

Year 1 
 [***] 

Year 2 
 [***] 

Year 3 
 [***] 

Table of Contents

 [***] 

Year 1 
 [***] 

Year 2 
 [***] 

Year 3 
 [***] 

Table of Contents

 [***] 

Year 1 
 [***] 

Year 2 
 [***] 

Year 3 
 [***] 

Table of Contents

 [***] 

Year 1 
 [***] 

Year 2 
 [***] 

Year 3 
 [***] 

Table of Contents

 [***] 

Year 1 
 [***] 

Year 2 
 [***] 

Year 3 
 [***] 

Table of Contents

 [***] 

Year 2 
 [***] 

Year 3 
 [***] 

Table of Contents

 Other potential programs need to be discussed with BioNTech to identify desired targets through the JSC.
Potential pathogens may include: 
 [***] 
 Additional
pathogens – many of these are currently under investigation with academic collaborators. Positive vaccine results would move them to the active investigation list either replacing a pathogen whose vaccine is not performing well or bumping a
pathogen to later study. 
 Other potential pathogens that can be considered for vaccine development. Some studies are ongoing: 

[***] 

Table of Contents

 Exhibit D 

Licensed Indications 
 None as of the
Effective Date 

Table of Contents

 Exhibit E 

Research Indications 
 The initial
Research Indications under the Agreement are: 
 [***] 

Table of Contents

 Exhibit F 

Option Patents 
  

													
	 	  	[***]

Table of Contents

 Exhibit G 

Research Program Budget 
 [***] 

Table of Contents

 Exhibit H 

Material Transfer Terms 
 Penn agrees to
provide certain Penn Materials to Licensee, and Licensee agrees to provide certain BioNTech Materials to Penn, under the following conditions: 
  

	1.	 The Penn Materials and the BioNTech Materials are considered proprietary to the providing Party. The providing
Party shall be free, in its sole discretion, to distribute its proprietary Materials to others and to use such Materials for its own purposes, unless otherwise stated in the Agreement. 

 

	2.	 Materials provided by a Party may only be utilized for research by the receiving Party at the receiving
Party’s facility and the facility of any permitted third party. The receiving Party shall not distribute or release the other Party’s Materials to any person other than laboratory personnel under the receiving Party’s direct
supervision, or other personnel and third parties permitted by the Agreement. The receiving Party shall ensure that no one will be allowed to take or send Materials received from the providing Party to any location in violation of the Agreement.

  

	3.	 The transfer of Materials are for the receiving Party’s use of the Materials solely for the performance of
the Research Program, subject to the terms of the Agreement. Each Party agrees that nothing herein shall be deemed to grant any additional rights under any Patent Rights except to those contained in the Agreement and to the extent provided therein.
Materials received from the providing Party will not be used by or on behalf of the receiving Party in research that is subject to consulting or licensing obligations to any Third Party, other than obligations to the U.S. government resulting from
research that is funded by the U.S. government. 

  

	4.	 Each Party agrees to use Materials received from the providing Party in compliance with all laws and
regulations, including current EPA, FDA, USDA, and NIH guidelines. All Materials are supplied solely for research purposes. 

  

	5.	 Neither Party shall have rights in the Materials received from the providing Party other than as provided in
this Agreement, and at the request of the providing Party, the receiving Party will return all unused Materials received from the providing Party. It is understood that any and all proprietary rights, including Patent Rights, trademarks, and
proprietary rights, in and to the Materials and replications or derivatives of the Materials shall be and remain in the providing Party, subject to the rights granted herein. 

 

	6.	 Materials will be considered Confidential Information of the providing Party, and subject to the terms of
Article 7 of the Agreement. 

  

	7.	 Each Party acknowledges that Materials received from the providing Party are experimental in nature and they
are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. THE PROVIDING PARTY MAKES NO REPRESENTATION OR WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE ANY PATENT OR
OTHER PROPRIETARY RIGHTS. 

  

	8.	 For clarity, the terms of this Exhibit H shall not be interpreted to limit any rights granted, or to grant any
rights other than those granted, elsewhere in the body Agreement. The terms set forth in the body of the Agreement shall prevail in the event of a conflict between this Exhibit H and any term set forth in the body of the Agreement.

Table of Contents

 Exhibit I 

Information to be provided in SDR Report 

Summary of work completed by each Third Party Sublicensee; 

Summary of work in progress by each Third Party Sublicensee; and 

Current schedule of anticipated events or milestone with respect to each Third Party Sublicensee 

Table of Contents

 Exhibit J 

Form of Financial Report 
  

																							
	 Licensee:
	  	  
	  	 	                	 	  	Agreement #	  	  
	  				  				  			
	Inventor(s):	  	  
	  				  	Patent #(s):	  	  
	  				  				  			
	Period Covered:	  		  				  	Prepared By	  	  
	  				  				  			
	From	  	  
	  				  	Date	  	  
	  				  				  			
	To	  	  
	  				  	Approved By	  	  
	  				  				  			
		  		  				  	Date	  	  
	  				  				  			
		
		  	If license covers several major product lines, please prepare a separate report for each line. Then combine all product lines into a summary report.	  

						
	Report Type:	  	☐ Single Product Line Report	  		  				  				  			
		  	☐ Multiple product Summary Report Page              of              pages	  
	  				  			
		  	☐ Product Line Detail:	  
	  	Line:	  	  
	  				  	 	            	 	  			
		  		  				  	Trade Name	  	  
	  				  				  			
		  		  				  	Page	  	  
	  				  				  			
	Report Currency:	  	                ☐ US Dollars	  				  	            ☐ Other (specify)	  	                                    
                            	  

  

																	
	 	  	 	  	 	  	 	  	 	  	Period Royalty Amount
	 Country
	  	Gross Sales	  	Allowances	  	Net Sales	  	Royalty Rate	  	This Quarter	  	This Year to
Date	  	This Quarter-
Prior Year	  	Year to date
Prior Year
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
		  		  		  		  		  	0	  		  		  	
	Total	  	0	  	0	  	0	  		  	0	  	0	  	0	  	0
	Conversion rate if other than US Dollars	  	                                    
                        	  		  		  	
	Royalties in US Dollars	  	                                    
                        	  		  		  	

Table of Contents

 Exhibit K 

Third Party Patents 
 None as of the
Effective Date. 

Table of Contents

 Exhibit L 

Format of Invoice 
 To be discussed and
agreed to by the Parties.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]